mRNA Vaccines
“…based on “conservative assumptions, the estimated harms of the COVID-19 mRNA vaccines greatly outweigh the rewards: for every life saved, there were nearly 14 times more deaths caused by the modified mRNA injections.”
https://www.zerohedge.com/medical/mrna-covid-19-vaccines-caused-more-deaths-saved-study
WEDNESDAY, FEB 07, 2024
Authored by Naveen Athrappully via The Epoch Times (emphasis ours),
With considerably lower efficacy rates, mRNA COVID-19 vaccines cause more deaths than save lives, according to a new study whose researchers called for a “global moratorium” on the shots and “immediate removal” from childhood immunization schedule.
The peer-reviewed study, published in the Cureus journal on Jan. 24, analyzed reports from the initial phase 3 trials of Pfizer and Moderna COVID-19 mRNA vaccines. These trials led to the shots being approved under Emergency Use Authorization (EUA) in the United States. The study also looked into several other research and reviews of the trials. It found that the vaccines had “dramatically lower” efficacy rates than the vaccine companies claimed.
Moreover, based on “conservative assumptions, the estimated harms of the COVID-19 mRNA vaccines greatly outweigh the rewards: for every life saved, there were nearly 14 times more deaths caused by the modified mRNA injections.”
“Given the well-documented SAEs (serious adverse events) and unacceptable harm-to-reward ratio, we urge governments to endorse and enforce a global moratorium on these modified mRNA products until all relevant questions pertaining to causality, residual DNA, and aberrant protein production are answered.”
The authors also recommended an “immediate removal” of the COVID-19 vaccines from the childhood immunization schedule. They pointed out that children were at very low risk from the infection.
“It is unethical and unconscionable to administer an experimental vaccine to a child who has a near-zero risk of dying from COVID-19 but a well-established 2.2 percent risk of permanent heart damage based on the best prospective data available.”
Very Low Efficacy Rate
Following the first trials of Pfizer and Moderna, it was claimed that mRNA COVID-19 vaccines had a 95 percent reduction of symptomatic COVID-19. The study pointed out that this efficacy assumption was false.
Pfizer’s claim was based on the fact that only eight out of 22,000 vaccine recipients contracted COVID-19 during the trial compared to 162 out of 22,000 people in the placebo group. In total, 170 confirmed COVID-19 cases were reported in both groups.
However, the researchers pointed out that a large number of infections fell under the “suspected” COVID-19 category, which was ignored. A total of 3,410 such suspected cases were identified in the trial, which is 20 times the 170 confirmed cases.
“There were 1,594 such cases in the vaccinated group and 1,816 in the placebo. When factoring in both confirmed and suspected cases, vaccine efficacy against developing symptoms drops to only 19 percent, far below the 50 percent RR (relative risk) reduction threshold required for regulatory authorization,” the study said.
“Thus, when considering both confirmed and suspected cases, vaccine efficacy appears to have been dramatically lower than the official 95 percent claim.”
The study’s authors declared no financial support from any organization for their work. A few conflict of interest disclosures were made.
One author received a grant from Quanta Computer Inc. Another author, cardiologist Peter A. McCullough, declared employment and owning stock/stock options in The Wellness Company. A third author is the founder of the Vaccine Safety Research Foundation (VSRF).
Lives Saved Versus Deaths
Researchers criticized the Pfizer and Moderna trial reports for “exclusive focus” on relative risk or RR measure while omitting absolute risk reduction. They argued that absolute risk reduction “gives a better indication of a drug’s clinical utility.”
“Both types of risk estimation are required to avoid reporting bias and to provide a more comprehensive perspective on vaccine efficacy. Omitting the absolute risk statistics leads to overestimation of the clinical benefits of the vaccines.”
In contrast with the 95 percent efficacy rate using the RR measure, absolute risk reduction for Pfizer and Moderna vaccines were 0.7 percent and 1.1 percent, respectively, the study stated.
“An absolute risk reduction of approximately 1 percent for the COVID-19 mRNA vaccinations meant that a substantial number of individuals would need to be injected in order to prevent a single mild-to-moderate case of COVID-19.”
To prevent one case of COVID-19 infection, 142 individuals would need to be vaccinated with Pfizer’s shot, the study said. When it came to Moderna, 88 people had to be injected.
Taking into account these numbers as well as the infection fatality rates of COVID-19, the researchers concluded that roughly 52,000 people would need to be vaccinated to prevent one COVID-19-related death.
This would mean two lives saved for roughly 100,000 injections of the Pfizer vaccine. However, there is a risk of 27 deaths per 100,000 doses of Pfizer shot, the researchers calculated. As such, for every life saved by the jab, almost 14 lives would be lost due to the mRNA vaccine, the study stated.
Authors noted that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) “did not include absolute risk reduction measures” when reviewing vaccine data.
This action deviated from FDA guidelines “which state that both approaches are crucial in order to avoid the misguided use of pharmaceuticals.”
Serious Adverse Events
Researchers cited a September 2022 analysis to detail the pervasiveness of serious adverse effects (SAE) among the vaccinated group in the trials. The analysis looked at both Pfizer and Moderna trial data, discovering roughly 125 SAEs per 100,000 vaccine recipients. This indicated one SAE per 800 vaccines.
“The Pfizer trial exhibited a 36 percent higher risk of serious adverse events in the vaccine group (compared to placebo) … The Moderna trial exhibited a 6 percent higher risk of serious adverse events in the vaccine group,” the analysis stated.
“These findings stand in sharp contrast with the FDA’s initial claim that SAEs reported by the two pivotal trials were ‘balanced between treatment groups,’” researchers from the Jan. 24 study noted.
This discrepancy could be because the FDA only counted the number of individuals with serious adverse events rather than the total SAEs experienced by the trial subjects, they said.
Since a single person can have multiple SAEs, counting only individuals would produce a lower number than the total number of such adverse events.
“When the SAEs were viewed collectively, the risks in the vaccine group were substantially elevated beyond those previously determined by the FDA,” the researchers wrote.
The analysis found that the excess risk of serious adverse events of special interest (AESI) among the placebo group was 10.1 per 10,000 individuals. However, the risk reduction for COVID-19 hospitalization in this group was only 2.3 per 10,000 people.
This meant that the subjects were at over four times the risk of suffering AESIs after getting vaccinated than they were of getting hospitalized from the infection. In the Moderna trial, subjects were more than two times at risk of experiencing AESI than being hospitalized.
“To put these findings in perspective, the official SAE rate for other vaccines is only 1-2 per million,” the Jan. 24 study said. The 2020 analysis’ “estimate based on the Pfizer trial data (1,250 SAEs per million) exceeds this benchmark by at least 600-fold.”
Rushed Vaccines
In the Jan. 24 study, researchers noted that the safety of mRNA products was “never assessed” in a manner consistent with scientific standards for vaccines or for gene therapy products (GPT), which they claim is “the more accurate classification” for these jabs. “Many key trial findings were either misreported or omitted entirely from published reports.”
The usual safety testing protocols and toxicology requirements were bypassed by the FDA and vaccine manufacturers. As the two trials were terminated prematurely, there was never an “unbiased assessment” of potential serious adverse events.
“It was only after the EUA that the serious biological consequences of rushing the trials became evident, with numerous cardiovascular, neurological, reproductive, hematological, malignant, and autoimmune SAEs identified and published in the peer-reviewed medical literature.”
In addition, the COVID-19 mRNA vaccines produced and evaluated in the trials were not the same ones that were manufactured and administered to people around the world. The global vaccination campaign used a vaccine produced by a different process, which has been shown to have “varying degrees of DNA contamination.”
The researchers pointed out that several excess deaths, cardiac events, strokes, and other serious adverse events have wrongly been ascribed to COVID-19 rather than the COVID-19 mRNA vaccines since early 2021.
Injuries from these vaccines overlap with both post-acute COVID-19 syndrome (PACS) and severe acute COVID-19 illness, which end up often obscuring the vaccine’s contribution to such conditions. “Multiple booster injections appear to cause immune dysfunction, thereby paradoxically contributing to heightened susceptibility to COVID-19 infections with successive doses.”
For the “vast majority” of adults below 50 years of age, the perceived benefits of the mRNA vaccines were dwarfed by their “potential disabling and life-threatening harm.” The study said older adults may be at higher risk of such harm.
CDC and FDA Criticized
Commenting on the study, Mat Staver, the founder and chairman of nonprofit Liberty Counsel, said that in the paper, scientists “confirm what sound scientific research has been showing for years, that these shots have never been safe nor effective.”
“The FDA and the CDC are supposed to protect the people, but they have become the lapdog of the pharmaceutical industry. This must change.”
The CDC is currently under scrutiny for suppressing an alert for myocarditis from COVID-19 vaccination. Myocarditis is an inflammation of the heart muscle called the myocardium.
A document recently obtained by The Epoch Times shows that in May 2021, the CDC had prepared a draft alert for myocarditis related to the jabs.
The agency was supposed to send the alert to federal, state, and local public health officials and doctors nationwide through its Health Alert Network (HAN). However, the alert was never sent as some officials were worried about appearing “alarmist.”
The Epoch Times reached out to the agencies for comment.
Moderna’s Covid booster caused 1 in 35 people to have heart injuries detectable with blood tests, Swiss doctors report. Will the Centers for Disease Control or American researchers take note?
https://alexberenson.substack.com/p/mrna-covid-jabs-have-caused-silent
July 27, 2023
A dose of Moderna’s Covid jab injured the hearts of about 3 percent of people who received it, Swiss researchers have found.
The vaccinated people did not show obvious signs of heart damage. But when researchers ran blood tests three days after the jabs, they found high levels of troponin, a protein the heart releases when it is injured, in many recipients.
“Subclinical mRNA vaccine-associated myocardial injury is much more common than estimated based on passive surveillance,” the researchers concluded. The paper was published last week in the peer-reviewed European Journal of Heart Failure.
Over 1 billion people have received mRNA jabs. The study suggests tens of millions of them may have suffered heart damage – and don’t even know they’ve been hurt.
The researchers conducted the tests on 777 employees at University Hospital Basel, one of Switzerland’s top medical centers, from December 2021 through February 2022.
The employees had already been scheduled to receive mRNA boosters and were asked if they would undergo a blood test for troponin levels three days later.
In other words, the researchers conducted “active surveillance” on them to trace potential side effects, as opposed to “passive surveillance” vaccine safety systems like the federal government’s VAERS, which depend on patients or doctors to report problems.
The Moderna vaccinees were a healthy group, with an average age of 37 and few preexisting heart problems. About 70 percent were women.
But post-jab blood tests found that 40 of the jab recipients had highly elevated troponin levels, above the 99th percentile for average women or men. About five times as many people had extremely high troponin as should have in a random sample.
After the scientists removed anyone with a plausible non-jab explanation, 22 people – or 1 in 35 of those they tested – remained injured by the Moderna jab.
—
(Swiss researchers doing the studies American scientists won’t)
(SOURCE)
—
The study contained another striking finding.
The researchers reported that 20 of the injured recipients were women, while only two were men. Even adjusting for the fact that more women were tested, women were almost five times as likely to have elevated troponin.
Many large studies have shown that young men are at the highest risk from mRNA-caused myocarditis and pericarditis, or acute heart inflammation, following the jabs. But this study suggests women may be suffering more subtle damage.
Unlike organs such as the liver, the heart cannot regenerate dead muscle tissue. So even a minor cardiac injury can raise the risk for problems years later. In 2016, a long-term study found that people whose troponin levels rose over time had a much higher risk of heart failure and death.
The researchers referred to the damage as “transient.”
That view was somewhat optimistic. The scientists conducted only one follow-up troponin test on the injured people, a day after the first test. The second test showed that many of them, especially those with the highest troponin levels in the first test, had only small declines in their troponin levels.
Without further tests, no one can be sure the declines continued, or how quickly – if ever – troponin levels returned to normal.
—
(Transient? Maybe.)
—
In their discussion, the researchers noted that this is the third – and largest – study using blood tests shortly after vaccination to examine post-mRNA heart injury. (The two previous studies took place in Israel and Thailand.) All three papers have shown far higher rates of damage than “passive surveillance” vaccine safety systems.
“Additional active surveillance studies are needed,” they wrote.
But if the last three years are any guide, those studies will not be run in the United States.
Nearly every important finding on mRNA safety has come from researchers based outside the United States – even though Moderna and Pfizer are American companies and the United States administered far more mRNA shots than anywhere else.
When it comes to mRNA safety, American researchers seem to have decided that what they don’t know can’t hurt their careers.
At least they can’t keep the rest of the world from looking for the truth.
https://www.globalresearch.ca/covid-19-vaccines-scientific-proof-lethality/5767711
By SUN
Global Research, April 15, 2023
SUN 5 January 2022
Region: Europe
Theme: Media Disinformation, Science and Medicine
First published by Global Research on January 21, 2022
Since the publication of this article, the number of studies has increased. The evidence is overwhelming.
***
Over One Thousand Scientific Studies Prove That the COVID-19 Vaccines Are Dangerous, and All Those Pushing This Agenda Are Committing the Indictable Crime of Gross Misconduct in Public Office
Just over 12 months from deployment of the COVID 19 emergency use experimental vaccines, scientific studies in the thousands, and reports of criminal complaints of assault and murder from the illegal, unlawful use of biochemical poisons made to police forces around the country, verify an assault on an unsuspecting UK population. Irrefutable science shows that the COVID 19 vaccine is not safe and not effective in limiting transmission or infection from the SARS-CoV-2, coronavirus pathogens.
The “safe and effective” false propaganda, put out by public officials who now are continuing to push this vaccine, is a clear breach of duty. A public office holder is subject to, and aware of, a duty to prevent death or serious injury that arises only by virtue of the functions of the public office.
Many have breached that duty and, in doing so, are recklessly causing a risk of death or serious injury, by carrying on regardless of the now-confirmed dangers associated with COVID 19 injections. Some of these risks are blood clotting, myocarditis, pericarditis, thrombosis, thrombocytopenia, anaphylaxis, Bell’s palsy, Guillain-Barre, cancer including deaths, etc.
All of these are confirmed in the following science-and-government-gathered data from the UK Health and Security agency on COVID 19 regarding vaccine damage.
The term “vaccine” was changed recently to incorporate this illegal, unlawful medical experiment to facilitate usage of mRNA technology that is demonstrably not a vaccine, and which contains biologically toxic nano-metamaterials associated with 5G urban data gathering capability.
Metal nanoparticulates are known in science to be genotoxic—a poison that can also cause sterilization. The dangers posed to the victims in the near term from this medical battery are now known. However, the long term lethality of this weapon is not as yet realized due to the debilitating effects it has on the immune system, causing Acquired Immunodeficiency Syndrome(AIDS).
The Medicines and Healthcare (products) Regulatory Agency (MHRA) had prior warning of the expected large numbers of adverse reactions before the deployment—confirming the premeditated nature of the crime and public conduct offences then and now.
- Cerebral venous thrombosis after COVID-19 vaccination in the UK: a multicentre cohort study: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01608-1/
- Vaccine-induced immune thrombotic thrombocytopenia with disseminated intravascular coagulation and death after ChAdOx1 nCoV-19 vaccination: https://www.sciencedirect.com/science/article/pii/S1052305721003414
- Fatal cerebral hemorrhage after COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33928772/
- Myocarditis after mRNA vaccination against SARS-CoV-2, a case series: https://www.sciencedirect.com/science/article/pii/S2666602221000409
- Three cases of acute venous thromboembolism in women after vaccination against COVID-19: https://www.sciencedirect.com/science/article/pii/S2213333X21003929
- Acute thrombosis of the coronary tree after vaccination against COVID-19: https://www.sciencedirect.com/science/article/abs/pii/S1936879821003988
- US case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with Ad26.COV2.S (against covid-19), March 2 to April 21, 2020: https://pubmed.ncbi.nlm.nih.gov/33929487/
- Portal vein thrombosis associated with ChAdOx1 nCov-19 vaccine: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00197-7/
- Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): position statement of the Italian Society for the Study of Hemostasis and Thrombosis (SISET): https://pubmed.ncbi.nlm.nih.gov/33871350/
- Vaccine-induced immune immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with COVID-19; a systematic review: https://www.sciencedirect.com/science/article/pii/S0022510X21003014
- Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines: https://www.sciencedirect.com/science/article/abs/pii/S0735675721004381
- Covid-19 vaccine-induced thrombosis and thrombocytopenia: a commentary on an important and practical clinical dilemma: https://www.sciencedirect.com/science/article/abs/pii/S0033062021000505
- Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector vaccines: https://www.sciencedirect.com/science/article/abs/pii/S0953620521001904
- COVID-19 vaccine-induced immune-immune thrombotic thrombocytopenia: an emerging cause of splanchnic vein thrombosis: https://www.sciencedirect.com/science/article/pii/S1665268121000557
- The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic immune thrombocytopenia (covid): https://www.sciencedirect.com/science/article/pii/S1050173821000967
- Roots of autoimmunity of thrombotic events after COVID-19 vaccination: https://www.sciencedirect.com/science/article/abs/pii/S1568997221002160
- Cerebral venous sinus thrombosis after vaccination: the United Kingdom experience: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01788-8/fulltext
- Thrombotic immune thrombocytopenia induced by SARS-CoV-2 vaccine: https://www.nejm.org/doi/full/10.1056/nejme2106315
- Myocarditis after immunization with COVID-19 mRNA vaccines in members of the US military. This article reports that in “23 male patients, including 22 previously healthy military members, myocarditis was identified within 4 days after receipt of the vaccine”: https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601
- Thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19: https://www.nejm.org/doi/full/10.1056/NEJMoa2104882?query=recirc_curatedRelated_article
- Association of myocarditis with the BNT162b2 messenger RNA COVID-19 vaccine in a case series of children: https://pubmed.ncbi.nlm.nih.gov/34374740/
- Thrombotic thrombocytopenia after vaccination with ChAdOx1 nCov-19: https://www.nejm.org/doi/full/10.1056/NEJMoa2104840?query=recirc_curatedRelated_article
- Post-mortem findings in vaccine-induced thrombotic thrombocytopenia (covid-19): https://haematologica.org/article/view/haematol.2021.279075
- Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19 mRNA vaccines reported to the Vaccine Adverse Event Reporting System (VAERS): https://www.sciencedirect.com/science/article/pii/S0264410X21005247
- Acute symptomatic myocarditis in seven adolescents after Pfizer-BioNTech COVID-19 vaccination: https://pediatrics.aappublications.org/content/early/2021/06/04/peds.2021-052478
- Aphasia seven days after the second dose of an mRNA-based SARS-CoV-2 vaccine. Brain MRI revealed an intracerebral hemorrhage (ICBH) in the left temporal lobe in a 52-year-old man. https://www.sciencedirect.com/science/article/pii/S2589238X21000292#f0005
- Comparison of vaccine-induced thrombotic episodes between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines: https://www.sciencedirect.com/science/article/abs/pii/S0896841121000895
- Hypothesis behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination: https://www.sciencedirect.com/science/article/abs/pii/S0049384821003315
- Blood clots and bleeding episodes after BNT162b2 and ChAdOx1 nCoV-19 vaccination: analysis of European data: https://www.sciencedirect.com/science/article/pii/S0896841121000937
- Cerebral venous thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine: https://www.sciencedirect.com/science/article/abs/pii/S1052305721003098
- Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia induced by the Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine (VITT): https://www.sciencedirect.com/science/article/pii/S0953620521002363
- Myocarditis and pericarditis after vaccination with COVID-19 mRNA: practical considerations for care providers: https://www.sciencedirect.com/science/article/pii/S0828282X21006243
- “Portal vein thrombosis occurring after the first dose of SARS-CoV-2 mRNA vaccine in a patient with antiphospholipid syndrome”: https://www.sciencedirect.com/science/article/pii/S2666572721000389
- Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with Ad26.COV2.S: https://www.sciencedirect.com/science/article/pii/S0196064421003425
- Myocarditis, pericarditis and cardiomyopathy after COVID-19 vaccination: https://www.sciencedirect.com/science/article/pii/S1443950621011562
- Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection: https://www.sciencedirect.com/science/article/abs/pii/S0896841121000706
- Prothrombotic immune thrombocytopenia after COVID-19 vaccination: https://www.sciencedirect.com/science/article/pii/S0006497121009411
- Vaccine-induced thrombotic thrombocytopenia: the dark chapter of a success story: https://www.sciencedirect.com/science/article/pii/S2589936821000256
- Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin based anticoagulation: https://www.sciencedirect.com/science/article/pii/S1871402121002046
- Thrombosis after COVID-19 vaccination: possible link to ACE pathways: https://www.sciencedirect.com/science/article/pii/S0049384821004369
- Cerebral venous sinus thrombosis in the U.S. population after SARS-CoV-2 vaccination with adenovirus and after COVID-19: https://www.sciencedirect.com/science/article/pii/S0735109721051949
- A rare case of a middle-aged Asian male with cerebral venous thrombosis after AstraZeneca COVID-19 vaccination: https://www.sciencedirect.com/science/article/pii/S0735675721005714
- Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom: https://www.sciencedirect.com/science/article/abs/pii/S088915912100163X
- Immune thrombocytopenic purpura after vaccination with COVID-19 vaccine (ChAdOx1 nCov-19): https://www.sciencedirect.com/science/article/abs/pii/S0006497121013963.
- Antiphospholipid antibodies and risk of thrombophilia after COVID-19 vaccination: the straw that breaks the camel’s back?: https://docs.google.com/document/d/1XzajasO8VMMnC3CdxSBKks1o7kiOLXFQ
- Vaccine-induced thrombotic thrombocytopenia, a rare but severe case of friendly fire in the battle against the COVID-19 pandemic: What pathogenesis?: https://www.sciencedirect.com/science/article/pii/S0953620521002314
- Diagnostic-therapeutic recommendations of the ad-hoc FACME expert working group on the management of cerebral venous thrombosis related to COVID-19 vaccination: https://www.sciencedirect.com/science/article/pii/S0213485321000839
- Thrombocytopenia and intracranial venous sinus thrombosis after exposure to the “AstraZeneca COVID-19 vaccine”: https://pubmed.ncbi.nlm.nih.gov/33918932/
- Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/33606296/
- Severe and refractory immune thrombocytopenia occurring after SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/33854395/
- Purpuric rash and thrombocytopenia after mRNA-1273 (Modern) COVID-19 vaccine: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996471/
- COVID-19 vaccination: information on the occurrence of arterial and venous thrombosis using data from VigiBase: https://pubmed.ncbi.nlm.nih.gov/33863748/
- Cerebral venous thrombosis associated with the covid-19 vaccine in Germany: https://onlinelibrary.wiley.com/doi/10.1002/ana.26172
- Cerebral venous thrombosis following BNT162b2 mRNA vaccination of BNT162b2 against SARS-CoV-2: a black swan event: https://pubmed.ncbi.nlm.nih.gov/34133027/
- The importance of recognizing cerebral venous thrombosis following anti-COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34001390/
- Thrombosis with thrombocytopenia after messenger RNA vaccine -1273: https://pubmed.ncbi.nlm.nih.gov/34181446/
- Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an analysis of European data: https://pubmed.ncbi.nlm.nih.gov/34174723/
- First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic, and hemorrhagic events in Scotland: https://www.nature.com/articles/s41591-021-01408-4
- Exacerbation of immune thrombocytopenia after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34075578/
- First report of a de novo iTTP episode associated with a COVID-19 mRNA-based anti-COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34105244/
- PF4 immunoassays in vaccine-induced thrombotic thrombocytopenia: https://www.nejm.org/doi/full/10.1056/NEJMc2106383
- Antibody epitopes in vaccine-induced immune immune thrombotic thrombocytopenia: https://www.nature.com/articles/s41586-021-03744-4
- Myocarditis with COVID-19 mRNA vaccines: https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.056135
- Myocarditis and pericarditis after COVID-19 vaccination: https://jamanetwork.com/journals/jama/fullarticle/2782900
- Myocarditis temporally associated with COVID-19 vaccination: https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.055891.
- COVID-19 Vaccination Associated with Myocarditis in Adolescents: https://pediatrics.aappublications.org/content/pediatrics/early/2021/08/12/peds.2021-053427.full.pdf
- Acute myocarditis after administration of BNT162b2 vaccine against COVID-19: https://pubmed.ncbi.nlm.nih.gov/33994339/
- Temporal association between COVID-19 vaccine Ad26.COV2.S and acute myocarditis: case report and review of the literature: https://www.sciencedirect.com/science/article/pii/S1553838921005789
- COVID-19 vaccine-induced myocarditis: a case report with review of the literature: https://www.sciencedirect.com/science/article/pii/S1871402121002253
- Potential association between COVID-19 vaccine and myocarditis: clinical and CMR findings: https://www.sciencedirect.com/science/article/pii/S1936878X2100485X
- Recurrence of acute myocarditis temporally associated with receipt of coronavirus mRNA disease vaccine 2019 (COVID-19) in a male adolescent: https://www.sciencedirect.com/science/article/pii/S002234762100617X
- Fulminant myocarditis and systemic hyper inflammation temporally associated with BNT162b2 COVID-19 mRNA vaccination in two patients: https://www.sciencedirect.com/science/article/pii/S0167527321012286.
- Acute myocarditis after administration of BNT162b2 vaccine: https://www.sciencedirect.com/science/article/pii/S2214250921001530
- Lymphohistocytic myocarditis after vaccination with COVID-19 Ad26.COV2.S viral vector: https://www.sciencedirect.com/science/article/pii/S2352906721001573
- Myocarditis following vaccination with BNT162b2 in a healthy male: https://www.sciencedirect.com/science/article/pii/S0735675721005362
- Acute myocarditis after Comirnaty (Pfizer) vaccination in a healthy male with previous SARS-CoV-2 infection: https://www.sciencedirect.com/science/article/pii/S1930043321005549
- Myopericarditis after Pfizer mRNA COVID-19 vaccination in adolescents: https://www.sciencedirect.com/science/article/pii/S002234762100665X
- Pericarditis after administration of BNT162b2 mRNA COVID-19 mRNA vaccine: https://www.sciencedirect.com/science/article/pii/S1885585721002218
- Acute myocarditis after vaccination with SARS-CoV-2 mRNA-1273 mRNA: https://www.sciencedirect.com/science/article/pii/S2589790X21001931
- Temporal relationship between the second dose of BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection: https://www.sciencedirect.com/science/article/pii/S2352906721000622
- Myopericarditis after vaccination with COVID-19 mRNA in adolescents 12 to 18 years of age: https://www.sciencedirect.com/science/article/pii/S0022347621007368
- Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old man: https://www.sciencedirect.com/science/article/pii/S0870255121003243
- Important information on myopericarditis after vaccination with Pfizer COVID-19 mRNA in adolescents: https://www.sciencedirect.com/science/article/pii/S0022347621007496
- A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-1279 and BNT162b2: https://www.sciencedirect.com/science/article/pii/S1936878X21004861
- Takotsubo cardiomyopathy after vaccination with mRNA COVID-19: https://www.sciencedirect.com/science/article/pii/S1443950621011331
- COVID-19 mRNA vaccination and myocarditis: https://pubmed.ncbi.nlm.nih.gov/34268277/
- COVID-19 vaccine and myocarditis: https://pubmed.ncbi.nlm.nih.gov/34399967/
- Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resourc e/en/covidwho-1360706.
- COVID-19 vaccines and myocarditis: https://pubmed.ncbi.nlm.nih.gov/34246566/
- Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccines https://www.cureus.com/articles/61030-myocarditis-and-other-cardiovascular-comp lications-of-the-mrna-based-covid-19-vaccines https://www.cureus.com/articles/61030-myocarditis-and-other-cardiovascular-complications-of-the-mrna-based-covid-19-vaccines
- Myocarditis, pericarditis, and cardiomyopathy after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34340927/
- Myocarditis with covid-19 mRNA vaccines: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056135
- Association of myocarditis with COVID-19 mRNA vaccine in children: https://media.jamanetwork.com/news-item/association-of-myocarditis-with-mrna-co vid-19-vaccine-in-children/
- Association of myocarditis with COVID-19 messenger RNA vaccine BNT162b2 in a case series of children: https://jamanetwork.com/journals/jamacardiology/fullarticle/2783052
- Myocarditis after immunization with COVID-19 mRNA vaccines in members of the U.S. military: https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601%5C
- Myocarditis occurring after immunization with COVID-19 mRNA-based COVID-19 vaccines: https://jamanetwork.com/journals/jamacardiology/fullarticle/2781600
- Myocarditis following immunization with Covid-19 mRNA: https://www.nejm.org/doi/full/10.1056/NEJMc2109975
- Patients with acute myocarditis after vaccination withCOVID-19 mRNA: https://jamanetwork.com/journals/jamacardiology/fullarticle/2781602
- Myocarditis associated with vaccination with COVID-19 mRNA: https://pubs.rsna.org/doi/10.1148/radiol.2021211430
- Symptomatic Acute Myocarditis in 7 Adolescents after Pfizer-BioNTech COVID-19 Vaccination: https://pediatrics.aappublications.org/content/148/3/e2021052478
- Cardiovascular magnetic resonance imaging findings in young adult patients with acute myocarditis after COVID-19 mRNA vaccination: a case series: https://jcmr-online.biomedcentral.com/articles/10.1186/s12968-021-00795-4
- Clinical Guidance for Young People with Myocarditis and Pericarditis after Vaccination with COVID-19 mRNA: https://www.cps.ca/en/documents/position/clinical-guidance-for-youth-with-myocarditis-and-pericarditis
- Cardiac imaging of acute myocarditis after vaccination with COVID-19 mRNA: https://pubmed.ncbi.nlm.nih.gov/34402228/
- Case report: acute myocarditis after second dose of mRNA-1273 SARS-CoV-2 mRNA vaccine: https://academic.oup.com/ehjcr/article/5/8/ytab319/6339567
- Myocarditis / pericarditis associated with COVID-19 vaccine: https://science.gc.ca/eic/site/063.nsf/eng/h_98291.html
- Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine: https://journals.lww.com/pidj/Abstract/9000/Transient_Cardiac_Injury_in_Adolesce nts_Receiving.95800.aspx
- Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine: https://academic.oup.com/jpids/advance-article/doi/10.1093/jpids/piab060/6329543
- The new COVID-19 mRNA vaccine platform and myocarditis: clues to the possible underlying mechanism: https://pubmed.ncbi.nlm.nih.gov/34312010/
- Acute myocardial injury after COVID-19 vaccination: a case report and review of current evidence from the Vaccine Adverse Event Reporting System database: https://pubmed.ncbi.nlm.nih.gov/34219532/
- Be alert to the risk of adverse cardiovascular events after COVID-19 vaccination: https://www.xiahepublishing.com/m/2472-0712/ERHM-2021-00033
- Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac tomography, and magnetic resonance imaging findings: https://www.ahajournals.org/doi/10.1161/CIRCIMAGING.121.013236
- In-depth evaluation of a case of presumed myocarditis after the second dose of COVID-19 mRNA vaccine: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056038
- Occurrence of acute infarct-like myocarditis after COVID-19 vaccination: just an accidental coincidence or rather a vaccination-associated autoimmune myocarditis?: https://pubmed.ncbi.nlm.nih.gov/34333695/
- Recurrence of acute myocarditis temporally associated with receipt of coronavirus mRNA disease vaccine 2019 (COVID-19) in a male adolescent: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216855/
- Myocarditis after SARS-CoV-2 vaccination: a vaccine-induced reaction?: https://pubmed.ncbi.nlm.nih.gov/34118375/
- Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34180390/
- Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report: https://pubmed.ncbi.nlm.nih.gov/34133825/
- Biopsy-proven lymphocytic myocarditis after first COVID-19 mRNA vaccination in a 40-year-old man: case report: https://pubmed.ncbi.nlm.nih.gov/34487236/
- Insights from a murine model of COVID-19 mRNA vaccine-induced myopericarditis: could accidental intravenous injection of a vaccine induce myopericarditis https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab741/6359059
- Unusual presentation of acute perimyocarditis after modern SARS-COV-2 mRNA-1237 vaccination: https://pubmed.ncbi.nlm.nih.gov/34447639/
- Perimyocarditis after the first dose of mRNA-1273 SARS-CoV-2 (Modern) mRNA-1273 vaccine in a young healthy male: case report: https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-021-02183
- Acute myocarditis after the second dose of SARS-CoV-2 vaccine: serendipity or causal relationship: https://pubmed.ncbi.nlm.nih.gov/34236331/
- Rhabdomyolysis and fasciitis induced by the COVID-19 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34435250/
- COVID-19 vaccine-induced rhabdomyolysis: case report with literature review: https://pubmed.ncbi.nlm.nih.gov/34186348/.
- GM1 ganglioside antibody and COVID-19-related Guillain Barre syndrome: case report, systemic review, and implications for vaccine development: https://www.sciencedirect.com/science/article/pii/S2666354621000065
- Guillain-Barré syndrome after AstraZeneca COVID-19 vaccination: causal or casual association: https://www.sciencedirect.com/science/article/pii/S0303846721004169
- Sensory Guillain-Barré syndrome after ChAdOx1 nCov-19 vaccine: report of two cases and review of the literature: https://www.sciencedirect.com/science/article/pii/S0165572821002186
- Guillain-Barré syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association: https://www.sciencedirect.com/science/article/pii/S2214250921000998.
- Guillain-Barré syndrome presenting as facial diplegia after vaccination with COVID-19: a case report: https://www.sciencedirect.com/science/article/pii/S0736467921006442
- Guillain-Barré syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first report: https://www.sciencedirect.com/science/article/pii/S0035378721005853.
- SARS-CoV-2 vaccines are not safe for those with Guillain-Barre syndrome following vaccination: https://www.sciencedirect.com/science/article/pii/S2049080121005343
- Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: a case report: https://www.sciencedirect.com/science/article/pii/S2049080121007536
- Facial nerve palsy following administration of COVID-19 mRNA vaccines: analysis of self-report database: https://www.sciencedirect.com/science/article/pii/S1201971221007049
- Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence: https://www.sciencedirect.com/science/article/pii/S0899707121003557.
- New-onset refractory status epilepticus after ChAdOx1 nCoV-19 vaccination: https://www.sciencedirect.com/science/article/pii/S0165572821001569
- Acute myelitis and ChAdOx1 nCoV-19 vaccine: coincidental or causal association: https://www.sciencedirect.com/science/article/pii/S0165572821002137
- Bell’s palsy and SARS-CoV-2 vaccines: an unfolding story: https://www.sciencedirect.com/science/article/pii/S1473309921002735
- Bell’s palsy after the second dose of the Pfizer COVID-19 vaccine in a patient with a history of recurrent Bell’s palsy: https://www.sciencedirect.com/science/article/pii/S266635462100020X
- Acute-onset central serous retinopathy after immunization with COVID-19 mRNA vaccine:. https://www.sciencedirect.com/science/article/pii/S2451993621001456.
- Bell’s palsy after COVID-19 vaccination: case report: https://www.sciencedirect.com/science/article/pii/S217358082100122X.
- An academic hospital experience assessing the risk of COVID-19 mRNA vaccine using patient’s allergy history: https://www.sciencedirect.com/science/article/pii/S2213219821007972
- COVID-19 vaccine-induced axillary and pectoral lymphadenopathy in PET: https://www.sciencedirect.com/science/article/pii/S1930043321002612
- ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine: https://www.sciencedirect.com/science/article/pii/S0272638621007423
- Late cutaneous reactions after administration of COVID-19 mRNA vaccines: https://www.sciencedirect.com/science/article/pii/S2213219821007996
- COVID-19 vaccine-induced rhabdomyolysis: case report with review of the literature: https://www.sciencedirect.com/science/article/pii/S1871402121001880
- Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-REPP: a registry-based study: https://www.sciencedirect.com/science/article/pii/S0190962221024427
- Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines:. https://www.sciencedirect.com/science/article/abs/pii/S0735675721004381.
- COVID-19 vaccine-associated anaphylaxis: a statement from the Anaphylaxis Committee of the World Allergy Organization:. https://www.sciencedirect.com/science/article/pii/S1939455121000119.
- Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in an elderly, non-comorbid Indian male treated with conventional heparin-warfarin-based anticoagulation:. https://www.sciencedirect.com/science/article/pii/S1871402121002046.
- Acute myocarditis after administration of BNT162b2 vaccine against COVID-19:. https://www.sciencedirect.com/science/article/abs/pii/S188558572100133X
- Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccine: an analysis of European data:. https://www.sciencedirect.com/science/article/pii/S0896841121000937.
- immune thrombocytopenia associated with Pfizer-BioNTech’s COVID-19 BNT162b2 mRNA vaccine:. https://www.sciencedirect.com/science/article/pii/S2214250921002018.
- Bullous drug eruption after the second dose of COVID-19 mRNA-1273 (Moderna) vaccine: Case report: https://www.sciencedirect.com/science/article/pii/S1876034121001878.
- COVID-19 RNA-based vaccines and the risk of prion disease: https://scivisionpub.com/pdfs/covid19rna-based-vaccines-and-the-risk-of-prion-dis ease-1503.pdf
- This study notes that 115 pregnant women lost their babies, out of 827 who participated in a study on the safety of covid-19 vaccines: https://www.nejm.org/doi/full/10.1056/NEJMoa2104983.
- Process-related impurities in the ChAdOx1 nCov-19 vaccine: https://www.researchsquare.com/article/rs-477964/v1
- COVID-19 mRNA vaccine causing CNS inflammation: a case series: https://link.springer.com/article/10.1007/s00415-021-10780-7
- Allergic reactions, including anaphylaxis, after receiving the first dose of the Pfizer-BioNTech COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33475702/
- Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol: https://pubmed.ncbi.nlm.nih.gov/33320974/
- Pfizer Vaccine Raises Allergy Concerns: https://pubmed.ncbi.nlm.nih.gov/33384356/
- Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14-23, 2020: https://pubmed.ncbi.nlm.nih.gov/33444297/
- Allergic reactions, including anaphylaxis, after receiving first dose of Modern COVID-19 vaccine – United States, December 21, 2020-January 10, 2021: https://pubmed.ncbi.nlm.nih.gov/33507892/
- Reports of anaphylaxis after coronavirus disease vaccination 2019, South Korea, February 26-April 30, 2021: https://pubmed.ncbi.nlm.nih.gov/34414880/
- Reports of anaphylaxis after receiving COVID-19 mRNA vaccines in the U.S.-Dec 14, 2020-Jan 18, 2021: https://pubmed.ncbi.nlm.nih.gov/33576785/
- Immunization practices and risk of anaphylaxis: a current, comprehensive update of COVID-19 vaccination data: https://pubmed.ncbi.nlm.nih.gov/34269740/
- Relationship between pre-existing allergies and anaphylactic reactions following administration of COVID-19 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34215453/
- Anaphylaxis Associated with COVID-19 mRNA Vaccines: Approach to Allergy Research: https://pubmed.ncbi.nlm.nih.gov/33932618/
- Severe Allergic Reactions after COVID-19 Vaccination with the Pfizer / BioNTech Vaccine in Great Britain and the USA: Position Statement of the German Allergy Societies: German Medical Association of Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA): https://pubmed.ncbi.nlm.nih.gov/33643776/
- Allergic reactions and anaphylaxis to LNP-based COVID-19 vaccines: https://pubmed.ncbi.nlm.nih.gov/33571463/
- Reported orofacial adverse effects from COVID-19 vaccines: the known and the unknown: https://pubmed.ncbi.nlm.nih.gov/33527524/
- Cutaneous adverse effects of available COVID-19 vaccines: https://pubmed.ncbi.nlm.nih.gov/34518015/
- Cumulative adverse event report of anaphylaxis following injections of COVID-19 mRNA vaccine (Pfizer-BioNTech) in Japan: the first month report: https://pubmed.ncbi.nlm.nih.gov/34347278/
- COVID-19 vaccines increase the risk of anaphylaxis: https://pubmed.ncbi.nlm.nih.gov/33685103/
- Biphasic anaphylaxis after exposure to the first dose of the Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34050949/
- Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation: https://pubmed.ncbi.nlm.nih.gov/33657648/
- Polyethylene glycol (PEG) is a cause of anaphylaxis to Pfizer / BioNTech mRNA COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33825239/
- Acute allergic reactions to COVID-19 mRNA vaccines: https://pubmed.ncbi.nlm.nih.gov/33683290/
- Polyethylene glycole allergy of the SARS CoV2 vaccine recipient: case report of a young adult recipient and management of future exposure to SARS-CoV2: https://pubmed.ncbi.nlm.nih.gov/33919151/
- Elevated rates of anaphylaxis after vaccination with Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers; a secondary analysis of initial post-approval safety data: https://pubmed.ncbi.nlm.nih.gov/34128049/
- Allergic reactions and adverse events associated with administration of mRNA-based vaccines. A health system experience: https://pubmed.ncbi.nlm.nih.gov/34474708/
- Allergic reactions to COVID-19 vaccines: statement of the Belgian Society of Allergy and Clinical Immunology (BelSACI): https://www.tandfonline.com/doi/abs/10.1080/17843286.2021.1909447
- .IgE-mediated allergy to polyethylene glycol (PEG) as a cause of anaphylaxis to COVID-19 mRNA vaccines: https://pubmed.ncbi.nlm.nih.gov/34318537/
- Allergic reactions after COVID-19 vaccination: putting the risk in perspective: https://pubmed.ncbi.nlm.nih.gov/34463751/
- Anaphylactic reactions to COVID-19 mRNA vaccines: a call for further studies: https://pubmed.ncbi.nlm.nih.gov/33846043/ 188.
- Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin disease: practical recommendations. An ETFAD position statement with external experts: https://pubmed.ncbi.nlm.nih.gov/33752263/
- COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis: https://pubmed.ncbi.nlm.nih.gov/34073536/
- Fatal brain hemorrhage after COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33928772/
- A case series of skin reactions to COVID-19 vaccine in the Department of Dermatology at Loma Linda University: https://pubmed.ncbi.nlm.nih.gov/34423106/
- Skin reactions reported after Moderna and Pfizer’s COVID-19 vaccination: a study based on a registry of 414 cases: https://pubmed.ncbi.nlm.nih.gov/33838206/
- Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-REPP: a registry-based study: https://pubmed.ncbi.nlm.nih.gov/34517079/
- Skin reactions after vaccination against SARS-COV-2: a nationwide Spanish cross-sectional study of 405 cases: https://pubmed.ncbi.nlm.nih.gov/34254291/
- Varicella zoster virus and herpes simplex virus reactivation after vaccination with COVID-19: review of 40 cases in an international dermatologic registry: https://pubmed.ncbi.nlm.nih.gov/34487581/
- Immune thrombosis and thrombocytopenia (VITT) associated with the COVID-19 vaccine: diagnostic and therapeutic recommendations for a new syndrome: https://pubmed.ncbi.nlm.nih.gov/33987882/
- Laboratory testing for suspicion of COVID-19 vaccine-induced thrombotic (immune) thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34138513/
- Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: the first fatal case in Korea: https://pubmed.ncbi.nlm.nih.gov/34402235/
- Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study: https://pubmed.ncbi.nlm.nih.gov/34446426/
- Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after covid-19 vaccination; a systematic review: https://pubmed.ncbi.nlm.nih.gov/34365148/.
- Nerve and muscle adverse events after vaccination with COVID-19: a systematic review and meta-analysis of clinical trials: https://pubmed.ncbi.nlm.nih.gov/34452064/.
- A rare case of cerebral venous thrombosis and disseminated intravascular coagulation temporally associated with administration of COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33917902/
- Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia induced by Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine (VITT): https://pubmed.ncbi.nlm.nih.gov/34256983/
- Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34247246/.
- Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after administration of AstraZeneca COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34132839/
- 59-year-old woman with extensive deep venous thrombosis and pulmonary thromboembolism 7 days after a first dose of Pfizer-BioNTech BNT162b2 mRNA vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34117206/
- Cerebral venous thrombosis and vaccine-induced thrombocytopenia.a. Oxford-AstraZeneca COVID-19: a missed opportunity for a rapid return on experience: https://pubmed.ncbi.nlm.nih.gov/34033927/
- Myocarditis and other cardiovascular complications of mRNA-based COVID-19 vaccines: https://pubmed.ncbi.nlm.nih.gov/34277198/
- Pericarditis after administration of COVID-19 mRNA BNT162b2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34364831/
- Unusual presentation of acute pericarditis after vaccination against SARS-COV-2 mRNA-1237 Modern: https://pubmed.ncbi.nlm.nih.gov/34447639/
- Case report: acute myocarditis after second dose of SARS-CoV-2 mRNA-1273 vaccine mRNA-1273: https://pubmed.ncbi.nlm.nih.gov/34514306/
- Immune-mediated disease outbreaks or recent-onset disease in 27 subjects after mRNA/DNA vaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/33946748/
- Insights from a murine model of myopericarditis induced by COVID-19 mRNA vaccine: could accidental intravenous injection of a vaccine induce myopericarditis: https://pubmed.ncbi.nlm.nih.gov/34453510/
- Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33476455/
- propylthiouracil-induced neutrophil anti-cytoplasmic antibody-associated vasculitis after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34451967/
- Secondary immune thrombocytopenia (ITP) associated with ChAdOx1 Covid-19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34377889/
- Thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination: risk-benefit analysis for persons <60 years in Australia: https://pubmed.ncbi.nlm.nih.gov/34272095/
- COVID-19 vaccination association and facial nerve palsy: A case-control study: https://pubmed.ncbi.nlm.nih.gov/34165512/
- The association between COVID-19 vaccination and Bell’s palsy: https://pubmed.ncbi.nlm.nih.gov/34411533/
- Bell’s palsy after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33611630/
- Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 vaccine (AZD1222): https://pubmed.ncbi.nlm.nih.gov/33981305/
- Bell’s palsy after 24 hours of mRNA-1273 SARS-CoV-2 mRNA-1273 vaccine: https://pubmed.ncbi.nlm.nih.gov/34336436/
- Sequential contralateral facial nerve palsy after first and second doses of COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34281950/.
- Transverse myelitis induced by SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34458035/
- Peripheral facial nerve palsy after vaccination with BNT162b2 (COVID-19): https://pubmed.ncbi.nlm.nih.gov/33734623/
- Acute abducens nerve palsy after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34044114/.
- Facial nerve palsy after administration of COVID-19 mRNA vaccines: analysis of self-report database: https://pubmed.ncbi.nlm.nih.gov/34492394/
- Transient oculomotor paralysis after administration of RNA-1273 messenger vaccine for SARS-CoV-2 diplopia after COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34369471/
- Bell’s palsy after Ad26.COV2.S COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34014316/
- Bell’s palsy after COVID-19 vaccination: case report: https://pubmed.ncbi.nlm.nih.gov/34330676/
- A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy following ChAdOx1 nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34272622/
- Guillian Barré syndrome after vaccination with mRNA-1273 against COVID-19: https://pubmed.ncbi.nlm.nih.gov/34477091/
- Acute facial paralysis as a possible complication of SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/33975372/.
- Bell’s palsy after COVID-19 vaccination with high antibody response in CSF: https://pubmed.ncbi.nlm.nih.gov/34322761/.
- Parsonage-Turner syndrome associated with SARS-CoV-2 or SARS-CoV-2 vaccination. Comment on: “Neuralgic amyotrophy and COVID-19 infection: 2 cases of accessory spinal nerve palsy” by Coll et al. Articular Spine 2021; 88: 10519: https://pubmed.ncbi.nlm.nih.gov/34139321/.
- Bell’s palsy after a single dose of vaccine mRNA. SARS-CoV-2: case report: https://pubmed.ncbi.nlm.nih.gov/34032902/.
- Autoimmune hepatitis developing after coronavirus disease vaccine 2019 (COVID-19): causality or victim?: https://pubmed.ncbi.nlm.nih.gov/33862041/
- Autoimmune hepatitis triggered by vaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/34332438/
- Acute autoimmune-like hepatitis with atypical antimitochondrial antibody after vaccination with COVID-19 mRNA: a new clinical entity: https://pubmed.ncbi.nlm.nih.gov/34293683/.
- Autoimmune hepatitis after COVID vaccine: https://pubmed.ncbi.nlm.nih.gov/34225251/
- A novel case of bifacial diplegia variant of Guillain-Barré syndrome after vaccination with Janssen COVID-19: https://pubmed.ncbi.nlm.nih.gov/34449715/
- Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines: https://pubmed.ncbi.nlm.nih.gov/34139631/.
- Bilateral superior ophthalmic vein thrombosis, ischemic stroke and immune thrombocytopenia after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/33864750/
- Diagnosis and treatment of cerebral venous sinus thrombosis with vaccine-induced immune-immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/33914590/
- Venous sinus thrombosis after vaccination with ChAdOx1 nCov-19: https://pubmed.ncbi.nlm.nih.gov/34420802/
- Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency: https://pubmed.ncbi.nlm.nih.gov/34293217/
- Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study: https://pubmed.ncbi.nlm.nih.gov/34446426/
- Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an analysis of European data: https://pubmed.ncbi.nlm.nih.gov/34174723/
- Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study: https://pubmed.ncbi.nlm.nih.gov/33952445/
- First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland: https://pubmed.ncbi.nlm.nih.gov/34108714/
- Cerebral venous thrombosis associated with COVID-19 vaccine in Germany: https://pubmed.ncbi.nlm.nih.gov/34288044/
- Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34341358/
- celiac artery and splenic artery thrombosis complicated by splenic infarction 7 days after the first dose of Oxford vaccine, causal relationship or coincidence: https://pubmed.ncbi.nlm.nih.gov/34261633/.
- Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 (VITT) vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34256983/
- Thrombocytopenia after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34332437/.
- Cerebral venous sinus thrombosis associated with thrombocytopenia after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33845870/.
- Thrombosis with thrombocytopenia syndrome after COVID-19 immunization: https://pubmed.ncbi.nlm.nih.gov/34236343/
- Acute myocardial infarction within 24 hours after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34364657/.
- Bilateral acute macular neuroretinopathy after SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34287612/
- central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental: https://pubmed.ncbi.nlm.nih.gov/34478433/
- Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: the first fatal case in Korea: https://pubmed.ncbi.nlm.nih.gov/34402235/
- Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin-based anticoagulation: https://pubmed.ncbi.nlm.nih.gov/34186376/
- Cerebral venous sinus thrombosis 2 weeks after first dose of SARS-CoV-2 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34101024/
- A case of multiple thrombocytopenia and thrombosis following vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/34137813/
- Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines: https://pubmed.ncbi.nlm.nih.gov/34191218/
- Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy: https://pubmed.ncbi.nlm.nih.gov/34175640/
- New-onset refractory status epilepticus after ChAdOx1 nCoV-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34153802/
- Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector vaccines: https://pubmed.ncbi.nlm.nih.gov/34092488/
- Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34261635/
- Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after administration of the AstraZeneca COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34132839/.
- Spontaneous HIT syndrome: knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34144250/
- Deep venous thrombosis (DVT) occurring shortly after second dose of SARS-CoV-2 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/33687691/
- Procoagulant antibody-mediated procoagulant platelets in immune thrombotic thrombocytopenia associated with SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34011137/.
- Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with high mortality rate: a case series: https://pubmed.ncbi.nlm.nih.gov/34393988/.
- Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis: https://pubmed.ncbi.nlm.nih.gov/34129181/.
- Atypical thrombosis associated with the vaccine VaxZevria® (AstraZeneca): data from the French network of regional pharmacovigilance centers: https://pubmed.ncbi.nlm.nih.gov/34083026/.
- Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34247246/.
- Vaccine-induced thrombosis and thrombocytopenia with bilateral adrenal haemorrhage: https://pubmed.ncbi.nlm.nih.gov/34235757/.
- Palmar digital vein thrombosis after Oxford-AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34473841/.
- Cutaneous thrombosis associated with cutaneous necrosis following Oxford-AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34189756/
- Cerebral venous thrombosis following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34045111/.
- Lipschütz ulcers after AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34366434/.
- Amyotrophic Neuralgia secondary to Vaxzevri vaccine (AstraZeneca) COVID-19: https://pubmed.ncbi.nlm.nih.gov/34330677/
- Thrombosis with thrombocytopenia after Messenger vaccine RNA-1273: https://pubmed.ncbi.nlm.nih.gov/34181446/
- Intracerebral hemorrhage twelve days after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34477089/
- Thrombotic thrombocytopenia after vaccination with COVID-19: in search of the underlying mechanism: https://pubmed.ncbi.nlm.nih.gov/34071883/
- Coronavirus (COVID-19) Vaccine-induced immune thrombotic thrombocytopenia (VITT): https://pubmed.ncbi.nlm.nih.gov/34033367/
- Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis in unusual sites: https://pubmed.ncbi.nlm.nih.gov/34375510/
- Immunoglobulin adjuvant for vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34107198/
- Severe vaccine-induced thrombotic thrombocytopenia following vaccination with COVID-19: an autopsy case report and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34355379/.
- A case of acute pulmonary embolism after immunization with SARS-CoV-2 mRNA: https://pubmed.ncbi.nlm.nih.gov/34452028/
- Neurosurgical considerations regarding decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic thrombocytopenia-VITT: https://pubmed.ncbi.nlm.nih.gov/34202817/
- Thrombosis and SARS-CoV-2 vaccines: vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34237213/.
- Acquired thrombotic thrombocytopenic thrombocytopenic purpura: a rare disease associated with the BNT162b2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34105247/.
- Immune complexes, innate immunity and NETosis in ChAdOx1 vaccine-induced thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34405870/.
- Sensory Guillain-Barré syndrome following ChAdOx1 nCov-19 vaccine: report of two cases and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34416410/.
- Vogt-Koyanagi-Harada syndrome after COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccination: https://pubmed.ncbi.nlm.nih.gov/34462013/.
- Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, after anti-SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34224024/.
- Post-vaccinal encephalitis after ChAdOx1 nCov-19: https://pubmed.ncbi.nlm.nih.gov/34324214/
- Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence?: https://pubmed.ncbi.nlm.nih.gov/34507266/
- Fatal systemic capillary leak syndrome after SARS-COV-2 vaccination in a patient with multiple myeloma: https://pubmed.ncbi.nlm.nih.gov/34459725/
- Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-19: https://pubmed.ncbi.nlm.nih.gov/34463066/
- Three cases of subacute thyroiditis after SARS-CoV-2 vaccination: post-vaccination ASIA syndrome: https://pubmed.ncbi.nlm.nih.gov/34043800/.
- Facial diplegia: a rare and atypical variant of Guillain-Barré syndrome and the Ad26.COV2.S vaccine: https://pubmed.ncbi.nlm.nih.gov/34447646/
- Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study: https://pubmed.ncbi.nlm.nih.gov/34479760/.
- fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 COVID-19 mRNA vaccination in two patients: https://pubmed.ncbi.nlm.nih.gov/34416319/.
- Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, centered on cerebral venous sinus thrombosis (CVST): https://pubmed.ncbi.nlm.nih.gov/34092166/
- Induction and exacerbation of subacute cutaneous lupus erythematosus erythematosus after mRNA- or adenoviral vector-based SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34291477/
- Petechiae and peeling of fingers after immunization with BTN162b2 messenger RNA (mRNA)-based COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34513435/
- Hepatitis C virus reactivation after COVID-19 vaccination: a case report: https://pubmed.ncbi.nlm.nih.gov/34512037/
- Bilateral immune-mediated keratolysis after immunization with SARS-CoV-2 recombinant viral vector vaccine: https://pubmed.ncbi.nlm.nih.gov/34483273/.
- Immune-mediated thrombocytopenic purpura after Pfizer-BioNTech COVID-19 vaccine in an elderly woman: https://pubmed.ncbi.nlm.nih.gov/34513446/
- Platelet activation and modulation in thrombosis with thrombocytopenia syndrome associated with the ChAdO × 1 nCov-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34474550/
- Reactive arthritis after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34033732/.
- Two cases of Graves’ disease after SARS-CoV-2 vaccination: an autoimmune / inflammatory syndrome induced by adjuvants: https://pubmed.ncbi.nlm.nih.gov/33858208/
- Acute relapse and impaired immunization after COVID-19 vaccination in a patient with multiple sclerosis treated with rituximab: https://pubmed.ncbi.nlm.nih.gov/34015240/
- Widespread fixed bullous drug eruption after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34482558/
- COVID-19 mRNA vaccine causing CNS inflammation: a case series: https://pubmed.ncbi.nlm.nih.gov/34480607/
- Thymic hyperplasia after Covid-19 mRNA-based vaccination with Covid-19: https://pubmed.ncbi.nlm.nih.gov/34462647/
- Acute disseminated encephalomyelitis following vaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/34325334/
- Tolosa-Hunt syndrome occurring after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34513398/
- Systemic capillary extravasation syndrome following vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34362727/
- Immune-mediated thrombocytopenia associated with Ad26.COV2.S vaccine (Janssen; Johnson & Johnson): https://pubmed.ncbi.nlm.nih.gov/34469919/.
- Transient thrombocytopenia with glycoprotein-specific platelet autoantibodies after vaccination with Ad26.COV2.S: case report: https://pubmed.ncbi.nlm.nih.gov/34516272/.
- Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: case report: https://pubmed.ncbi.nlm.nih.gov/34512961/
- Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34077949/
- Autoimmune hepatitis developing after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34171435/
- Severe relapse of multiple sclerosis after COVID-19 vaccination: a case report: https://pubmed.ncbi.nlm.nih.gov/34447349/
- Lymphohistocytic myocarditis after vaccination with the COVID-19 viral vector Ad26.COV2.S: https://pubmed.ncbi.nlm.nih.gov/34514078/
- Hemophagocytic lymphohistiocytosis after vaccination with ChAdOx1 nCov-19: https://pubmed.ncbi.nlm.nih.gov/34406660/.
- IgA vasculitis in adult patient after vaccination with ChadOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34509658/
- A case of leukocytoclastic vasculitis after vaccination with a SARS-CoV2 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34196469/.
- Onset / outbreak of psoriasis after Corona virus ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca / Covishield): report of two cases: https://pubmed.ncbi.nlm.nih.gov/34350668/
- Hailey-Hailey disease exacerbation after SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34436620/
- Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: https://pubmed.ncbi.nlm.nih.gov/34116295/.
- COVID-19 vaccine, immune thrombotic thrombocytopenia, jaundice, hyperviscosity: concern in cases with underlying hepatic problems: https://pubmed.ncbi.nlm.nih.gov/34509271/.
- Report of the International Cerebral Venous Thrombosis Consortium on cerebral venous thrombosis after SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34462996/
- Immune thrombocytopenia after vaccination during the COVID-19 pandemic: https://pubmed.ncbi.nlm.nih.gov/34435486/
- COVID-19: lessons from the Norwegian tragedy should be taken into account in planning for vaccine launch in less developed/developing countries: https://pubmed.ncbi.nlm.nih.gov/34435142/
- Rituximab-induced acute lympholysis and pancytopenia following vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34429981/
- Exacerbation of plaque psoriasis after COVID-19 inactivated mRNA and BNT162b2 vaccines: report of two cases: https://pubmed.ncbi.nlm.nih.gov/34427024/
- Vaccine-induced interstitial lung disease: a rare reaction to COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34510014/.
- Vesiculobullous cutaneous reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34236711/
- Vaccine-induced thrombocytopenia with severe headache: https://pubmed.ncbi.nlm.nih.gov/34525282/
- Acute perimyocarditis after the first dose of COVID-19 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34515024/
- Rhabdomyolysis and fasciitis induced by COVID-19 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34435250/.
- Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34363637/
- Immune thrombocytopenia associated with the Pfizer-BioNTech COVID-19 mRNA vaccine BNT162b2: https://www.sciencedirect.com/science/article/pii/S2214250921002018
- Secondary immune thrombocytopenia putatively attributable to COVID-19 vaccination: https://casereports.bmj.com/content/14/5/e242220.abstract.
- Immune thrombocytopenia following Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34155844/
- Newly diagnosed idiopathic thrombocytopenia after COVID-19 vaccine administration: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176657/.
- Idiopathic thrombocytopenic purpura and the Modern Covid-19 vaccine: https://www.annemergmed.com/article/S0196-0644(21)00122-0/fulltext.
- Thrombocytopenia after Pfizer and Moderna SARS vaccination – CoV -2: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014568/.
- Immune thrombocytopenic purpura and acute liver injury after COVID-19 vaccination: https://casereports.bmj.com/content/14/7/e242678.
- Collection of complement-mediated and autoimmune-mediated hematologic conditions after SARS-CoV-2 vaccination: https://ashpublications.org/bloodadvances/article/5/13/2794/476324/Autoimmune-and-complement-mediated-hematologic
- Petechial rash associated with CoronaVac vaccination: first report of cutaneous side effects before phase 3 results: https://ejhp.bmj.com/content/early/2021/05/23/ejhpharm-2021-002794
- COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria: https://ashpublications.org/blood/article/137/26/3670/475905/COVID-19-vaccines-induce-severe-hemolysis-in
- Cerebral venous thrombosis associated with COVID-19 vaccine in Germany: https://pubmed.ncbi.nlm.nih.gov/34288044/.
- Cerebral venous sinus thrombosis after COVID-19 vaccination : Neurological and radiological management: https://pubmed.ncbi.nlm.nih.gov/34327553/.
- Cerebral venous thrombosis and thrombocytopenia after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33878469/.
- Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom: https://pubmed.ncbi.nlm.nih.gov/33857630/.
- Cerebral venous thrombosis induced by SARS-CoV-2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34090750/.
- Carotid artery immune thrombosis induced by adenovirus-vectored COVID-19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34312301/.
- Cerebral venous sinus thrombosis associated with vaccine-induced thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34333995/
- The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune-immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34455073/
- Cerebral venous thrombosis after the BNT162b2 mRNA SARS-CoV-2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34111775/.
- Cerebral venous thrombosis after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34045111/
- Lethal cerebral venous sinus thrombosis after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33983464/
- Cerebral venous sinus thrombosis in the U.S. population, After SARS-CoV-2 vaccination with adenovirus and after COVID-19: https://pubmed.ncbi.nlm.nih.gov/34116145/
- Cerebral venous thrombosis after COVID-19 vaccination: is the risk of thrombosis increased by intravascular administration of the vaccine: https://pubmed.ncbi.nlm.nih.gov/34286453/.
- Central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental: https://pubmed.ncbi.nlm.nih.gov/34478433/
- Cerebral venous sinus thrombosis after ChAdOx1 nCov-19 vaccination with a misleading first brain MRI: https://pubmed.ncbi.nlm.nih.gov/34244448/
- Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with Ad26.COV2.S: https://pubmed.ncbi.nlm.nih.gov/34226070/
- Cerebral venous sinus thrombosis associated with post-vaccination thrombocytopenia by COVID-19: https://pubmed.ncbi.nlm.nih.gov/33845870/.
- Cerebral venous sinus thrombosis 2 weeks after the first dose of SARS-CoV-2 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34101024/.
- Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with a high mortality rate: a case series: https://pubmed.ncbi.nlm.nih.gov/34393988/.
- Adenovirus interactions with platelets and coagulation and vaccine-associated autoimmune thrombocytopenia thrombosis syndrome: https://pubmed.ncbi.nlm.nih.gov/34407607/.
- Headache attributed to COVID-19 (SARS-CoV-2 coronavirus) vaccination with the ChAdOx1 nCoV-19 (AZD1222) vaccine: a multicenter observational cohort study: https://pubmed.ncbi.nlm.nih.gov/34313952/
- Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, focus on cerebral venous sinus thrombosis (CVST): https://pubmed.ncbi.nlm.nih.gov/34092166/
- Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency: https://pubmed.ncbi.nlm.nih.gov/34293217/
- A rare case of a middle-age Asian male with cerebral venous thrombosis after COVID-19 AstraZeneca vaccination: https://pubmed.ncbi.nlm.nih.gov/34274191/
- Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin-based anticoagulation: https://pubmed.ncbi.nlm.nih.gov/34186376/
- Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study: https://pubmed.ncbi.nlm.nih.gov/33952445/
- Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis: https://pubmed.ncbi.nlm.nih.gov/34129181/
- S. case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with Ad26.COV2.S, March 2-April 21, 2021: https://pubmed.ncbi.nlm.nih.gov/33929487/.
- Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34341358/
- Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy: https://pubmed.ncbi.nlm.nih.gov/34175640/
- Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations: https://pubmed.ncbi.nlm.nih.gov/34159588/.
- Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34402666/
- Autoimmunity roots of thrombotic events after vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34508917/
- Cerebral venous sinus thrombosis after vaccination: the UK experience: https://pubmed.ncbi.nlm.nih.gov/34370974/
- Massive cerebral venous thrombosis and venous basin infarction as late complications of COVID-19: a case report: https://pubmed.ncbi.nlm.nih.gov/34373991/
- Australian and New Zealand approach to the diagnosis and treatment of vaccine-induced immune thrombosis and immune thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34490632/
- An observational study to identify the prevalence of thrombocytopenia and anti-PF4 / polyanion antibodies in Norwegian health care workers after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33909350/
- Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 (AZD1222) vaccine: https://pubmed.ncbi.nlm.nih.gov/33981305/.
- A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine:. https://pubmed.ncbi.nlm.nih.gov/34272622/
- Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine:. https://pubmed.ncbi.nlm.nih.gov/33877737/
- Predicted and observed incidence of thromboembolic events among Koreans vaccinated with the ChAdOx1 nCoV-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34254476/
- First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic, and hemorrhagic events in Scotland: https://pubmed.ncbi.nlm.nih.gov/34108714/
- ChAdOx1 nCoV-19 vaccine-associated thrombocytopenia: three cases of immune thrombocytopenia after 107,720 doses of ChAdOx1 vaccination in Thailand: https://pubmed.ncbi.nlm.nih.gov/34483267/.
- Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34261635/
- Neurosurgical considerations with respect to decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic thrombocytopenia-VITT: https://pubmed.ncbi.nlm.nih.gov/34202817/
- Large hemorrhagic stroke after vaccination against ChAdOx1 nCoV-19: a case report: https://pubmed.ncbi.nlm.nih.gov/34273119/
- Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-19: https://pubmed.ncbi.nlm.nih.gov/34463066/
- A rare case of thrombosis and thrombocytopenia of the superior ophthalmic vein after ChAdOx1 nCoV-19 vaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/34276917/
- Thrombosis and severe acute respiratory syndrome Coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34237213/.
- Renal vein thrombosis and pulmonary embolism secondary to vaccine-induced thrombotic immune thrombocytopenia (VITT): https://pubmed.ncbi.nlm.nih.gov/34268278/.
- Limb ischemia and pulmonary artery thrombosis after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): a case of vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/33990339/.
- Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study: https://pubmed.ncbi.nlm.nih.gov/34479760/.
- Secondary thrombocytopenia after SARS-CoV-2 vaccination: case report of haemorrhage and hematoma after minor oral surgery: https://pubmed.ncbi.nlm.nih.gov/34314875/.
- Venous thromboembolism and mild thrombocytopenia after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34384129/
- Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after successful initial therapy with intravenous immunoglobulins: a rationale for monitoring immunoglobulin G levels: https://pubmed.ncbi.nlm.nih.gov/34382387/
- A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?: https://pubmed.ncbi.nlm.nih.gov/34416184/.
- Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman: https://pubmed.ncbi.nlm.nih.gov/34261297/
- Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34261296/
- Nephrotic syndrome after ChAdOx1 nCoV-19 vaccine against SARScoV-2: https://pubmed.ncbi.nlm.nih.gov/34250318/.
- A case of vaccine-induced immune-immune thrombotic thrombocytopenia with massive arteriovenous thrombosis: https://pubmed.ncbi.nlm.nih.gov/34059191/
- Cutaneous thrombosis associated with cutaneous necrosis following Oxford-AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34189756/
- Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34331506/
- Vaccine-induced thrombocytopenia with severe headache: https://pubmed.ncbi.nlm.nih.gov/34525282/
- Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17 years: stratified analysis of a national database: https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1
- COVID-19 mRNA vaccination and development of CMR-confirmed myopericarditis: https://www.medrxiv.org/content/10.1101/2021.09.13.21262182v1.full?s=09.
- Severe autoimmune hemolytic anemia after receipt of SARS-CoV-2 mRNA vaccine: https://onlinelibrary.wiley.com/doi/10.1111/trf.16672
- Intravenous injection of coronavirus disease 2019 (COVID-19) mRNA vaccine can induce acute myopericarditis in a mouse model: https://t.co/j0IEM8cMXI
- A report of myocarditis adverse events in the U.S. Vaccine Adverse Event Reporting System. (VAERS) in association with COVID-19 injectable biologics: https://pubmed.ncbi.nlm.nih.gov/34601006/
- This study concludes that: “The vaccine was associated with an excess risk of myocarditis (1 to 5 events per 100,000 persons). The risk of this potentially serious adverse event and of many other serious adverse events increased substantially after SARS-CoV-2 infection”: https://www.nejm.org/doi/full/10.1056/NEJMoa2110475
- Bilateral uveitis after inoculation with COVID-19 vaccine: a case report: https://www.sciencedirect.com/science/article/pii/S1201971221007797
- Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17 years: stratified analysis of a national database: https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1.
- Immune-mediated hepatitis with the Moderna vaccine is no longer a coincidence but confirmed: https://www.sciencedirect.com/science/article/pii/S0168827821020936
- Extensive investigations revealed consistent pathophysiologic alterations after vaccination with COVID-19 vaccines: https://www.nature.com/articles/s41421-021-00329-3
- Lobar hemorrhage with ventricular rupture shortly after the first dose of an mRNA-based SARS-CoV-2 vaccine: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8553377/
- Mrna COVID vaccines dramatically increase endothelial inflammatory markers and risk of Acute Coronary Syndrome as measured by PULS cardiac testing: a caution: https://www.ahajournals.org/doi/10.1161/circ.144.suppl_1.10712
- ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome:https://www.science.org/doi/10.1126/sciadv.abl8213
- Lethal vaccine-induced immune thrombotic immune thrombocytopenia (VITT) following announcement 26.COV2.S: first documented case outside the U.S.: https://pubmed.ncbi.nlm.nih.gov/34626338/
- A prothrombotic thrombocytopenic disorder resembling heparin-induced thrombocytopenia after coronavirus-19 vaccination: https://europepmc.org/article/PPR/PPR304469 435.
- VITT (vaccine-induced immune thrombotic thrombocytopenia) after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34731555/
- Vaccine-induced immune thrombotic thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations: https://pubmed.ncbi.nlm.nih.gov/34159588/
- Treatment of acute ischemic stroke associated with ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34461442/
- Spectrum of neurological complications after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34719776/.
- Cerebral venous sinus thrombosis after vaccination: the UK experience: https://pubmed.ncbi.nlm.nih.gov/34370974/
- Cerebral venous vein/venous sinus thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34373413/
- Portal vein thrombosis due to vaccine-induced immune thrombotic immune thrombocytopenia (VITT) after Covid vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34598301/
- Hematuria, a generalized petechial rash and headaches after Oxford AstraZeneca ChAdOx1 nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34620638/
- Myocardial infarction and azygos vein thrombosis after vaccination with ChAdOx1 nCoV-19 in a hemodialysis patient: https://pubmed.ncbi.nlm.nih.gov/34650896/
- Takotsubo (stress) cardiomyopathy after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34625447/
- Humoral response induced by Prime-Boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines in a patient with multiple sclerosis treated with teriflunomide: https://pubmed.ncbi.nlm.nih.gov/34696248/
- Guillain-Barré syndrome after ChAdOx1 nCoV-19 COVID-19 vaccination: a case series: https://pubmed.ncbi.nlm.nih.gov/34548920/
- Refractory vaccine-induced immune thrombotic thrombocytopenia (VITT) treated with delayed therapeutic plasma exchange (TPE): https://pubmed.ncbi.nlm.nih.gov/34672380/.
- Rare case of COVID-19 vaccine-associated intracranial hemorrhage with venous sinus thrombosis: https://pubmed.ncbi.nlm.nih.gov/34556531/.
- Delayed headache after COVID-19 vaccination: a warning sign for vaccine-induced cerebral venous thrombosis: https://pubmed.ncbi.nlm.nih.gov/34535076/.
- Clinical features of vaccine-induced thrombocytopenia and immune thrombosis: https://pubmed.ncbi.nlm.nih.gov/34379914/.
- Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score: https://pubmed.ncbi.nlm.nih.gov/34545400/
- Ischemic stroke as a presenting feature of immune thrombotic thrombocytopenia induced by ChAdOx1-nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34035134/
- In-hospital observational study of neurological disorders in patients recently vaccinated with COVID-19 mRNA vaccines: https://pubmed.ncbi.nlm.nih.gov/34688190/
- Endovascular treatment for vaccine-induced cerebral venous sinus thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19: report of three cases: https://pubmed.ncbi.nlm.nih.gov/34782400/
- Cardiovascular, neurological, and pulmonary events after vaccination with BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: an analysis of European data: https://pubmed.ncbi.nlm.nih.gov/34710832/
- Cerebral venous thrombosis developing after vaccination. COVID-19: VITT, VATT, TTS and more: https://pubmed.ncbi.nlm.nih.gov/34695859/
- Cerebral venous thrombosis and myeloproliferative neoplasms: a three-center study of 74 consecutive cases: https://pubmed.ncbi.nlm.nih.gov/34453762/.
- Possible triggers of thrombocytopenia and/or hemorrhage by BNT162b2 vaccine, Pfizer-BioNTech: https://pubmed.ncbi.nlm.nih.gov/34660652/.
- Multiple sites of arterial thrombosis in a 35-year-old patient after vaccination with ChAdOx1 (AstraZeneca), which required emergency femoral and carotid surgical thrombectomy: https://pubmed.ncbi.nlm.nih.gov/34644642/
- Case series of vaccine-induced thrombotic thrombocytopenia in a London teaching hospital: https://pubmed.ncbi.nlm.nih.gov/34694650/
- Neuro-ophthalmic complications with thrombocytopenia and thrombosis induced by ChAdOx1 nCoV-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34726934/
- Thrombotic events after COVID-19 vaccination in over 50 years of age: results of a population-based study in Italy: https://pubmed.ncbi.nlm.nih.gov/34835237/
- Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman: https://pubmed.ncbi.nlm.nih.gov/34261297/
- Age- and sex-specific incidence of cerebral venous sinus thrombosis associated with Ad26.COV2.S COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34724036/.
- Genital necrosis with cutaneous thrombosis following vaccination with COVID-19 mRNA: https://pubmed.ncbi.nlm.nih.gov/34839563/
- Cerebral venous sinus thrombosis after mRNA-based COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34783932/.
- COVID-19 vaccine-induced immune thrombosis with thrombocytopenia thrombosis (VITT) and shades of gray in thrombus formation: https://pubmed.ncbi.nlm.nih.gov/34624910/
- Inflammatory myositis after vaccination with ChAdOx1: https://pubmed.ncbi.nlm.nih.gov/34585145/
- Acute ST-segment elevation myocardial infarction secondary to vaccine-induced immune thrombosis with thrombocytopenia (VITT): https://pubmed.ncbi.nlm.nih.gov/34580132/.
- A rare case of COVID-19 vaccine-induced thrombotic thrombocytopenia (VITT) affecting the venosplanchnic and pulmonary arterial circulation from a UK district general hospital: https://pubmed.ncbi.nlm.nih.gov/34535492/
- COVID-19 vaccine-induced thrombotic thrombocytopenia: a case series: https://pubmed.ncbi.nlm.nih.gov/34527501/
- Thrombosis with thrombocytopenia syndrome (TTS) after vaccination with AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19: a risk-benefit analysis for persons <60% risk-benefit analysis for people <60 years in Australia: https://pubmed.ncbi.nlm.nih.gov/34272095/
- Immune thrombocytopenia after immunization with Vaxzevria ChadOx1-S vaccine (AstraZeneca), Victoria, Australia: https://pubmed.ncbi.nlm.nih.gov/34756770/
- Characteristics and outcomes of patients with cerebral venous sinus thrombosis in thrombotic immune thrombocytopenia induced by SARS-CoV-2 vaccine: https://jamanetwork.com/journals/jamaneurology/fullarticle/2784622
- Case study of thrombosis and thrombocytopenia syndrome after administration of the AstraZeneca COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34781321/
- Thrombosis with Thrombocytopenia Syndrome Associated with COVID-19 Vaccines: https://pubmed.ncbi.nlm.nih.gov/34062319/
- Cerebral venous sinus thrombosis following vaccination with ChAdOx1: the first case of definite thrombosis with thrombocytopenia syndrome in India: https://pubmed.ncbi.nlm.nih.gov/34706921/
- COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome (TTS): systematic review and post hoc analysis: https://pubmed.ncbi.nlm.nih.gov/34698582/.
- Case report of immune thrombocytopenia after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34751013/.
- Acute transverse myelitis after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34684047/.
- Concerns for adverse effects of thrombocytopenia and thrombosis after adenovirus-vectored COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34541935/
- Major hemorrhagic stroke after ChAdOx1 nCoV-19 vaccination: a case report: https://pubmed.ncbi.nlm.nih.gov/34273119/
- Cerebral venous sinus thrombosis after COVID-19 vaccination: neurologic and radiologic management: https://pubmed.ncbi.nlm.nih.gov/34327553/.
- Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33877737/
- Intracerebral hemorrhage and thrombocytopenia after AstraZeneca COVID-19 vaccine: clinical and diagnostic challenges of vaccine-induced thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34646685/
- Minimal change disease with severe acute kidney injury after Oxford-AstraZeneca COVID-19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34242687/.
- Case report: cerebral sinus vein thrombosis in two patients with AstraZeneca SARS-CoV-2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34609603/
- Case report: Pityriasis rosea-like rash after vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34557507/
- Extensive longitudinal transverse myelitis after ChAdOx1 nCOV-19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34641797/.
- Acute eosinophilic pneumonia associated with anti-COVID-19 vaccine AZD1222: https://pubmed.ncbi.nlm.nih.gov/34812326/.
- Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19 mRNA vaccines reported to the Vaccine Adverse Event Reporting System (VAERS): https://pubmed.ncbi.nlm.nih.gov/34006408/
- A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?: https://pubmed.ncbi.nlm.nih.gov/34416184/
- Vaccine-induced immune thrombosis and thrombocytopenia syndrome after adenovirus-vectored severe acute respiratory syndrome coronavirus 2 vaccination: a new hypothesis on mechanisms and implications for future vaccine development: https://pubmed.ncbi.nlm.nih.gov/34664303/.
- Thrombosis in peripheral artery disease and thrombotic thrombocytopenia following adenoviral COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34649281/.
- Newly diagnosed immune thrombocytopenia in a pregnant patient after coronavirus disease 2019 vaccination: https://pubmed.ncbi.nlm.nih.gov/34420249/
- Cerebral venous sinus thrombosis and thrombotic events after vector-based COVID-19 vaccines: systematic review and meta-analysis: https://pubmed.ncbi.nlm.nih.gov/34610990/.
- Sweet’s syndrome after Oxford-AstraZeneca COVID-19 vaccine (AZD1222) in an elderly woman: https://pubmed.ncbi.nlm.nih.gov/34590397/
- Sudden sensorineural hearing loss after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34670143/.
- Prevalence of serious adverse events among health care professionals after receiving the first dose of ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021: https://pubmed.ncbi.nlm.nih.gov/34819146/.
- Acute hemichorea-hemibalismus after COVID-19 (AZD1222) vaccination: https://pubmed.ncbi.nlm.nih.gov/34581453/
- Recurrence of alopecia areata after covid-19 vaccination: a report of three cases in Italy: https://pubmed.ncbi.nlm.nih.gov/34741583/
- Shingles-like skin lesion after vaccination with AstraZeneca for COVID-19: a case report: https://pubmed.ncbi.nlm.nih.gov/34631069/
- Thrombosis after COVID-19 vaccination: possible link to ACE pathways: https://pubmed.ncbi.nlm.nih.gov/34479129/
- Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34331506/
- Leukocytoclastic vasculitis as a cutaneous manifestation of ChAdOx1 corona virus vaccine nCoV-19 (recombinant): https://pubmed.ncbi.nlm.nih.gov/34546608/
- Abdominal pain and bilateral adrenal hemorrhage from immune thrombotic thrombocytopenia induced by COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34546343/
- Longitudinally extensive cervical myelitis after vaccination with inactivated virus based COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34849183/
- Induction of cutaneous leukocytoclastic vasculitis after ChAdOx1 nCoV-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34853744/.
- A case of toxic epidermal necrolysis after vaccination with ChAdOx1 nCoV-19 (AZD1222): https://pubmed.ncbi.nlm.nih.gov/34751429/.
- Ocular adverse events following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34559576/
- Depression after ChAdOx1-S / nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34608345/.
- Venous thromboembolism and mild thrombocytopenia after ChAdOx1 nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34384129/.
- Recurrent ANCA-associated vasculitis after Oxford AstraZeneca ChAdOx1-S COVID-19 vaccination: a case series of two patients: https://pubmed.ncbi.nlm.nih.gov/34755433/
- Major artery thrombosis and vaccination against ChAdOx1 nCov-19: https://pubmed.ncbi.nlm.nih.gov/34839830/
- Rare case of contralateral supraclavicular lymphadenopathy after vaccination with COVID-19: computed tomography and ultrasound findings: https://pubmed.ncbi.nlm.nih.gov/34667486/
- Cutaneous lymphocytic vasculitis after administration of the second dose of AZD1222 (Oxford-AstraZeneca) Severe acute respiratory syndrome Coronavirus 2 vaccine: chance or causality: https://pubmed.ncbi.nlm.nih.gov/34726187/.
- Pancreas allograft rejection after ChAdOx1 nCoV-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34781027/
- Understanding the risk of thrombosis with thrombocytopenia syndrome following Ad26.COV2.S vaccination: https://pubmed.ncbi.nlm.nih.gov/34595694/
- Cutaneous adverse reactions of 35,229 doses of COVID-19 Sinovac and AstraZeneca vaccine COVID-19: a prospective cohort study in health care workers: https://pubmed.ncbi.nlm.nih.gov/34661934/
- Comments on thrombosis after vaccination: spike protein leader sequence could be responsible for thrombosis and antibody-mediated thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34788138
- Eosinophilic dermatosis after AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34753210/.
- Severe immune thrombocytopenia following COVID-19 vaccination: report of four cases and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34653943/.
- Relapse of immune thrombocytopenia after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34591991/
- Thrombosis in pre- and post-vaccination phase of COVID-19; https://pubmed.ncbi.nlm.nih.gov/34650382/
- A look at the role of postmortem immunohistochemistry in understanding the inflammatory pathophysiology of COVID-19 disease and vaccine-related thrombotic adverse events: a narrative review: https://pubmed.ncbi.nlm.nih.gov/34769454/
- COVID-19 vaccine in patients with hypercoagulability disorders: a clinical perspective: https://pubmed.ncbi.nlm.nih.gov/34786893/
- Vaccine-associated thrombocytopenia and thrombosis: venous endotheliopathy leading to combined venous micro-macrothrombosis: https://pubmed.ncbi.nlm.nih.gov/34833382/
- Thrombosis and thrombocytopenia syndrome causing isolated symptomatic carotid occlusion after COVID-19 Ad26.COV2.S vaccine (Janssen): https://pubmed.ncbi.nlm.nih.gov/34670287/
- An unusual presentation of acute deep vein thrombosis after Modern COVID-19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34790811/
- Immediate high-dose intravenous immunoglobulins followed by direct treatment with thrombin inhibitors is crucial for survival in vaccine-induced immune thrombotic thrombocytopenia Sars-Covid-19-vector adenoviral VITT with venous thrombosis of the cerebral sinus and portal vein: https://pubmed.ncbi.nlm.nih.gov/34023956/.
- Thrombosis formation after COVID-19 vaccination immunologic aspects: review article: https://pubmed.ncbi.nlm.nih.gov/34629931/
- Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34402666/
- Spectrum of neuroimaging findings in post-CoVID-19 vaccination: a case series and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34842783/
- Cerebral venous sinus thrombosis, pulmonary embolism, and thrombocytopenia after COVID-19 vaccination in a Taiwanese man: a case report and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34630307/
- Fatal cerebral venous sinus thrombosis after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33983464/
- Autoimmune roots of thrombotic events after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34508917/.
- New portal vein thrombosis in cirrhosis: is thrombophilia exacerbated by vaccine or COVID-19: https://www.jcehepatology.com/article/S0973-6883(21)00545-4/fulltext.
- Images of immune thrombotic thrombocytopenia induced by Oxford / AstraZeneca® COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33962903/.
- Cerebral venous sinus thrombosis after vaccination with COVID-19 mRNA of BNT162b2: https://pubmed.ncbi.nlm.nih.gov/34796065/.
- Increased risk of urticaria/angioedema after BNT162b2 mRNA COVID-19 vaccination in health care workers taking ACE inhibitors: https://pubmed.ncbi.nlm.nih.gov/34579248/
- A case of unusual mild clinical presentation of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with splanchnic vein thrombosis: https://pubmed.ncbi.nlm.nih.gov/34843991/
- Cerebral venous sinus thrombosis following vaccination with Pfizer-BioNTech COVID-19 (BNT162b2): https://pubmed.ncbi.nlm.nih.gov/34595867/
- A case of idiopathic thrombocytopenic purpura after a booster dose of COVID-19 BNT162b2 vaccine (Pfizer-Biontech): https://pubmed.ncbi.nlm.nih.gov/34820240/
- Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): targeting pathologic mechanisms with Bruton’s tyrosine kinase inhibitors: https://pubmed.ncbi.nlm.nih.gov/33851389/
- Thrombotic thrombocytopenic purpura after vaccination with Ad26.COV2-S: https://pubmed.ncbi.nlm.nih.gov/33980419/
- Thromboembolic events in younger females exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines: https://pubmed.ncbi.nlm.nih.gov/34264151/
- Potential risk of thrombotic events after COVID-19 vaccination with Oxford-AstraZeneca in women receiving estrogen: https://pubmed.ncbi.nlm.nih.gov/34734086/
- Thrombosis after adenovirus-vectored COVID-19 vaccination: a concern for underlying disease: https://pubmed.ncbi.nlm.nih.gov/34755555/
- Adenovirus interactions with platelets and coagulation and vaccine-induced immune thrombotic thrombocytopenia syndrome: https://pubmed.ncbi.nlm.nih.gov/34407607/
- Thrombotic thrombocytopenic purpura: a new threat after COVID bnt162b2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34264514/.
- Unusual site of deep vein thrombosis after vaccination against coronavirus mRNA-2019 coronavirus disease (COVID-19): https://pubmed.ncbi.nlm.nih.gov/34840204/
- Neurological side effects of SARS-CoV-2 vaccines: https://pubmed.ncbi.nlm.nih.gov/34750810/
- Coagulopathies after SARS-CoV-2 vaccination may derive from a combined effect of SARS-CoV-2 spike protein and adenovirus vector-activated signaling pathways: https://pubmed.ncbi.nlm.nih.gov/34639132/
- Isolated pulmonary embolism after COVID vaccination: 2 case reports and a review of acute pulmonary embolism complications and follow-up: https://pubmed.ncbi.nlm.nih.gov/34804412/
- Central retinal vein occlusion after vaccination with SARS-CoV-2 mRNA: case report: https://pubmed.ncbi.nlm.nih.gov/34571653/.
- Complicated case report of long-term vaccine-induced thrombotic immune thrombocytopenia A: https://pubmed.ncbi.nlm.nih.gov/34835275/.
- Deep venous thrombosis after vaccination with Ad26.COV2.S in adult males: https://pubmed.ncbi.nlm.nih.gov/34659839/.
- Neurological autoimmune diseases after SARS-CoV-2 vaccination: a case series: https://pubmed.ncbi.nlm.nih.gov/34668274/.
- Severe autoimmune hemolytic autoimmune anemia after receiving SARS-CoV-2 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34549821/
- Occurrence of COVID-19 variants among recipients of ChAdOx1 nCoV-19 vaccine (recombinant): https://pubmed.ncbi.nlm.nih.gov/34528522/
- Prevalence of thrombocytopenia, anti-platelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34568726/
- Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab989/644 5179.
- Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and determination of incidence rate: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab926/6420408
- Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine types: https://www.mdpi.com/2075-4426/11/11/1106
- Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study: https://pubmed.ncbi.nlm.nih.gov/34402230/
- Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients: https://pubmed.ncbi.nlm.nih.gov/34696294/
- Myocarditis Following mRNA COVID-19 Vaccine: https://journals.lww.com/pec-online/Abstract/2021/11000/Myocarditis_Following_ mRNA_COVID_19_Vaccine.9.aspx.
- Myocarditis following BNT162b2 mRNA Covid-19 mRNA vaccine in Israel: https://pubmed.ncbi.nlm.nih.gov/34614328/.
- Myocarditis, pericarditis, and cardiomyopathy following COVID-19 vaccination: https://www.heartlungcirc.org/article/S1443-9506(21)01156-2/fulltext
- Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccines: https://pubmed.ncbi.nlm.nih.gov/34277198/
- Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings: https://pubmed.ncbi.nlm.nih.gov/34246586/
- Hypersensitivity Myocarditis and COVID-19 Vaccines: https://pubmed.ncbi.nlm.nih.gov/34856634/.
- Severe myocarditis associated with COVID-19 vaccine: zebra or unicorn?: https://www.internationaljournalofcardiology.com/article/S0167-5273(21)01477-7/fulltext.
- Acute myocardial infarction and myocarditis after COVID-19 vaccination: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8522388/
- Myocarditis after Covid-19 vaccination in a large healthcare organization: https://www.nejm.org/doi/10.1056/NEJMoa2110737
- Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine in a case series of children: https://jamanetwork.com/journals/jamacardiology/fullarticle/2783052
- Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.121.056583?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
- STEMI mimicry: focal myocarditis in an adolescent patient after COVID-19 mRNA vaccination:. https://pubmed.ncbi.nlm.nih.gov/34756746/
- Myocarditis and pericarditis in association with COVID-19 mRNA vaccination: cases from a regional pharmacovigilance center: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8587334/
- Myocarditis after COVID-19 mRNA vaccines: https://pubmed.ncbi.nlm.nih.gov/34546329/.
- Patients with acute myocarditis after COVID-19 mRNA vaccination:. https://jamanetwork.com/journals/jamacardiology/fullarticle/2781602.
- Myocarditis after COVID-19 vaccination: a case series: https://www.sciencedirect.com/science/article/pii/S0264410X21011725?via%3Dihub.
- Myocarditis associated with COVID-19 vaccination in adolescents: https://publications.aap.org/pediatrics/article/148/5/e2021053427/181357
- Myocarditis findings on cardiac magnetic resonance imaging after vaccination with COVID-19 mRNA in adolescents:. https://pubmed.ncbi.nlm.nih.gov/34704459/
- Myocarditis after COVID-19 vaccination: magnetic resonance imaging study: https://academic.oup.com/ehjcimaging/advance-article/doi/10.1093/ehjci/jeab230/6 421640.
- Acute myocarditis after administration of the second dose of BNT162b2 COVID-19 vaccine: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8599115/
- Myocarditis after COVID-19 vaccination: https://www.sciencedirect.com/science/article/pii/S2352906721001603
- Case report: probable myocarditis after Covid-19 mRNA vaccine in a patient with arrhythmogenic left ventricular cardiomyopathy: https://pubmed.ncbi.nlm.nih.gov/34712717/.
- Acute myocarditis after administration of BNT162b2 vaccine against COVID-19: https://www.revespcardiol.org/en-linkresolver-acute-myocarditis-after-administration-bnt162b2-S188558572100133X.
- Myocarditis associated with COVID-19 mRNA vaccination: https://pubs.rsna.org/doi/10.1148/radiol.2021211430
- Acute myocarditis after COVID-19 vaccination: a case report: https://www.sciencedirect.com/science/article/pii/S0248866321007098
- Acute myopericarditis after COVID-19 vaccination in adolescents:. https://pubmed.ncbi.nlm.nih.gov/34589238/.
- Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccination: https://academic.oup.com/jpids/article/10/10/962/6329543.
- Acute myocarditis associated with anti-COVID-19 vaccination: https://ecevr.org/DOIx.php?id=10.7774/cevr.2021.10.2.196.
- Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac CT, and MRI findings:. https://pubmed.ncbi.nlm.nih.gov/34428917/.
- Acute symptomatic myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination:. https://pubmed.ncbi.nlm.nih.gov/34088762/.
- Myocarditis and pericarditis in adolescents after first and second doses of COVID-19 mRNA vaccines:. https://academic.oup.com/ehjqcco/advance-article/doi/10.1093/ehjqcco/qcab090/64 42104.
- COVID 19 vaccine for adolescents. Concern for myocarditis and pericarditis: https://www.mdpi.com/2036-7503/13/3/61.
- Cardiac imaging of acute myocarditis after vaccination with COVID-19 mRNA: https://pubmed.ncbi.nlm.nih.gov/34402228/
- Myocarditis temporally associated with COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34133885/
- Acute myocardial injury after COVID-19 vaccination: a case report and review of current evidence from the vaccine adverse event reporting system database: https://pubmed.ncbi.nlm.nih.gov/34219532/
- Acute myocarditis associated with COVID-19 vaccination: report of a case: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8639400/
- Myocarditis following vaccination with COVID-19 messenger RNA: a Japanese case series: https://pubmed.ncbi.nlm.nih.gov/34840235/.
- Myocarditis in the setting of a recent COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34712497/.
- Acute myocarditis after a second dose of COVID-19 mRNA vaccine: report of two cases: https://www.clinicalimaging.org/article/S0899-7071(21)00265-5/fulltext.
- Prevalence of thrombocytopenia, antiplatelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34568726/
- Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab989/6445179
- Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and incidence rate determination: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab926/6420408.
- Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine types: https://www.mdpi.com/2075-4426/11/11/1106
- Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study: https://pubmed.ncbi.nlm.nih.gov/34402230/
- Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients: https://pubmed.ncbi.nlm.nih.gov/34696294/
- Diffuse prothrombotic syndrome after administration of ChAdOx1 nCoV-19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34615534/
- Three cases of acute venous thromboembolism in women after coronavirus 2019 vaccination: https://pubmed.ncbi.nlm.nih.gov/34352418/
- Clinical and biological features of cerebral venous sinus thrombosis after vaccination with ChAdOx1 nCov-19; https://jnnp.bmj.com/content/early/2021/09/29/jnnp-2021-327340.
- COV2-S vaccination may reveal hereditary thrombophilia: massive cerebral venous sinus thrombosis in a young man with normal platelet count: https://pubmed.ncbi.nlm.nih.gov/34632750/
- Post-mortem findings in vaccine-induced thrombotic thrombocytopenia: https://haematologica.org/article/view/haematol.2021.279075
- COVID-19 vaccine-induced thrombosis: https://pubmed.ncbi.nlm.nih.gov/34802488/.
- Inflammation and platelet activation after COVID-19 vaccines: possible mechanisms behind vaccine-induced immune thrombocytopenia and thrombosis: https://pubmed.ncbi.nlm.nih.gov/34887867/.
- Anaphylactoid reaction and coronary thrombosis related to COVID-19 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34863404/.
- Vaccine-induced cerebral venous thrombosis and thrombocytopenia. Oxford-AstraZeneca COVID-19: a missed opportunity for rapid return on experience: https://www.sciencedirect.com/science/article/pii/S235255682100093X
- Occurrence of splenic infarction due to arterial thrombosis after vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34876440/
- Deep venous thrombosis more than two weeks after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33928773/
- Case report: Take a second look: Cerebral venous thrombosis related to Covid-19 vaccination and thrombotic thrombocytopenia syndrome: https://pubmed.ncbi.nlm.nih.gov/34880826/
- Information on ChAdOx1 nCoV-19 vaccine-induced immune-mediated thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34587242/
- Change in blood viscosity after COVID-19 vaccination: estimation for persons with underlying metabolic syndrome: https://pubmed.ncbi.nlm.nih.gov/34868465/
- Management of a patient with a rare congenital limb malformation syndrome after SARS-CoV-2 vaccine-induced thrombosis and thrombocytopenia (VITT): https://pubmed.ncbi.nlm.nih.gov/34097311/
- Bilateral thalamic stroke: a case of COVID-19 (VITT) vaccine-induced immune thrombotic thrombocytopenia or a coincidence due to underlying risk factors: https://pubmed.ncbi.nlm.nih.gov/34820232/.
- Thrombocytopenia and splanchnic thrombosis after vaccination with Ad26.COV2.S successfully treated with transjugular intrahepatic intrahepatic portosystemic shunt and thrombectomy: https://onlinelibrary.wiley.com/doi/10.1002/ajh.26258
- Incidence of acute ischemic stroke after coronavirus vaccination in Indonesia: case series: https://pubmed.ncbi.nlm.nih.gov/34579636/
- Successful treatment of vaccine-induced immune immune thrombotic thrombocytopenia in a 26-year-old female patient: https://pubmed.ncbi.nlm.nih.gov/34614491/
- Case report: vaccine-induced immune immune thrombotic thrombocytopenia in a patient with pancreatic cancer after vaccination with messenger RNA-1273: https://pubmed.ncbi.nlm.nih.gov/34790684/
- Idiopathic idiopathic external jugular vein thrombophlebitis after coronavirus disease vaccination (COVID-19): https://pubmed.ncbi.nlm.nih.gov/33624509/.
- Squamous cell carcinoma of the lung with hemoptysis following vaccination with tozinameran (BNT162b2, Pfizer-BioNTech): https://pubmed.ncbi.nlm.nih.gov/34612003/
- Vaccine-induced thrombotic thrombocytopenia after Ad26.COV2.S vaccination in a man presenting as acute venous thromboembolism: https://pubmed.ncbi.nlm.nih.gov/34096082/
- Myocarditis associated with COVID-19 vaccination in three adolescent boys: https://pubmed.ncbi.nlm.nih.gov/34851078/.
- Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis after COVID-19 mRNA vaccination: a case series: https://pubmed.ncbi.nlm.nih.gov/34496880/
- Perimyocarditis after vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34866957/
- Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: https://pubmed.ncbi.nlm.nih.gov/34849657/.
- Myocarditis-induced sudden death after BNT162b2 COVID-19 mRNA vaccination in Korea: case report focusing on histopathological findings: https://pubmed.ncbi.nlm.nih.gov/34664804/
- Acute myocarditis after vaccination with COVID-19 mRNA in adults aged 18 years or older: https://pubmed.ncbi.nlm.nih.gov/34605853/
- Recurrence of acute myocarditis temporally associated with receipt of the 2019 coronavirus mRNA disease vaccine (COVID-19) in an adolescent male: https://pubmed.ncbi.nlm.nih.gov/34166671/
- Young male with myocarditis after mRNA-1273 coronavirus disease-2019 (COVID-19) mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34744118/
- Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old male: https://pubmed.ncbi.nlm.nih.gov/34334935/.
- Ga-DOTATOC digital PET images of inflammatory cell infiltrates in myocarditis after vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34746968/
- Occurrence of acute infarct-like myocarditis after vaccination with COVID-19: just an accidental coincidence or rather a vaccination-associated autoimmune myocarditis?”: https://pubmed.ncbi.nlm.nih.gov/34333695/.
- Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with BNT162b2 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34180390/
- Myocarditis Following Immunization with COVID-19 mRNA Vaccines in Members of the U.S. Military: https://pubmed.ncbi.nlm.nih.gov/34185045/
- Myocarditis after BNT162b2 vaccination in a healthy male: https://pubmed.ncbi.nlm.nih.gov/34229940/
- Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report: https://pubmed.ncbi.nlm.nih.gov/34133825/
- Acute myocarditis after SARS-CoV-2 mRNA-1273 mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34308326/.
- Chest pain with abnormal electrocardiogram redevelopment after injection of COVID-19 vaccine manufactured by Moderna: https://pubmed.ncbi.nlm.nih.gov/34866106/
- Biopsy-proven lymphocytic myocarditis after first vaccination with COVID-19 mRNA in a 40-year-old man: case report: https://pubmed.ncbi.nlm.nih.gov/34487236/
- Multimodality imaging and histopathology in a young man presenting with fulminant lymphocytic myocarditis and cardiogenic shock after vaccination with mRNA-1273: https://pubmed.ncbi.nlm.nih.gov/34848416/
- Report of a case of myopericarditis after vaccination with BNT162b2 COVID-19 mRNA in a young Korean male: https://pubmed.ncbi.nlm.nih.gov/34636504/
- Acute myocarditis after Comirnaty vaccination in a healthy male with previous SARS-CoV-2 infection: https://pubmed.ncbi.nlm.nih.gov/34367386/
- Acute myocarditis in a young adult two days after vaccination with Pfizer: https://pubmed.ncbi.nlm.nih.gov/34709227/
- Case report: acute fulminant myocarditis and cardiogenic shock after messenger RNA coronavirus vaccination in 2019 requiring extracorporeal cardiopulmonary resuscitation: https://pubmed.ncbi.nlm.nih.gov/34778411/
- Acute myocarditis after 2019 coronavirus disease vaccination: https://pubmed.ncbi.nlm.nih.gov/34734821/
- A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-1279 and BNT162b2: https://pubmed.ncbi.nlm.nih.gov/34246585/
- Myopericarditis after Pfizer messenger ribonucleic acid coronavirus coronavirus disease vaccine in adolescents: https://pubmed.ncbi.nlm.nih.gov/34228985/
- Post-vaccination multisystem inflammatory syndrome in adults without evidence of prior SARS-CoV-2 infection: https://pubmed.ncbi.nlm.nih.gov/34852213/
- Acute myocarditis defined after vaccination with 2019 mRNA of coronavirus disease: https://pubmed.ncbi.nlm.nih.gov/34866122/
- Biventricular systolic dysfunction in acute myocarditis after SARS-CoV-2 mRNA-1273 vaccination: https://pubmed.ncbi.nlm.nih.gov/34601566/
- Myocarditis following COVID-19 vaccination: MRI study: https://pubmed.ncbi.nlm.nih.gov/34739045/.
- Acute myocarditis after COVID-19 vaccination: case report: https://docs.google.com/document/d/1Hc4bh_qNbZ7UVm5BLxkRdMPnnI9zcCsl/e
- Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine COVID-19 in a case series of children: https://pubmed.ncbi.nlm.nih.gov/34374740/
- Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: https://pubmed.ncbi.nlm.nih.gov/34865500/
- Myocarditis following vaccination with Covid-19 in a large healthcare organization: https://pubmed.ncbi.nlm.nih.gov/34614329/
- AstraZeneca COVID-19 vaccine and Guillain-Barré syndrome in Tasmania: a causal link: https://pubmed.ncbi.nlm.nih.gov/34560365/
- COVID-19, Guillain-Barré and vaccineA dangerous mix: https://pubmed.ncbi.nlm.nih.gov/34108736/.
- Guillain-Barré syndrome after the first dose of Pfizer-BioNTech COVID-19 vaccine: case report and review of reported cases: https://pubmed.ncbi.nlm.nih.gov/34796417/.
- Guillain-Barre syndrome after BNT162b2 COVID-19 vaccine: https://link.springer.com/article/10.1007%2Fs10072-021-05523-5.
- COVID-19 adenovirus vaccines and Guillain-Barré syndrome with facial palsy: https://onlinelibrary.wiley.com/doi/10.1002/ana.26258.
- Association of receipt association of Ad26.COV2.S COVID-19 vaccine with presumed Guillain-Barre syndrome, February-July 2021: https://jamanetwork.com/journals/jama/fullarticle/2785009
- A case of Guillain-Barré syndrome after Pfizer COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34567447/
- Guillain-Barré syndrome associated with COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34648420/.
- Rate of recurrent Guillain-Barré syndrome after COVID-19 BNT162b2 mRNA vaccine: https://jamanetwork.com/journals/jamaneurology/fullarticle/2783708
- Guillain-Barre syndrome after COVID-19 vaccination in an adolescent: https://www.pedneur.com/article/S0887-8994(21)00221-6/fulltext.
- Guillain-Barre syndrome after ChAdOx1-S / nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34114256/.
- Guillain-Barre syndrome after COVID-19 mRNA-1273 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34767184/.
- Guillain-Barre syndrome following SARS-CoV-2 vaccination in 19 patients: https://pubmed.ncbi.nlm.nih.gov/34644738/.
- Guillain-Barre syndrome presenting with facial diplegia following vaccination with COVID-19 in two patients: https://pubmed.ncbi.nlm.nih.gov/34649856/
- A rare case of Guillain-Barré syndrome after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34671572/
- Neurological complications of COVID-19: Guillain-Barre syndrome after Pfizer COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33758714/
- COVID-19 vaccine causing Guillain-Barre syndrome, an uncommon potential side effect: https://pubmed.ncbi.nlm.nih.gov/34484780/
- Guillain-Barre syndrome after the first dose of COVID-19 vaccination: case report; https://pubmed.ncbi.nlm.nih.gov/34779385/.
- Miller Fisher syndrome after Pfizer COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34817727/.
- Miller Fisher syndrome after 2019 BNT162b2 mRNA coronavirus vaccination: https://pubmed.ncbi.nlm.nih.gov/34789193/.
- Bilateral facial weakness with a variant of paresthesia of Guillain-Barre syndrome after Vaxzevria COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34261746/
- Guillain-Barre syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first report: https://pubmed.ncbi.nlm.nih.gov/34217513/.
- A case of sensory ataxic Guillain-Barre syndrome with immunoglobulin G anti-GM1 antibodies after first dose of COVID-19 BNT162b2 mRNA vaccine (Pfizer): https://pubmed.ncbi.nlm.nih.gov/34871447/
- Reporting of acute inflammatory neuropathies with COVID-19 vaccines: subgroup disproportionality analysis in VigiBase: https://pubmed.ncbi.nlm.nih.gov/34579259/
- A variant of Guillain-Barré syndrome after SARS-CoV-2 vaccination: AMSAN: https://pubmed.ncbi.nlm.nih.gov/34370408/.
- A rare variant of Guillain-Barré syndrome after vaccination with Ad26.COV2.S: https://pubmed.ncbi.nlm.nih.gov/34703690/.
- Guillain-Barré syndrome after SARS-CoV-2 vaccination in a patient with previous vaccine-associated Guillain-Barré syndrome: https://pubmed.ncbi.nlm.nih.gov/34810163/
- Guillain-Barré syndrome in an Australian state using mRNA and adenovirus-vector SARS-CoV-2 vaccines: https://onlinelibrary.wiley.com/doi/10.1002/ana.26218.
- Acute transverse myelitis after SARS-CoV-2 vaccination: case report and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34482455/.
- Variant Guillain-Barré syndrome occurring after SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34114269/.
- Guillian-Barre syndrome with axonal variant temporally associated with Modern SARS-CoV-2 mRNA-based vaccine: https://pubmed.ncbi.nlm.nih.gov/34722067/
- Guillain-Barre syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association: https://pubmed.ncbi.nlm.nih.gov/33968610/
- SARS-CoV-2 vaccines can be complicated not only by Guillain-Barré syndrome but also by distal small fiber neuropathy: https://pubmed.ncbi.nlm.nih.gov/34525410/
- Clinical variant of Guillain-Barré syndrome with prominent facial diplegia after AstraZeneca 2019 coronavirus disease vaccine: https://pubmed.ncbi.nlm.nih.gov/34808658/
- Adverse event reporting and risk of Bell’s palsy after COVID-19 vaccination: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00646-0/fulltext.
- Bilateral facial nerve palsy and COVID-19 vaccination: causality or coincidence: https://pubmed.ncbi.nlm.nih.gov/34522557/
- Left Bell’s palsy after the first dose of mRNA-1273 SARS-CoV-2 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34763263/.
- Bell’s palsy after inactivated vaccination with COVID-19 in a patient with a history of recurrent Bell’s palsy: case report: https://pubmed.ncbi.nlm.nih.gov/34621891/
- Neurological complications after the first dose of COVID-19 vaccines and SARS-CoV-2 infection: https://pubmed.ncbi.nlm.nih.gov/34697502/
- Type I interferons as a potential mechanism linking COVID-19 mRNA vaccines with Bell’s palsy: https://pubmed.ncbi.nlm.nih.gov/33858693/
- Acute transverse myelitis following inactivated COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34370410/
- Acute transverse myelitis after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34579245/.
- A case of longitudinally extensive transverse myelitis following Covid-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34182207/
- Post COVID-19 transverse myelitis; a case report with review of the literature: https://pubmed.ncbi.nlm.nih.gov/34457267/.
- Beware of neuromyelitis optica spectrum disorder after vaccination with inactivated virus for COVID-19: https://pubmed.ncbi.nlm.nih.gov/34189662/
- Neuromyelitis optica in a healthy woman after vaccination against severe acute respiratory syndrome coronavirus 2 mRNA-1273: https://pubmed.ncbi.nlm.nih.gov/34660149/
- Acute bilateral bilateral optic neuritis/chiasm with longitudinal extensive transverse myelitis in long-standing stable multiple sclerosis after vector-based vaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/34131771/
- A case series of acute pericarditis after vaccination with COVID-19 in the context of recent reports from Europe and the United States: https://pubmed.ncbi.nlm.nih.gov/34635376/
- Acute pericarditis and cardiac tamponade after vaccination with Covid-19: https://pubmed.ncbi.nlm.nih.gov/34749492/
- Myocarditis and pericarditis in adolescents after the first and second doses of COVID-19 mRNA vaccines: https://pubmed.ncbi.nlm.nih.gov/34849667/
- Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34319393/
- Acute myopericarditis after COVID-19 vaccine in adolescents: https://pubmed.ncbi.nlm.nih.gov/34589238/
- Pericarditis after administration of the BNT162b2 mRNA vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34149145/
- Case report: symptomatic pericarditis post COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34693198/.
- An outbreak of Still’s disease after COVID-19 vaccination in a 34-year-old patient: https://pubmed.ncbi.nlm.nih.gov/34797392/
- Hemophagocytic lymphohistiocytosis following COVID-19 vaccination (ChAdOx1 nCoV-19): https://pubmed.ncbi.nlm.nih.gov/34862234/
- Myocarditis after SARS-CoV-2 mRNA vaccination, a case series: https://pubmed.ncbi.nlm.nih.gov/34396358/.
- Miller-Fisher syndrome and Guillain-Barré syndrome overlap syndrome in a patient after Oxford-AstraZeneca SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34848426/.
- Immune-mediated disease outbreaks or new-onset disease in 27 subjects after mRNA/DNA vaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/33946748/
- Post-mortem investigation of deaths after vaccination with COVID-19 vaccines: https://pubmed.ncbi.nlm.nih.gov/34591186/
- Acute kidney injury with macroscopic hematuria and IgA nephropathy after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34352309/
- Relapse of immune thrombocytopenia after covid-19 vaccination in young male patient: https://pubmed.ncbi.nlm.nih.gov/34804803/.
- Immune thrombocytopenic purpura associated with COVID-19 mRNA vaccine Pfizer-BioNTech BNT16B2b2: https://pubmed.ncbi.nlm.nih.gov/34077572/
- Retinal hemorrhage after SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34884407/.
- Case report: anti-neutrophil cytoplasmic antibody-associated vasculitis with acute renal failure and pulmonary hemorrhage can occur after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34859017/
- Intracerebral hemorrhage due to vasculitis following COVID-19 vaccination: case report: https://pubmed.ncbi.nlm.nih.gov/34783899/
- Peduncular, symptomatic cavernous bleeding after immune thrombocytopenia-induced SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34549178/.
- Brain death in a vaccinated patient with COVID-19 infection: https://pubmed.ncbi.nlm.nih.gov/34656887/
- Generalized purpura annularis telangiectodes after SARS-CoV-2 mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34236717/.
- Lobar hemorrhage with ventricular rupture shortly after the first dose of a SARS-CoV-2 mRNA-based SARS-CoV-2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34729467/.
- A case of outbreak of macroscopic hematuria and IgA nephropathy after SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/33932458/
- Acral hemorrhage after administration of the second dose of SARS-CoV-2 vaccine. A post-vaccination reaction: https://pubmed.ncbi.nlm.nih.gov/34092400/742.
- Severe immune thrombocytopenic purpura after SARS-CoV-2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34754937/
- Gross hematuria after severe acute respiratory syndrome coronavirus 2 vaccination in 2 patients with IgA nephropathy: https://pubmed.ncbi.nlm.nih.gov/33771584/
- Autoimmune encephalitis after ChAdOx1-S SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34846583/
- COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis: https://pubmed.ncbi.nlm.nih.gov/34073536/
- Bell’s palsy after vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and a nested case-control study: https://pubmed.ncbi.nlm.nih.gov/34411532/
- Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada: by vaccine product, schedule, and interval: https://www.medrxiv.org/content/10.1101/2021.12.02.21267156v1
- Anaphylaxis following Covid-19 vaccine in a patient with cholinergic urticaria: https://pubmed.ncbi.nlm.nih.gov/33851711/
- Anaphylaxis induced by CoronaVac COVID-19 vaccine: clinical features and results of revaccination: https://pubmed.ncbi.nlm.nih.gov/34675550/.
- Anaphylaxis after Modern COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34734159/.
- Association of self-reported history of high-risk allergy with allergy symptoms after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34698847/
- Sex differences in the incidence of anaphylaxis to LNP-mRNA vaccines COVID-19: https://pubmed.ncbi.nlm.nih.gov/34020815/
- Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14 to 23, 2020: https://pubmed.ncbi.nlm.nih.gov/33641264/
- Allergic reactions, including anaphylaxis, after receiving the first dose of Modern COVID-19 vaccine – United States, December 21, 2020 to January 10, 2021: https://pubmed.ncbi.nlm.nih.gov/33641268/
- Prolonged anaphylaxis to Pfizer 2019 coronavirus disease vaccine: a case report and mechanism of action: https://pubmed.ncbi.nlm.nih.gov/33834172/
- Anaphylaxis reactions to Pfizer BNT162b2 vaccine: report of 3 cases of anaphylaxis following vaccination with Pfizer BNT162b2: https://pubmed.ncbi.nlm.nih.gov/34579211/
- Biphasic anaphylaxis after first dose of 2019 messenger RNA coronavirus disease vaccine with positive polysorbate 80 skin test result: https://pubmed.ncbi.nlm.nih.gov/34343674/
- Acute myocardial infarction and myocarditis after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34586408/
- Takotsubo syndrome after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34539938/.
- Takotsubo cardiomyopathy after coronavirus 2019 vaccination in patient on maintenance hemodialysis: https://pubmed.ncbi.nlm.nih.gov/34731486/.
- Premature myocardial infarction or side effect of COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33824804/
- Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in persons aged 75 years or older: https://pubmed.ncbi.nlm.nih.gov/34807248/
- Kounis syndrome type 1 induced by inactivated SARS-COV-2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34148772/
- Acute myocardial infarction within 24 hours after COVID-19 vaccination: is Kounis syndrome the culprit: https://pubmed.ncbi.nlm.nih.gov/34702550/
- Deaths associated with the recently launched SARS-CoV-2 vaccination (Comirnaty®): https://pubmed.ncbi.nlm.nih.gov/33895650/
- Deaths associated with recently launched SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34425384/
- A case of acute encephalopathy and non-ST-segment elevation myocardial infarction after vaccination with mRNA-1273: possible adverse effect: https://pubmed.ncbi.nlm.nih.gov/34703815/
- COVID-19 vaccine-induced urticarial vasculitis: https://pubmed.ncbi.nlm.nih.gov/34369046/.
- ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34280507/.
- New-onset leukocytoclastic vasculitis after COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34241833/
- Cutaneous small vessel vasculitis after COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34529877/.
- Outbreak of leukocytoclastic vasculitis after COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33928638/
- Leukocytoclastic vasculitis after exposure to COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34836739/
- Vasculitis and bursitis in [ 18 F] FDG-PET/CT after COVID-19 mRNA vaccine: post hoc ergo propter hoc?; https://pubmed.ncbi.nlm.nih.gov/34495381/.
- Cutaneous lymphocytic vasculitis after administration of COVID-19 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34327795
- Cutaneous leukocytoclastic vasculitis induced by Sinovac COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34660867/.
- Case report: ANCA-associated vasculitis presenting with rhabdomyolysis and crescentic Pauci-Inmune glomerulonephritis after vaccination with Pfizer-BioNTech COVID-19 mRNA: https://pubmed.ncbi.nlm.nih.gov/34659268/
- Reactivation of IgA vasculitis after vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34848431/
- Varicella-zoster virus-related small-vessel vasculitis after Pfizer-BioNTech COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34310759/.
- Imaging in vascular medicine: leukocytoclastic vasculitis after COVID-19 vaccine booster: https://pubmed.ncbi.nlm.nih.gov/34720009/
- A rare case of Henoch-Schönlein purpura after a case report of COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34518812/
- Cutaneous vasculitis following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34611627/.
- Possible case of COVID-19 mRNA vaccine-induced small-vessel vasculitis: https://pubmed.ncbi.nlm.nih.gov/34705320/.
- IgA vasculitis following COVID-19 vaccination in an adult: https://pubmed.ncbi.nlm.nih.gov/34779011/
- Propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis following vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34451967/
- Coronavirus disease vaccine 2019 (COVID-19) in systemic lupus erythematosus and neutrophil anti-cytoplasmic antibody-associated vasculitis: https://pubmed.ncbi.nlm.nih.gov/33928459/
- Reactivation of IgA vasculitis after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34250509/
- Clinical and histopathologic spectrum of delayed adverse skin reactions after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34292611/.
- First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: case report: https://pubmed.ncbi.nlm.nih.gov/34530771/.
- Nephrotic syndrome and vasculitis after SARS-CoV-2 vaccine: true association or circumstantial: https://pubmed.ncbi.nlm.nih.gov/34245294/.
- Occurrence of de novo cutaneous vasculitis after vaccination against coronavirus disease (COVID-19): https://pubmed.ncbi.nlm.nih.gov/34599716/.
- Asymmetric cutaneous vasculitis after COVID-19 vaccination with unusual preponderance of eosinophils: https://pubmed.ncbi.nlm.nih.gov/34115904/.
- Henoch-Schönlein purpura occurring after vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34247902/.
- Henoch-Schönlein purpura following the first dose of COVID-19 viral vector vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34696186/.
- Granulomatous vasculitis after AstraZeneca anti-SARS-CoV-2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34237323/.
- Acute retinal necrosis due to varicella zoster virus reactivation after vaccination with BNT162b2 COVID-19 mRNA: https://pubmed.ncbi.nlm.nih.gov/34851795/.
- A case of generalized Sweet’s syndrome with vasculitis triggered by recent vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34849386/
- Small-vessel vasculitis following Oxford-AstraZeneca vaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/34310763/
- Relapse of microscopic polyangiitis after COVID-19 vaccination: case report: https://pubmed.ncbi.nlm.nih.gov/34251683/.
- Cutaneous vasculitis after severe acute respiratory syndrome coronavirus 2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34557622/.
- Recurrent herpes zoster after COVID-19 vaccination in patients with chronic urticaria on cyclosporine treatment – A report of 3 cases: https://pubmed.ncbi.nlm.nih.gov/34510694/
- Leukocytoclastic vasculitis after coronavirus disease vaccination 2019: https://pubmed.ncbi.nlm.nih.gov/34713472/803
- Outbreaks of mixed cryoglobulinemia vasculitis after vaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/34819272/
- Cutaneous small-vessel vasculitis after vaccination with a single dose of Janssen Ad26.COV2.S: https://pubmed.ncbi.nlm.nih.gov/34337124/
- Case of immunoglobulin A vasculitis after vaccination against coronavirus disease 2019: https://pubmed.ncbi.nlm.nih.gov/34535924/
- Rapid progression of angioimmunoblastic T-cell lymphoma after BNT162b2 mRNA booster vaccination: case report: https://www.frontiersin.org/articles/10.3389/fmed.2021.798095/
- COVID-19 mRNA vaccination-induced lymphadenopathy mimics lymphoma progression on FDG PET / CT: https://pubmed.ncbi.nlm.nih.gov/33591026/
- Lymphadenopathy in COVID-19 vaccine recipients: diagnostic dilemma in oncology patients: https://pubmed.ncbi.nlm.nih.gov/33625300/
- Hypermetabolic lymphadenopathy after administration of BNT162b2 mRNA vaccine Covid-19: incidence assessed by [ 18 F] FDG PET-CT and relevance for study interpretation: https://pubmed.ncbi.nlm.nih.gov/33774684/
- Lymphadenopathy after COVID-19 vaccination: review of imaging findings: https://pubmed.ncbi.nlm.nih.gov/33985872/
- Evolution of bilateral hypermetabolic axillary hypermetabolic lymphadenopathy on FDG PET/CT after 2-dose COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34735411/
- Lymphadenopathy associated with COVID-19 vaccination on FDG PET/CT: distinguishing features in adenovirus-vectored vaccine: https://pubmed.ncbi.nlm.nih.gov/34115709/.
- COVID-19 vaccination-induced lymphadenopathy in a specialized breast imaging clinic in Israel: analysis of 163 cases: https://pubmed.ncbi.nlm.nih.gov/34257025/.
- COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: case series with literature review: https://pubmed.ncbi.nlm.nih.gov/34836672/.
- Coronavirus disease vaccine 2019 mimics lymph node metastases in patients undergoing skin cancer follow-up: a single-center study: https://pubmed.ncbi.nlm.nih.gov/34280870/
- COVID-19 post-vaccination lymphadenopathy: report of fine-needle aspiration biopsy cytologic findings: https://pubmed.ncbi.nlm.nih.gov/34432391/
- Regional lymphadenopathy after COVID-19 vaccination: review of the literature and considerations for patient management in breast cancer care: https://pubmed.ncbi.nlm.nih.gov/34731748/
- Subclinical axillary lymphadenopathy associated with COVID-19 vaccination on screening mammography: https://pubmed.ncbi.nlm.nih.gov/34906409/
- Adverse events of COVID injection that may occur in children.Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021: https://pubmed.ncbi.nlm.nih.gov/33706861/
- Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: https://pubmed.ncbi.nlm.nih.gov/34116295/
- Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET / CT, not just an FDG finding: https://pubmed.ncbi.nlm.nih.gov/33661328/
- Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34050949/
- Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-up recommendations in 23 women: https://pubmed.ncbi.nlm.nih.gov/33624520/
- A case of cervical lymphadenopathy following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34141500/
- Unique imaging findings of neurologic phantosmia after Pfizer-BioNtech COVID-19 vaccination: a case report: https://pubmed.ncbi.nlm.nih.gov/34096896/
- Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database: https://pubmed.ncbi.nlm.nih.gov/34835256/
- Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties: https://pubmed.ncbi.nlm.nih.gov/33713605/
- Unilateral axillary adenopathy in the setting of COVID-19 vaccination: follow-up: https://pubmed.ncbi.nlm.nih.gov/34298342/
- A systematic review of cases of CNS demyelination following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34839149/
- Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic: https://pubmed.ncbi.nlm.nih.gov/33685772/
- COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other malignancies: cross-sectional imaging findings on MRI, CT and PET-CT: https://pubmed.ncbi.nlm.nih.gov/34719892/
- Adenopathy after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33625299/.
- Incidence of axillary adenopathy on breast imaging after vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34292295/.
- COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit: https://pubmed.ncbi.nlm.nih.gov/33947605/.
- Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services: https://pubmed.ncbi.nlm.nih.gov/34526175/
- Lymphadenopathy associated with the COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33786231/
- Evolution of lymphadenopathy on PET/MRI after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33625301/.
- Autoimmune hepatitis triggered by SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34332438/.
- New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report and literature review: https://pubmed.ncbi.nlm.nih.gov/34342187/.
- Massive cervical lymphadenopathy following vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34601889/
- ANCA glomerulonephritis following Modern COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34081948/
- Extensive longitudinal transverse myelitis following AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34507942/.
- Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34362727/
- Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRI allowing benign evaluation: https://pubmed.ncbi.nlm.nih.gov/34325221/
- Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new diagnostic dilemma: https://pubmed.ncbi.nlm.nih.gov/34825530/.
- Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34000278/
- COVID-19 vaccine-induced unilateral axillary adenopathy: follow-up evaluation in the USA: https://pubmed.ncbi.nlm.nih.gov/34655312/.
- Gastroparesis after Pfizer-BioNTech COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34187985/.
- Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021: https://pubmed.ncbi.nlm.nih.gov/33706861/
- Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: https://pubmed.ncbi.nlm.nih.gov/34116295/
- Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET / CT, not just an FDG finding: https://pubmed.ncbi.nlm.nih.gov/33661328/
- Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34050949/
- Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-up recommendations in 23 women: https://pubmed.ncbi.nlm.nih.gov/33624520/
- A case of cervical lymphadenopathy following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34141500/
- Unique imaging findings of neurologic phantosmia after Pfizer-BioNtech COVID-19 vaccination: a case report: https://pubmed.ncbi.nlm.nih.gov/34096896/
- Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database: https://pubmed.ncbi.nlm.nih.gov/34835256/
- Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties: https://pubmed.ncbi.nlm.nih.gov/33713605/
- Unilateral axillary adenopathy in the setting of COVID-19 vaccination: follow-up: https://pubmed.ncbi.nlm.nih.gov/34298342/
- A systematic review of cases of CNS demyelination following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34839149/
- Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic: https://pubmed.ncbi.nlm.nih.gov/33685772/
- COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other malignancies: cross-sectional imaging findings on MRI, CT and PET-CT: https://pubmed.ncbi.nlm.nih.gov/34719892/
- Adenopathy after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33625299/.
- Incidence of axillary adenopathy on breast imaging after vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34292295/.
- COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit: https://pubmed.ncbi.nlm.nih.gov/33947605/.
- Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services: https://pubmed.ncbi.nlm.nih.gov/34526175/
- Lymphadenopathy associated with the COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33786231/
- Evolution of lymphadenopathy on PET/MRI after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33625301/.
- Autoimmune hepatitis triggered by SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34332438/.
- New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report and literature review: https://pubmed.ncbi.nlm.nih.gov/34342187/.
- Massive cervical lymphadenopathy following vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34601889/
- ANCA glomerulonephritis following Modern COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34081948/
- Extensive longitudinal transverse myelitis following AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34507942/.
- Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34362727/
- Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRI allowing benign evaluation: https://pubmed.ncbi.nlm.nih.gov/34325221/
- Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new diagnostic dilemma: https://pubmed.ncbi.nlm.nih.gov/34825530/.
- Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34000278/
- COVID-19 vaccine-induced unilateral axillary adenopathy: follow-up evaluation in the USA: https://pubmed.ncbi.nlm.nih.gov/34655312/.
- Gastroparesis after Pfizer-BioNTech COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34187985/.
- Abbate, A., Gavin, J., Madanchi, N., Kim, C., Shah, P. R., Klein, K., . . . Danielides, S. (2021). Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients. Int J Cardiol, 340, 119-121. doi:10.1016/j.ijcard.2021.08.018. https://www.ncbi.nlm.nih.gov/pubmed/34416319
- Abu Mouch, S., Roguin, A., Hellou, E., Ishai, A., Shoshan, U., Mahamid, L., . . . Berar Yanay, N. (2021). Myocarditis following COVID-19 mRNA vaccination. Vaccine, 39(29), 3790-3793. doi:10.1016/j.vaccine.2021.05.087. https://www.ncbi.nlm.nih.gov/pubmed/34092429
- Albert, E., Aurigemma, G., Saucedo, J., & Gerson, D. S. (2021). Myocarditis following COVID-19 vaccination. Radiol Case Rep, 16(8), 2142-2145. doi:10.1016/j.radcr.2021.05.033. https://www.ncbi.nlm.nih.gov/pubmed/34025885
- Aye, Y. N., Mai, A. S., Zhang, A., Lim, O. Z. H., Lin, N., Ng, C. H., . . . Chew, N. W. S. (2021). Acute Myocardial Infarction and Myocarditis following COVID-19 Vaccination. QJM. doi:10.1093/qjmed/hcab252. https://www.ncbi.nlm.nih.gov/pubmed/34586408
- Azir, M., Inman, B., Webb, J., & Tannenbaum, L. (2021). STEMI Mimic: Focal Myocarditis in an Adolescent Patient After mRNA COVID-19 Vaccine. J Emerg Med, 61(6), e129-e132. doi:10.1016/j.jemermed.2021.09.017. https://www.ncbi.nlm.nih.gov/pubmed/34756746
- Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., . . . Balicer, R. D. (2021). Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med, 385(12), 1078-1090. doi:10.1056/NEJMoa2110475. https://www.ncbi.nlm.nih.gov/pubmed/34432976
- Bhandari, M., Pradhan, A., Vishwakarma, P., & Sethi, R. (2021). Coronavirus and cardiovascular manifestations- getting to the heart of the matter. World J Cardiol, 13(10), 556-565. doi:10.4330/wjc.v13.i10.556. https://www.ncbi.nlm.nih.gov/pubmed/34754400
- Bozkurt, B., Kamat, I., & Hotez, P. J. (2021). Myocarditis With COVID-19 mRNA Vaccines. Circulation, 144(6), 471-484. doi:10.1161/CIRCULATIONAHA.121.056135. https://www.ncbi.nlm.nih.gov/pubmed/34281357
- Buchhorn, R., Meyer, C., Schulze-Forster, K., Junker, J., & Heidecke, H. (2021). Autoantibody Release in Children after Corona Virus mRNA Vaccination: A Risk Factor of Multisystem Inflammatory Syndrome? Vaccines (Basel), 9(11). doi:10.3390/vaccines9111353. https://www.ncbi.nlm.nih.gov/pubmed/34835284
- Calcaterra, G., Bassareo, P. P., Barilla, F., Romeo, F., & Mehta, J. L. (2022). Concerning the unexpected prothrombotic state following some coronavirus disease 2019 vaccines. J Cardiovasc Med (Hagerstown), 23(2), 71-74. doi:10.2459/JCM.0000000000001232. https://www.ncbi.nlm.nih.gov/pubmed/34366403
- Calcaterra, G., Mehta, J. L., de Gregorio, C., Butera, G., Neroni, P., Fanos, V., & Bassareo, P. P. (2021). COVID 19 Vaccine for Adolescents. Concern about Myocarditis and Pericarditis. Pediatr Rep, 13(3), 530-533. doi:10.3390/pediatric13030061. https://www.ncbi.nlm.nih.gov/pubmed/34564344
- Chai, Q., Nygaard, U., Schmidt, R. C., Zaremba, T., Moller, A. M., & Thorvig, C. M. (2022). Multisystem inflammatory syndrome in a male adolescent after his second Pfizer-BioNTech COVID-19 vaccine. Acta Paediatr, 111(1), 125-127. doi:10.1111/apa.16141. https://www.ncbi.nlm.nih.gov/pubmed/34617315
- Chamling, B., Vehof, V., Drakos, S., Weil, M., Stalling, P., Vahlhaus, C., . . . Yilmaz, A. (2021). Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis? Clin Res Cardiol, 110(11), 1850-1854. doi:10.1007/s00392-021-01916-w. https://www.ncbi.nlm.nih.gov/pubmed/34333695
- Chang, J. C., & Hawley, H. B. (2021). Vaccine-Associated Thrombocytopenia and Thrombosis: Venous Endotheliopathy Leading to Venous Combined Micro-Macrothrombosis. Medicina (Kaunas), 57(11). doi:10.3390/medicina57111163. https://www.ncbi.nlm.nih.gov/pubmed/34833382
- Chelala, L., Jeudy, J., Hossain, R., Rosenthal, G., Pietris, N., & White, C. (2021). Cardiac MRI Findings of Myocarditis After COVID-19 mRNA Vaccination in Adolescents. AJR Am J Roentgenol. doi:10.2214/AJR.21.26853. https://www.ncbi.nlm.nih.gov/pubmed/34704459
- Choi, S., Lee, S., Seo, J. W., Kim, M. J., Jeon, Y. H., Park, J. H., . . . Yeo, N. S. (2021). Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological Findings. J Korean Med Sci, 36(40), e286. doi:10.3346/jkms.2021.36.e286. https://www.ncbi.nlm.nih.gov/pubmed/34664804
- Chouchana, L., Blet, A., Al-Khalaf, M., Kafil, T. S., Nair, G., Robblee, J., . . . Liu, P. P. (2021). Features of Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a Global Level. Clin Pharmacol Ther. doi:10.1002/cpt.2499. https://www.ncbi.nlm.nih.gov/pubmed/34860360
- Chua, G. T., Kwan, M. Y. W., Chui, C. S. L., Smith, R. D., Cheung, E. C., Tian, T., . . . Ip, P. (2021). Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination. Clin Infect Dis. doi:10.1093/cid/ciab989. https://www.ncbi.nlm.nih.gov/pubmed/34849657
- Clarke, R., & Ioannou, A. (2021). Should T2 mapping be used in cases of recurrent myocarditis to differentiate between the acute inflammation and chronic scar? J Pediatr. doi:10.1016/j.jpeds.2021.12.026. https://www.ncbi.nlm.nih.gov/pubmed/34933012
- Colaneri, M., De Filippo, M., Licari, A., Marseglia, A., Maiocchi, L., Ricciardi, A., . . . Bruno, R. (2021). COVID vaccination and asthma exacerbation: might there be a link? Int J Infect Dis, 112, 243-246. doi:10.1016/j.ijid.2021.09.026. https://www.ncbi.nlm.nih.gov/pubmed/34547487
- Das, B. B., Kohli, U., Ramachandran, P., Nguyen, H. H., Greil, G., Hussain, T., . . . Khan, D. (2021). Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age. J Pediatr, 238, 26-32 e21. doi:10.1016/j.jpeds.2021.07.044. https://www.ncbi.nlm.nih.gov/pubmed/34339728
- Das, B. B., Moskowitz, W. B., Taylor, M. B., & Palmer, A. (2021). Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far? Children (Basel), 8(7). doi:10.3390/children8070607. https://www.ncbi.nlm.nih.gov/pubmed/34356586
- Deb, A., Abdelmalek, J., Iwuji, K., & Nugent, K. (2021). Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events Reporting System Database. J Prim Care Community Health, 12, 21501327211029230. doi:10.1177/21501327211029230. https://www.ncbi.nlm.nih.gov/pubmed/34219532
- Dickey, J. B., Albert, E., Badr, M., Laraja, K. M., Sena, L. M., Gerson, D. S., . . . Aurigemma, G. P. (2021). A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2. JACC Cardiovasc Imaging, 14(9), 1862-1863. doi:10.1016/j.jcmg.2021.06.003. https://www.ncbi.nlm.nih.gov/pubmed/34246585
- Dimopoulou, D., Spyridis, N., Vartzelis, G., Tsolia, M. N., & Maritsi, D. N. (2021). Safety and tolerability of the COVID-19 mRNA-vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF-inhibitors. Arthritis Rheumatol. doi:10.1002/art.41977. https://www.ncbi.nlm.nih.gov/pubmed/34492161
- Dimopoulou, D., Vartzelis, G., Dasoula, F., Tsolia, M., & Maritsi, D. (2021). Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors. Ann Rheum Dis. doi:10.1136/annrheumdis-2021-221607. https://www.ncbi.nlm.nih.gov/pubmed/34844930
- Ehrlich, P., Klingel, K., Ohlmann-Knafo, S., Huttinger, S., Sood, N., Pickuth, D., & Kindermann, M. (2021). Biopsy-proven lymphocytic myocarditis following first mRNA COVID-19 vaccination in a 40-year-old male: case report. Clin Res Cardiol, 110(11), 1855-1859. doi:10.1007/s00392-021-01936-6. https://www.ncbi.nlm.nih.gov/pubmed/34487236
- El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M., Anderson, E. J., . . . Group, C. S. (2021). Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med, 385(19), 1774-1785. doi:10.1056/NEJMoa2113017. https://www.ncbi.nlm.nih.gov/pubmed/34551225
- Facetti, S., Giraldi, M., Vecchi, A. L., Rogiani, S., & Nassiacos, D. (2021). [Acute myocarditis in a young adult two days after Pfizer vaccination]. G Ital Cardiol (Rome), 22(11), 891-893. doi:10.1714/3689.36746. https://www.ncbi.nlm.nih.gov/pubmed/34709227
- Fazlollahi, A., Zahmatyar, M., Noori, M., Nejadghaderi, S. A., Sullman, M. J. M., Shekarriz-Foumani, R., . . . Safiri, S. (2021). Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series. Rev Med Virol, e2318. doi:10.1002/rmv.2318. https://www.ncbi.nlm.nih.gov/pubmed/34921468
- Fazolo, T., Lima, K., Fontoura, J. C., de Souza, P. O., Hilario, G., Zorzetto, R., . . . Bonorino, C. (2021). Pediatric COVID-19 patients in South Brazil show abundant viral mRNA and strong specific anti-viral responses. Nat Commun, 12(1), 6844. doi:10.1038/s41467-021-27120-y. https://www.ncbi.nlm.nih.gov/pubmed/34824230
- Fikenzer, S., & Laufs, U. (2021). Correction to: Response to Letter to the editors referring to Fikenzer, S., Uhe, T., Lavall, D., Rudolph, U., Falz, R., Busse, M., Hepp, P., & Laufs, U. (2020). Effects of surgical and FFP2/N95 face masks on cardiopulmonary exercise capacity. Clinical research in cardiology: official journal of the German Cardiac Society, 1-9. Advance online publication. https://doi.org/10.1007/s00392-020-01704-y. Clin Res Cardiol, 110(8), 1352. doi:10.1007/s00392-021-01896-x. https://www.ncbi.nlm.nih.gov/pubmed/34170372
- Foltran, D., Delmas, C., Flumian, C., De Paoli, P., Salvo, F., Gautier, S., . . . Montastruc, F. (2021). Myocarditis and Pericarditis in Adolescents after First and Second doses of mRNA COVID-19 Vaccines. Eur Heart J Qual Care Clin Outcomes. doi:10.1093/ehjqcco/qcab090. https://www.ncbi.nlm.nih.gov/pubmed/34849667
- Forgacs, D., Jang, H., Abreu, R. B., Hanley, H. B., Gattiker, J. L., Jefferson, A. M., & Ross, T. M. (2021). SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naive and Pre-Immune Humans. Front Immunol, 12, 728021. doi:10.3389/fimmu.2021.728021. https://www.ncbi.nlm.nih.gov/pubmed/34646267
- Furer, V., Eviatar, T., Zisman, D., Peleg, H., Paran, D., Levartovsky, D., . . . Elkayam, O. (2021). Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis, 80(10), 1330-1338. doi:10.1136/annrheumdis-2021-220647. https://www.ncbi.nlm.nih.gov/pubmed/34127481
- Galindo, R., Chow, H., & Rongkavilit, C. (2021). COVID-19 in Children: Clinical Manifestations and Pharmacologic Interventions Including Vaccine Trials. Pediatr Clin North Am, 68(5), 961-976. doi:10.1016/j.pcl.2021.05.004. https://www.ncbi.nlm.nih.gov/pubmed/34538306
- Gargano, J. W., Wallace, M., Hadler, S. C., Langley, G., Su, J. R., Oster, M. E., . . . Oliver, S. E. (2021). Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices – United States, June 2021. MMWR Morb Mortal Wkly Rep, 70(27), 977-982. doi:10.15585/mmwr.mm7027e2. https://www.ncbi.nlm.nih.gov/pubmed/34237049
- Gatti, M., Raschi, E., Moretti, U., Ardizzoni, A., Poluzzi, E., & Diemberger, I. (2021). Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase. Vaccines (Basel), 9(1). doi:10.3390/vaccines9010019. https://www.ncbi.nlm.nih.gov/pubmed/33406694
- Gautam, N., Saluja, P., Fudim, M., Jambhekar, K., Pandey, T., & Al’Aref, S. (2021). A Late Presentation of COVID-19 Vaccine-Induced Myocarditis. Cureus, 13(9), e17890. doi:10.7759/cureus.17890. https://www.ncbi.nlm.nih.gov/pubmed/34660088
- Gellad, W. F. (2021). Myocarditis after vaccination against covid-19. BMJ, 375, n3090. doi:10.1136/bmj.n3090. https://www.ncbi.nlm.nih.gov/pubmed/34916217
- Greenhawt, M., Abrams, E. M., Shaker, M., Chu, D. K., Khan, D., Akin, C., . . . Golden, D. B. K. (2021). The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. J Allergy Clin Immunol Pract, 9(10), 3546-3567. doi:10.1016/j.jaip.2021.06.006. https://www.ncbi.nlm.nih.gov/pubmed/34153517
- Haaf, P., Kuster, G. M., Mueller, C., Berger, C. T., Monney, P., Burger, P., . . . Tanner, F. C. (2021). The very low risk of myocarditis and pericarditis after mRNA COVID-19 vaccination should not discourage vaccination. Swiss Med Wkly, 151, w30087. doi:10.4414/smw.2021.w30087. https://www.ncbi.nlm.nih.gov/pubmed/34668687
- Hasnie, A. A., Hasnie, U. A., Patel, N., Aziz, M. U., Xie, M., Lloyd, S. G., & Prabhu, S. D. (2021). Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case report. BMC Cardiovasc Disord, 21(1), 375. doi:10.1186/s12872-021-02183-3. https://www.ncbi.nlm.nih.gov/pubmed/34348657
- Hause, A. M., Gee, J., Baggs, J., Abara, W. E., Marquez, P., Thompson, D., . . . Shay, D. K. (2021). COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years – United States, December 14, 2020-July 16, 2021. MMWR Morb Mortal Wkly Rep, 70(31), 1053-1058. doi:10.15585/mmwr.mm7031e1. https://www.ncbi.nlm.nih.gov/pubmed/34351881
- Helms, J. M., Ansteatt, K. T., Roberts, J. C., Kamatam, S., Foong, K. S., Labayog, J. S., & Tarantino, M. D. (2021). Severe, Refractory Immune Thrombocytopenia Occurring After SARS-CoV-2 Vaccine. J Blood Med, 12, 221-224. doi:10.2147/JBM.S307047. https://www.ncbi.nlm.nih.gov/pubmed/33854395
- Hippisley-Cox, J., Patone, M., Mei, X. W., Saatci, D., Dixon, S., Khunti, K., . . . Coupland, C. A. C. (2021). Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ, 374, n1931. doi:10.1136/bmj.n1931. https://www.ncbi.nlm.nih.gov/pubmed/34446426
- Ho, J. S., Sia, C. H., Ngiam, J. N., Loh, P. H., Chew, N. W., Kong, W. K., & Poh, K. K. (2021). A review of COVID-19 vaccination and the reported cardiac manifestations. Singapore Med J. doi:10.11622/smedj.2021210. https://www.ncbi.nlm.nih.gov/pubmed/34808708
- Iguchi, T., Umeda, H., Kojima, M., Kanno, Y., Tanaka, Y., Kinoshita, N., & Sato, D. (2021). Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report. Drug Saf, 44(11), 1209-1214. doi:10.1007/s40264-021-01104-9. https://www.ncbi.nlm.nih.gov/pubmed/34347278
- In brief: Myocarditis with the Pfizer/BioNTech and Moderna COVID-19 vaccines. (2021). Med Lett Drugs Ther, 63(1629), e9. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/34544112https://www.ncbi.nlm.nih.gov/pubmed/3454412
- Ioannou, A. (2021a). Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following Pfizer-BioNTech COVID-19 vaccination. QJM. doi:10.1093/qjmed/hcab231. https://www.ncbi.nlm.nih.gov/pubmed/34463755
- Ioannou, A. (2021b). T2 mapping should be utilised in cases of suspected myocarditis to confirm an acute inflammatory process. QJM. doi:10.1093/qjmed/hcab326. https://www.ncbi.nlm.nih.gov/pubmed/34931681
- Isaak, A., Feisst, A., & Luetkens, J. A. (2021). Myocarditis Following COVID-19 Vaccination. Radiology, 301(1), E378-E379. doi:10.1148/radiol.2021211766. https://www.ncbi.nlm.nih.gov/pubmed/34342500
- Istampoulouoglou, I., Dimitriou, G., Spani, S., Christ, A., Zimmermanns, B., Koechlin, S., . . . Leuppi-Taegtmeyer, A. B. (2021). Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre. Glob Cardiol Sci Pract, 2021(3), e202118. doi:10.21542/gcsp.2021.18. https://www.ncbi.nlm.nih.gov/pubmed/34805376
- Jaafar, R., Boschi, C., Aherfi, S., Bancod, A., Le Bideau, M., Edouard, S., . . . La Scola, B. (2021). High Individual Heterogeneity of Neutralizing Activities against the Original Strain and Nine Different Variants of SARS-CoV-2. Viruses, 13(11). doi:10.3390/v13112177. https://www.ncbi.nlm.nih.gov/pubmed/34834983
- Jain, S. S., Steele, J. M., Fonseca, B., Huang, S., Shah, S., Maskatia, S. A., . . . Grosse-Wortmann, L. (2021). COVID-19 Vaccination-Associated Myocarditis in Adolescents. Pediatrics, 148(5). doi:10.1542/peds.2021-053427. https://www.ncbi.nlm.nih.gov/pubmed/34389692
- Jhaveri, R., Adler-Shohet, F. C., Blyth, C. C., Chiotos, K., Gerber, J. S., Green, M., . . . Zaoutis, T. (2021). Weighing the Risks of Perimyocarditis With the Benefits of SARS-CoV-2 mRNA Vaccination in Adolescents. J Pediatric Infect Dis Soc, 10(10), 937-939. doi:10.1093/jpids/piab061. https://www.ncbi.nlm.nih.gov/pubmed/34270752
- Kaneta, K., Yokoi, K., Jojima, K., Kotooka, N., & Node, K. (2021). Young Male With Myocarditis Following mRNA-1273 Vaccination Against Coronavirus Disease-2019 (COVID-19). Circ J. doi:10.1253/circj.CJ-21-0818. https://www.ncbi.nlm.nih.gov/pubmed/34744118
- Kaul, R., Sreenivasan, J., Goel, A., Malik, A., Bandyopadhyay, D., Jin, C., . . . Panza, J. A. (2021). Myocarditis following COVID-19 vaccination. Int J Cardiol Heart Vasc, 36, 100872. doi:10.1016/j.ijcha.2021.100872. https://www.ncbi.nlm.nih.gov/pubmed/34568540
- Khogali, F., & Abdelrahman, R. (2021). Unusual Presentation of Acute Perimyocarditis Following SARS-COV-2 mRNA-1237 Moderna Vaccination. Cureus, 13(7), e16590. doi:10.7759/cureus.16590. https://www.ncbi.nlm.nih.gov/pubmed/34447639
- Kim, H. W., Jenista, E. R., Wendell, D. C., Azevedo, C. F., Campbell, M. J., Darty, S. N., . . . Kim, R. J. (2021). Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. JAMA Cardiol, 6(10), 1196-1201. doi:10.1001/jamacardio.2021.2828. https://www.ncbi.nlm.nih.gov/pubmed/34185046
- Kim, I. C., Kim, H., Lee, H. J., Kim, J. Y., & Kim, J. Y. (2021). Cardiac Imaging of Acute Myocarditis Following COVID-19 mRNA Vaccination. J Korean Med Sci, 36(32), e229. doi:10.3346/jkms.2021.36.e229. https://www.ncbi.nlm.nih.gov/pubmed/34402228
- King, W. W., Petersen, M. R., Matar, R. M., Budweg, J. B., Cuervo Pardo, L., & Petersen, J. W. (2021). Myocarditis following mRNA vaccination against SARS-CoV-2, a case series. Am Heart J Plus, 8, 100042. doi:10.1016/j.ahjo.2021.100042. https://www.ncbi.nlm.nih.gov/pubmed/34396358
- Klein, N. P., Lewis, N., Goddard, K., Fireman, B., Zerbo, O., Hanson, K. E., . . . Weintraub, E. S. (2021). Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA, 326(14), 1390-1399. doi:10.1001/jama.2021.15072. https://www.ncbi.nlm.nih.gov/pubmed/34477808
- Klimek, L., Bergmann, K. C., Brehler, R., Pfutzner, W., Zuberbier, T., Hartmann, K., . . . Worm, M. (2021). Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and OGAI. Allergo J Int, 1-17. doi:10.1007/s40629-021-00165-7. https://www.ncbi.nlm.nih.gov/pubmed/33898162
- Klimek, L., Novak, N., Hamelmann, E., Werfel, T., Wagenmann, M., Taube, C., . . . Worm, M. (2021). Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA: Position statement of the German Allergy Societies: Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA). Allergo J Int, 30(2), 51-55. doi:10.1007/s40629-020-00160-4. https://www.ncbi.nlm.nih.gov/pubmed/33643776
- Kohli, U., Desai, L., Chowdhury, D., Harahsheh, A. S., Yonts, A. B., Ansong, A., . . . Ang, J. Y. (2021). mRNA Coronavirus-19 Vaccine-Associated Myopericarditis in Adolescents: A Survey Study. J Pediatr. doi:10.1016/j.jpeds.2021.12.025. https://www.ncbi.nlm.nih.gov/pubmed/34952008
- Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A. A., & Tsatsakis, A. (2021a). Erratum to “Why are we vaccinating children against COVID-19?” [Toxicol. Rep. 8C (2021) 1665-1684 / 1193]. Toxicol Rep, 8, 1981. doi:10.1016/j.toxrep.2021.10.003. https://www.ncbi.nlm.nih.gov/pubmed/34642628
- Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A. A., & Tsatsakis, A. (2021b). Why are we vaccinating children against COVID-19? Toxicol Rep, 8, 1665-1684. doi:10.1016/j.toxrep.2021.08.010. https://www.ncbi.nlm.nih.gov/pubmed/34540594
- Kremsner, P. G., Mann, P., Kroidl, A., Leroux-Roels, I., Schindler, C., Gabor, J. J., . . . Group, C.-N.-S. (2021). Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial. Wien Klin Wochenschr, 133(17-18), 931-941. doi:10.1007/s00508-021-01922-y. https://www.ncbi.nlm.nih.gov/pubmed/34378087
- Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., . . . Stern, A. (2021). Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med, 27(8), 1379-1384. doi:10.1038/s41591-021-01413-7. https://www.ncbi.nlm.nih.gov/pubmed/34127854
- Kwan, M. Y. W., Chua, G. T., Chow, C. B., Tsao, S. S. L., To, K. K. W., Yuen, K. Y., . . . Ip, P. (2021). mRNA COVID vaccine and myocarditis in adolescents. Hong Kong Med J, 27(5), 326-327. doi:10.12809/hkmj215120. https://www.ncbi.nlm.nih.gov/pubmed/34393110
- Lee, E., Chew, N. W. S., Ng, P., & Yeo, T. J. (2021). Reply to “Letter to the editor: Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following PfizerBioNTech COVID-19 vaccination”. QJM. doi:10.1093/qjmed/hcab232. https://www.ncbi.nlm.nih.gov/pubmed/34463770
- Lee, E. J., Cines, D. B., Gernsheimer, T., Kessler, C., Michel, M., Tarantino, M. D., . . . Bussel, J. B. (2021). Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol, 96(5), 534-537. doi:10.1002/ajh.26132. https://www.ncbi.nlm.nih.gov/pubmed/33606296
- Levin, D., Shimon, G., Fadlon-Derai, M., Gershovitz, L., Shovali, A., Sebbag, A., . . . Gordon, B. (2021). Myocarditis following COVID-19 vaccination – A case series. Vaccine, 39(42), 6195-6200. doi:10.1016/j.vaccine.2021.09.004. https://www.ncbi.nlm.nih.gov/pubmed/34535317
- Li, J., Hui, A., Zhang, X., Yang, Y., Tang, R., Ye, H., . . . Zhu, F. (2021). Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nat Med, 27(6), 1062-1070. doi:10.1038/s41591-021-01330-9. https://www.ncbi.nlm.nih.gov/pubmed/33888900
- Li, M., Yuan, J., Lv, G., Brown, J., Jiang, X., & Lu, Z. K. (2021). Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types. J Pers Med, 11(11). doi:10.3390/jpm11111106. https://www.ncbi.nlm.nih.gov/pubmed/34834458
- Lim, Y., Kim, M. C., Kim, K. H., Jeong, I. S., Cho, Y. S., Choi, Y. D., & Lee, J. E. (2021). Case Report: Acute Fulminant Myocarditis and Cardiogenic Shock After Messenger RNA Coronavirus Disease 2019 Vaccination Requiring Extracorporeal Cardiopulmonary Resuscitation. Front Cardiovasc Med, 8, 758996. doi:10.3389/fcvm.2021.758996. https://www.ncbi.nlm.nih.gov/pubmed/34778411
- Long, S. S. (2021). Important Insights into Myopericarditis after the Pfizer mRNA COVID-19 Vaccination in Adolescents. J Pediatr, 238, 5. doi:10.1016/j.jpeds.2021.07.057. https://www.ncbi.nlm.nih.gov/pubmed/34332972
- Luk, A., Clarke, B., Dahdah, N., Ducharme, A., Krahn, A., McCrindle, B., . . . McDonald, M. (2021). Myocarditis and Pericarditis After COVID-19 mRNA Vaccination: Practical Considerations for Care Providers. Can J Cardiol, 37(10), 1629-1634. doi:10.1016/j.cjca.2021.08.001. https://www.ncbi.nlm.nih.gov/pubmed/34375696
- Madelon, N., Lauper, K., Breville, G., Sabater Royo, I., Goldstein, R., Andrey, D. O., . . . Eberhardt, C. S. (2021). Robust T cell responses in anti-CD20 treated patients following COVID-19 vaccination: a prospective cohort study. Clin Infect Dis. doi:10.1093/cid/ciab954. https://www.ncbi.nlm.nih.gov/pubmed/34791081
- Mangat, C., & Milosavljevic, N. (2021). BNT162b2 Vaccination during Pregnancy Protects Both the Mother and Infant: Anti-SARS-CoV-2 S Antibodies Persistently Positive in an Infant at 6 Months of Age. Case Rep Pediatr, 2021, 6901131. doi:10.1155/2021/6901131. https://www.ncbi.nlm.nih.gov/pubmed/34676123
- Mark, C., Gupta, S., Punnett, A., Upton, J., Orkin, J., Atkinson, A., . . . Alexander, S. (2021). Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase. Pediatr Blood Cancer, 68(11), e29295. doi:10.1002/pbc.29295. https://www.ncbi.nlm.nih.gov/pubmed/34398511
- Martins-Filho, P. R., Quintans-Junior, L. J., de Souza Araujo, A. A., Sposato, K. B., Souza Tavares, C. S., Gurgel, R. Q., . . . Santos, V. S. (2021). Socio-economic inequalities and COVID-19 incidence and mortality in Brazilian children: a nationwide register-based study. Public Health, 190, 4-6. doi:10.1016/j.puhe.2020.11.005. https://www.ncbi.nlm.nih.gov/pubmed/33316478
- McLean, K., & Johnson, T. J. (2021). Myopericarditis in a previously healthy adolescent male following COVID-19 vaccination: A case report. Acad Emerg Med, 28(8), 918-921. doi:10.1111/acem.14322. https://www.ncbi.nlm.nih.gov/pubmed/34133825
- Mevorach, D., Anis, E., Cedar, N., Bromberg, M., Haas, E. J., Nadir, E., . . . Alroy-Preis, S. (2021). Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med, 385(23), 2140-2149. doi:10.1056/NEJMoa2109730. https://www.ncbi.nlm.nih.gov/pubmed/34614328
- Minocha, P. K., Better, D., Singh, R. K., & Hoque, T. (2021). Recurrence of Acute Myocarditis Temporally Associated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccine in a Male Adolescent. J Pediatr, 238, 321-323. doi:10.1016/j.jpeds.2021.06.035. https://www.ncbi.nlm.nih.gov/pubmed/34166671
- Mizrahi, B., Lotan, R., Kalkstein, N., Peretz, A., Perez, G., Ben-Tov, A., . . . Patalon, T. (2021). Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine. Nat Commun, 12(1), 6379. doi:10.1038/s41467-021-26672-3. https://www.ncbi.nlm.nih.gov/pubmed/34737312
- Moffitt, K., Cheung, E., Yeung, T., Stamoulis, C., & Malley, R. (2021). Analysis of Staphylococcus aureus Transcriptome in Pediatric Soft Tissue Abscesses and Comparison to Murine Infections. Infect Immun, 89(4). doi:10.1128/IAI.00715-20. https://www.ncbi.nlm.nih.gov/pubmed/33526560
- Mohamed, L., Madsen, A. M. R., Schaltz-Buchholzer, F., Ostenfeld, A., Netea, M. G., Benn, C. S., & Kofoed, P. E. (2021). Reactivation of BCG vaccination scars after vaccination with mRNA-Covid-vaccines: two case reports. BMC Infect Dis, 21(1), 1264. doi:10.1186/s12879-021-06949-0. https://www.ncbi.nlm.nih.gov/pubmed/34930152
- Montgomery, J., Ryan, M., Engler, R., Hoffman, D., McClenathan, B., Collins, L., . . . Cooper, L. T., Jr. (2021). Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. JAMA Cardiol, 6(10), 1202-1206. doi:10.1001/jamacardio.2021.2833. https://www.ncbi.nlm.nih.gov/pubmed/34185045
- Murakami, Y., Shinohara, M., Oka, Y., Wada, R., Noike, R., Ohara, H., . . . Ikeda, T. (2021). Myocarditis Following a COVID-19 Messenger RNA Vaccination: A Japanese Case Series. Intern Med. doi:10.2169/internalmedicine.8731-21. https://www.ncbi.nlm.nih.gov/pubmed/34840235
- Nagasaka, T., Koitabashi, N., Ishibashi, Y., Aihara, K., Takama, N., Ohyama, Y., . . . Kaneko, Y. (2021). Acute Myocarditis Associated with COVID-19 Vaccination: A Case Report. J Cardiol Cases. doi:10.1016/j.jccase.2021.11.006. https://www.ncbi.nlm.nih.gov/pubmed/34876937
- Ntouros, P. A., Vlachogiannis, N. I., Pappa, M., Nezos, A., Mavragani, C. P., Tektonidou, M. G., . . . Sfikakis, P. P. (2021). Effective DNA damage response after acute but not chronic immune challenge: SARS-CoV-2 vaccine versus Systemic Lupus Erythematosus. Clin Immunol, 229, 108765. doi:10.1016/j.clim.2021.108765. https://www.ncbi.nlm.nih.gov/pubmed/34089859
- Nygaard, U., Holm, M., Bohnstedt, C., Chai, Q., Schmidt, L. S., Hartling, U. B., . . . Stensballe, L. G. (2022). Population-based Incidence of Myopericarditis After COVID-19 Vaccination in Danish Adolescents. Pediatr Infect Dis J, 41(1), e25-e28. doi:10.1097/INF.0000000000003389. https://www.ncbi.nlm.nih.gov/pubmed/34889875
- Oberhardt, V., Luxenburger, H., Kemming, J., Schulien, I., Ciminski, K., Giese, S., . . . Hofmann, M. (2021). Rapid and stable mobilization of CD8(+) T cells by SARS-CoV-2 mRNA vaccine. Nature, 597(7875), 268-273. doi:10.1038/s41586-021-03841-4. https://www.ncbi.nlm.nih.gov/pubmed/34320609
- Park, H., Yun, K. W., Kim, K. R., Song, S. H., Ahn, B., Kim, D. R., . . . Kim, Y. J. (2021). Epidemiology and Clinical Features of Myocarditis/Pericarditis before the Introduction of mRNA COVID-19 Vaccine in Korean Children: a Multicenter Study. J Korean Med Sci, 36(32), e232. doi:10.3346/jkms.2021.36.e232. https://www.ncbi.nlm.nih.gov/pubmed/34402230
- Park, J., Brekke, D. R., & Bratincsak, A. (2021). Self-limited myocarditis presenting with chest pain and ST segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine. Cardiol Young, 1-4. doi:10.1017/S1047951121002547. https://www.ncbi.nlm.nih.gov/pubmed/34180390
- Patel, Y. R., Louis, D. W., Atalay, M., Agarwal, S., & Shah, N. R. (2021). Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis following mRNA COVID-19 vaccination: a case series. J Cardiovasc Magn Reson, 23(1), 101. doi:10.1186/s12968-021-00795-4. https://www.ncbi.nlm.nih.gov/pubmed/34496880
- Patone, M., Mei, X. W., Handunnetthi, L., Dixon, S., Zaccardi, F., Shankar-Hari, M., . . . Hippisley-Cox, J. (2021). Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. doi:10.1038/s41591-021-01630-0. https://www.ncbi.nlm.nih.gov/pubmed/34907393
- Patrignani, A., Schicchi, N., Calcagnoli, F., Falchetti, E., Ciampani, N., Argalia, G., & Mariani, A. (2021). Acute myocarditis following Comirnaty vaccination in a healthy man with previous SARS-CoV-2 infection. Radiol Case Rep, 16(11), 3321-3325. doi:10.1016/j.radcr.2021.07.082. https://www.ncbi.nlm.nih.gov/pubmed/34367386
- Perez, Y., Levy, E. R., Joshi, A. Y., Virk, A., Rodriguez-Porcel, M., Johnson, M., . . . Swift, M. D. (2021). Myocarditis Following COVID-19 mRNA Vaccine: A Case Series and Incidence Rate Determination. Clin Infect Dis. doi:10.1093/cid/ciab926. https://www.ncbi.nlm.nih.gov/pubmed/34734240
- Perrotta, A., Biondi-Zoccai, G., Saade, W., Miraldi, F., Morelli, A., Marullo, A. G., . . . Peruzzi, M. (2021). A snapshot global survey on side effects of COVID-19 vaccines among healthcare professionals and armed forces with a focus on headache. Panminerva Med, 63(3), 324-331. doi:10.23736/S0031-0808.21.04435-9. https://www.ncbi.nlm.nih.gov/pubmed/34738774
- Pinana, J. L., Lopez-Corral, L., Martino, R., Montoro, J., Vazquez, L., Perez, A., . . . Cell Therapy, G. (2022). SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group. Am J Hematol, 97(1), 30-42. doi:10.1002/ajh.26385. https://www.ncbi.nlm.nih.gov/pubmed/34695229
- Revon-Riviere, G., Ninove, L., Min, V., Rome, A., Coze, C., Verschuur, A., . . . Andre, N. (2021). The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience. Eur J Cancer, 154, 30-34. doi:10.1016/j.ejca.2021.06.002. https://www.ncbi.nlm.nih.gov/pubmed/34233234
- Sanchez Tijmes, F., Thavendiranathan, P., Udell, J. A., Seidman, M. A., & Hanneman, K. (2021). Cardiac MRI Assessment of Nonischemic Myocardial Inflammation: State of the Art Review and Update on Myocarditis Associated with COVID-19 Vaccination. Radiol Cardiothorac Imaging, 3(6), e210252. doi:10.1148/ryct.210252. https://www.ncbi.nlm.nih.gov/pubmed/34934954
- Schauer, J., Buddhe, S., Colyer, J., Sagiv, E., Law, Y., Mallenahalli Chikkabyrappa, S., & Portman, M. A. (2021). Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents. J Pediatr, 238, 317-320. doi:10.1016/j.jpeds.2021.06.083. https://www.ncbi.nlm.nih.gov/pubmed/34228985
- Schneider, J., Sottmann, L., Greinacher, A., Hagen, M., Kasper, H. U., Kuhnen, C., . . . Schmeling, A. (2021). Postmortem investigation of fatalities following vaccination with COVID-19 vaccines. Int J Legal Med, 135(6), 2335-2345. doi:10.1007/s00414-021-02706-9. https://www.ncbi.nlm.nih.gov/pubmed/34591186
- Schramm, R., Costard-Jackle, A., Rivinius, R., Fischer, B., Muller, B., Boeken, U., . . . Gummert, J. (2021). Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients. Clin Res Cardiol, 110(8), 1142-1149. doi:10.1007/s00392-021-01880-5. https://www.ncbi.nlm.nih.gov/pubmed/34241676
- Sessa, F., Salerno, M., Esposito, M., Di Nunno, N., Zamboni, P., & Pomara, C. (2021). Autopsy Findings and Causality Relationship between Death and COVID-19 Vaccination: A Systematic Review. J Clin Med, 10(24). doi:10.3390/jcm10245876. https://www.ncbi.nlm.nih.gov/pubmed/34945172
- Sharif, N., Alzahrani, K. J., Ahmed, S. N., & Dey, S. K. (2021). Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Front Immunol, 12, 714170. doi:10.3389/fimmu.2021.714170. https://www.ncbi.nlm.nih.gov/pubmed/34707602
- Shay, D. K., Gee, J., Su, J. R., Myers, T. R., Marquez, P., Liu, R., . . . Shimabukuro, T. T. (2021). Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine – United States, March-April 2021. MMWR Morb Mortal Wkly Rep, 70(18), 680-684. doi:10.15585/mmwr.mm7018e2. https://www.ncbi.nlm.nih.gov/pubmed/33956784
- Shazley, O., & Alshazley, M. (2021). A COVID-Positive 52-Year-Old Man Presented With Venous Thromboembolism and Disseminated Intravascular Coagulation Following Johnson & Johnson Vaccination: A Case-Study. Cureus, 13(7), e16383. doi:10.7759/cureus.16383. https://www.ncbi.nlm.nih.gov/pubmed/34408937
- Shiyovich, A., Witberg, G., Aviv, Y., Eisen, A., Orvin, K., Wiessman, M., . . . Hamdan, A. (2021). Myocarditis following COVID-19 vaccination: magnetic resonance imaging study. Eur Heart J Cardiovasc Imaging. doi:10.1093/ehjci/jeab230. https://www.ncbi.nlm.nih.gov/pubmed/34739045
- Simone, A., Herald, J., Chen, A., Gulati, N., Shen, A. Y., Lewin, B., & Lee, M. S. (2021). Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older. JAMA Intern Med, 181(12), 1668-1670. doi:10.1001/jamainternmed.2021.5511. https://www.ncbi.nlm.nih.gov/pubmed/34605853
- Singer, M. E., Taub, I. B., & Kaelber, D. C. (2021). Risk of Myocarditis from COVID-19 Infection in People Under Age 20: A Population-Based Analysis. medRxiv. doi:10.1101/2021.07.23.21260998. https://www.ncbi.nlm.nih.gov/pubmed/34341797
- Smith, C., Odd, D., Harwood, R., Ward, J., Linney, M., Clark, M., . . . Fraser, L. K. (2021). Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year. Nat Med. doi:10.1038/s41591-021-01578-1. https://www.ncbi.nlm.nih.gov/pubmed/34764489
- Snapiri, O., Rosenberg Danziger, C., Shirman, N., Weissbach, A., Lowenthal, A., Ayalon, I., . . . Bilavsky, E. (2021). Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine. Pediatr Infect Dis J, 40(10), e360-e363. doi:10.1097/INF.0000000000003235. https://www.ncbi.nlm.nih.gov/pubmed/34077949
- Spinner, J. A., Julien, C. L., Olayinka, L., Dreyer, W. J., Bocchini, C. E., Munoz, F. M., & Devaraj, S. (2021). SARS-CoV-2 anti-spike antibodies after vaccination in pediatric heart transplantation: A first report. J Heart Lung Transplant. doi:10.1016/j.healun.2021.11.001. https://www.ncbi.nlm.nih.gov/pubmed/34911654
- Starekova, J., Bluemke, D. A., Bradham, W. S., Grist, T. M., Schiebler, M. L., & Reeder, S. B. (2021). Myocarditis Associated with mRNA COVID-19 Vaccination. Radiology, 301(2), E409-E411. doi:10.1148/radiol.2021211430. https://www.ncbi.nlm.nih.gov/pubmed/34282971
- Sulemankhil, I., Abdelrahman, M., & Negi, S. I. (2021). Temporal association between the COVID-19 Ad26.COV2.S vaccine and acute myocarditis: A case report and literature review. Cardiovasc Revasc Med. doi:10.1016/j.carrev.2021.08.012. https://www.ncbi.nlm.nih.gov/pubmed/34420869
- Tailor, P. D., Feighery, A. M., El-Sabawi, B., & Prasad, A. (2021). Case report: acute myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine. Eur Heart J Case Rep, 5(8), ytab319. doi:10.1093/ehjcr/ytab319. https://www.ncbi.nlm.nih.gov/pubmed/34514306
- Takeda, M., Ishio, N., Shoji, T., Mori, N., Matsumoto, M., & Shikama, N. (2021). Eosinophilic Myocarditis Following Coronavirus Disease 2019 (COVID-19) Vaccination. Circ J. doi:10.1253/circj.CJ-21-0935. https://www.ncbi.nlm.nih.gov/pubmed/34955479
- Team, C. C.-R., Food, & Drug, A. (2021). Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine – United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep, 70(2), 46-51. doi:10.15585/mmwr.mm7002e1. https://www.ncbi.nlm.nih.gov/pubmed/33444297
- Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H., Yoon, S. K., Meece, J., . . . Gaglani, M. (2021). Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. N Engl J Med, 385(4), 320-329. doi:10.1056/NEJMoa2107058. https://www.ncbi.nlm.nih.gov/pubmed/34192428
- Tinoco, M., Leite, S., Faria, B., Cardoso, S., Von Hafe, P., Dias, G., . . . Lourenco, A. (2021). Perimyocarditis Following COVID-19 Vaccination. Clin Med Insights Cardiol, 15, 11795468211056634. doi:10.1177/11795468211056634. https://www.ncbi.nlm.nih.gov/pubmed/34866957
- Truong, D. T., Dionne, A., Muniz, J. C., McHugh, K. E., Portman, M. A., Lambert, L. M., . . . Newburger, J. W. (2021). Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults. Circulation. doi:10.1161/CIRCULATIONAHA.121.056583. https://www.ncbi.nlm.nih.gov/pubmed/34865500
- Tutor, A., Unis, G., Ruiz, B., Bolaji, O. A., & Bob-Manuel, T. (2021). Spectrum of Suspected Cardiomyopathy Due to COVID-19: A Case Series. Curr Probl Cardiol, 46(10), 100926. doi:10.1016/j.cpcardiol.2021.100926. https://www.ncbi.nlm.nih.gov/pubmed/34311983
- Umei, T. C., Kishino, Y., Shiraishi, Y., Inohara, T., Yuasa, S., & Fukuda, K. (2021). Recurrence of myopericarditis following mRNA COVID-19 vaccination in a male adolescent. CJC Open. doi:10.1016/j.cjco.2021.12.002. https://www.ncbi.nlm.nih.gov/pubmed/34904134
- Vidula, M. K., Ambrose, M., Glassberg, H., Chokshi, N., Chen, T., Ferrari, V. A., & Han, Y. (2021). Myocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19 Vaccines. Cureus, 13(6), e15576. doi:10.7759/cureus.15576. https://www.ncbi.nlm.nih.gov/pubmed/34277198
- Visclosky, T., Theyyunni, N., Klekowski, N., & Bradin, S. (2021). Myocarditis Following mRNA COVID-19 Vaccine. Pediatr Emerg Care, 37(11), 583-584. doi:10.1097/PEC.0000000000002557. https://www.ncbi.nlm.nih.gov/pubmed/34731877
- Warren, C. M., Snow, T. T., Lee, A. S., Shah, M. M., Heider, A., Blomkalns, A., . . . Nadeau, K. C. (2021). Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System. JAMA Netw Open, 4(9), e2125524. doi:10.1001/jamanetworkopen.2021.25524. https://www.ncbi.nlm.nih.gov/pubmed/34533570
- Watkins, K., Griffin, G., Septaric, K., & Simon, E. L. (2021). Myocarditis after BNT162b2 vaccination in a healthy male. Am J Emerg Med, 50, 815 e811-815 e812. doi:10.1016/j.ajem.2021.06.051. https://www.ncbi.nlm.nih.gov/pubmed/34229940
- Weitzman, E. R., Sherman, A. C., & Levy, O. (2021). SARS-CoV-2 mRNA Vaccine Attitudes as Expressed in U.S. FDA Public Commentary: Need for a Public-Private Partnership in a Learning Immunization System. Front Public Health, 9, 695807. doi:10.3389/fpubh.2021.695807. https://www.ncbi.nlm.nih.gov/pubmed/34336774
- Welsh, K. J., Baumblatt, J., Chege, W., Goud, R., & Nair, N. (2021). Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS). Vaccine, 39(25), 3329-3332. doi:10.1016/j.vaccine.2021.04.054. https://www.ncbi.nlm.nih.gov/pubmed/34006408
- Witberg, G., Barda, N., Hoss, S., Richter, I., Wiessman, M., Aviv, Y., . . . Kornowski, R. (2021). Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. N Engl J Med, 385(23), 2132-2139. doi:10.1056/NEJMoa2110737. https://www.ncbi.nlm.nih.gov/pubmed/34614329
- Zimmermann, P., & Curtis, N. (2020). Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. Arch Dis Child. doi:10.1136/archdischild-2020-320338. https://www.ncbi.nlm.nih.gov/pubmed/33262177
Could it be the case that the genetic processes induced by covid vaccination have curtailed rational thought and promoted indifference to risk? In short, does mRNA vaccination drill down to the interface between consciousness and genetics – interfering with the very basis of mental clarity and physical health?
https://www.shtfplan.com/headline-news/what-effect-do-mrna-vaccines-have-on-human-consciousness
Apr 16, 2023
This article was originally published by Dr. Guy Hatchard at The Hatchard Report and found via The Daily Exposé.
The strategies we are currently employing aren’t working. Appealing to published science, data, rational debate, and ethical responsibility is water off a duck’s back. In fact, the response of governments around the world is to bury data and attack those asking questions.
Could it be the case that the genetic processes induced by covid vaccination have curtailed rational thought and promoted indifference to risk? In short, does mRNA vaccination drill down to the interface between consciousness and genetics – interfering with the very basis of mental clarity and physical health?
In an interview I recorded a couple of weeks ago with Paul Brennan of Reality Check Radio he asked me when I thought the authorities would come to their senses and realize that the“safe and effective” narrative is false. I found myself at a loss for words because I don’t see any indication that it is happening or will anytime soon.
Looking around the world, we see governments doubling down on mRNA vaccination, congratulating each other on their pandemic success (???), controlling the media, and denying their own statistics of unprecedented excess death and vaccine injury. You can’t win an argument without dialogue and rational discussion. We are trying to stop a runaway train without the benefit of brakes.
More worryingly, risky biotechnology experiments are proliferating. Gain-of-function experiments are continuing like THIS one, which could render the monkeypox virus 1000x more lethal than it currently is, by crossing the current mild version circulating in human populations with a deadly strain currently confined to mice populations. Research to put mRNA vaccines in food is also in progress, funded by Bill Gates.
It all comes to a head when you see that New Zealand’s PM and Health Minister publicly received their bivalent shots. They don’t appear to read or understand covid science. Haven’t they worked out that even in the original trials the vaccinated group had higher mortality, now reflected in national data? Or that the risk of injury and death increases with each subsequent covid jab?
It seems to me that we have completely underestimated the causes and extent of our communication problem. The strategies we are currently employing aren’t working. Appealing to published science, data, rational debate, and ethical responsibility is water off a duck’s back. In fact, the response of governments around the world is to bury data and attack those asking questions.
Does biotech medicine undermine rational thought?
Could it be the case that the genetic processes induced by covid vaccination have curtailed rational thought and promoted indifference to risk? In short, does mRNA vaccination drill down to the interface between consciousness and genetics – interfering with the very basis of mental clarity and physical health?
I want to emphasize that this is not a trivial supposition. The internal functioning of cells must be related to the projection of consciousness, yet the relationship between consciousness and genetic function has been largely ignored in consideration of gene editing safety. In the rush to develop biotechnology, there has been a fundamental misapprehension that consciousness can be safely left out of the equation, it can’t.
Currently, some research is focusing on the relationship between mental illness caused by trauma and epigenetic dysfunction. Research on mice has established that epigenetic editing can possibly alleviate induced trauma, but more worryingly it can also cause it. The complex physical counterparts of human mental illness are little understood, but it is slowly becoming clear that gene editing can disrupt mental health.
How are inter- and intra-cellular processes related to consciousness?
Recently under the title ‘The Gene Illusion that is Killing Us’ I wrote about the basic features of cell biology and the implications for mRNA vaccine safety. I suggested that a cell is a self-organizing entity whose defining characteristic is its ability to support self-referral consciousness in the whole organism and concluded: “The capacity of cells to network together to support a single conscious entity appears to be a fundamental property of life.”
Through what channels do cellular functions exhibit sentient properties and engage in information exchange?
Chemistry: Cells constantly receive and send chemical signals and extract energy from the chemistry of food.
Transcription Regulation: Because RNA is the direct output of genetic information, a significant proportion of a cell’s regulatory capabilities are focused on RNA synthesis, processing, transport, modification, and translation.
These eight objective properties of cells may be intimately linked with the functions of consciousness.
In a parallel description of the fundamentals of life, the Bhagavad Gita (7.4) also describes life as eightfold with five fundamental qualities of matter paired with five senses, then the mind, intellect, and ego. Despite the misleading rough English translation into earth, water, fire, air, and space, the similarity with the above list in an identical order is striking. The Bhagavad Gita is an ancient Indian text whose content inspired some of the founders of quantum mechanics including Einstein. The Gita is fundamentally a textbook of consciousness.
An eight-fold nature, or prakriti as it is called in Sanskrit, is considered to be the functioning expression of universal consciousness. We are not talking here as if a single human cell connects with universal consciousness, merely that cells appear to have structures and functions that are analogous to what are considered to be the structures and functions of human consciousness.
How do cellular networks support consciousness?
Cells network together within a single human identity, but they can only do so if they have certain exactly identical characteristics. If a person has a transplant, the body will reject the foreign organ in the absence of a lifelong course of immunosuppressant drugs, just because the organ’s cells aren’t genetically identical.
From this, we suppose that only a network of identical genetic characteristics and functions is capable of supporting human health and consciousness. At this point, it becomes very hard to maintain that the projection of consciousness from a network of 37 trillion cells is a mechanical process. Rather it is more plausible to suggest that individual consciousness is what holds the cells together, made possible by their identical properties. The readily definable moment when consciousness “leaves” the body at death strengthens this conception.
If, as we have discussed, the cell is the fundamental physical counterpart of individual life and consciousness, we must accept that wide-scale disruption of cellular function, as happens through mRNA vaccination, could have catastrophic consequences for conscious processes. Can it fracture the cellular identity that supports life and trigger immune conflicts? Hospitalization and excess death data increasingly suggests it does.
In addition to this, mRNA vaccination directly interferes with transcription regulation which, if the analogy with the Gita holds up, could possibly be related to the functioning of intelligence. The intellect is that part of consciousness that chooses or decides and RNA transcription is the process that determines which parts of the genome will be expressed and how.
Biotechnology has surged ahead on a wave of commercial and government investment driven by PR hype that has ignored safety considerations. Once we begin to explore its potential effects on consciousness, the biotech agenda takes on a distinctly transhuman character. If we are to heal the adverse effects of novel and highly invasive biotech medicine, we will have to consider options that restore balance at the most fundamental level of the mind and body—options that balance consciousness.
This may take us out of the intellectual comfort zone of reductionist science, but that is happening anyway in many disciplines of science and the broadening of discussions to include consciousness can only be welcomed. Significant and authoritative sources of knowledge about consciousness can be found in a number of ancient traditions still practiced today.
What if consciousness is primary and matter secondary?
The Indian system of Ayurveda begins its approach to health from the side of consciousness. It considers that our physiology develops under the umbrella of our consciousness. In other words, consciousness is primary, and matter secondary. Ayurveda holds that ‘the mistake of the intellect’ (pragyaparadha) is the fundamental cause of disease. Pragyaparadha results from the disruption of our conscious connection to universal consciousness, see HERE for a full discussion of this concept.
Modern science has wrongly equated both knowledge and consciousness with information and procedure (a mistake now being perpetuated by AI systems that have a fundamental difficulty distinguishing truth from falsehood). Essentially downgrading the role of consciousness to that of a library, storehouse, or computer program.
This conception also fails to recognize consciousness as an integral feature of the laws of nature. In fact, it is impossible to formulate consistent laws of physics and cosmology without reference to consciousness. Ayurveda goes further and identifies universal consciousness as the source of natural law and knowledge in general.
We have discussed possible relationships between consciousness and genetics in many articles so far, but we haven’t examined how we might begin to repair mRNA vaccine damage. Consciousness and matter are two sides of one coin. There are approaches from both sides that are known to benefit the individual and society. If consciousness is primary and matter secondary as Ayurveda suggests, consciousness-based approaches to health could be among our most promising health interventions.
How do we rebalance psychosocial dysfunction?
Divisions and social isolation caused by pandemic policies including lockdowns and vaccine mandates have apparently had a much larger effect on mental and physical health than previously realized. A Norwegian study ‘Prevalence and Characteristics Associated With Post–COVID-19 Condition Among Nonhospitalized Adolescents and Young Adults’ has found that psychosocial factors are of overwhelming importance in the development of so-called long covid but NOT covid infection itself (read Dr. Vinay Prasad, Professor of Epidemiology and Biostatistics at the University of California, San Francisco (UCSF) discussing these startling findings HERE).
In 1996 I published a paper in Psychology, Crime, and Law entitled ‘The Maharishi Effect: A Model for social improvement. Time series analysis of a phase transition to reduced crime in the Merseyside metropolitan area’. This documented the effect of a model village created to offer opportunities to practice meditation which dramatically reduced crime rates in the surrounding port city of Liverpool and its population of 1.5 million. The project eventually won a British Urban Renewal Award.
More than 50 scientific papers examining this effect in multiple settings around the world have been published. I discuss this widely verified effect of reduced crime, violence, and conflict, along with increased economic activity and reduced social stress, in the final three chapters of my book ‘Your DNA Diet’. The development of consciousness through individual and collective meditation is provably a powerful force for social justice and well-being. There are a number of others with ancient roots.
Ayurveda offers many approaches to mental and physical health. As well as meditation which includes yoga and breathing exercises. In addition, there are herbal preparations for individuals to take.
In order to further realize the benefits of consciousness-based natural approaches to health, new institutions of learning and medicine need to be explored. Educational institutions that develop consciousness can be cornerstones of society. One such school founded as part of the Merseyside project is now fully funded by the UK government. Its pupils have won numerous academic and artistic awards.
These consciousness-based approaches to health might seem counterintuitive to many, but they are open to scientific testing and verification. They offer a possibility to silently help rebalance our polarised collective consciousness without conflict or rancor.
In summary, we can acknowledge subjective or consciousness-based approaches to learning that complement and coexist with objective means of gaining knowledge. This does not mean that criteria of scientific validity need to be abandoned, quite the reverse, but it does mean that the exclusion of consciousness from science should be abandoned. Consciousness exists and it is a moving force of life, all life.
Biotechnology deliberately ignores the connection between consciousness and genetics. This omission may be the ultimate driver of the unfolding pandemic disaster. GLOBE is promoting a campaign for Global Legislation Outlawing Biotechnology Experimentation.
About the Author
Guy Hatchard, Ph.D., was formerly a senior manager at Genetic ID a global food testing and safety company (now known as FoodChain ID). You can subscribe to his websites HatchardReport.com and GLOBE.GLOBAL for regular updates by email. GLOBE.GLOBAL is a website dedicated to providing information about the dangers of biotechnology.
Every nation with a semi decent intelligence service knows that the US Govt is responsible for the creation of Covid-19 and 7+ million deaths worldwide. Any tolerance for US domination is well and truly over and the growing multipolar alliance unites to de-dollarize the world.
Global Research, March 25, 2023
Region: Europe
Theme: Media Disinformation, Science and Medicine
***
These days it isn’t difficult to be cynical about politicians. This is especially the case given the draconian public health policies that most of them supported during the COVID-19 pandemic.
After enduring repeated lockdowns and being coerced into accepting experimental gene-based vaccines, it’s no wonder that many people have lost faith in their lawmakers.
While only rarely do we see politicians who are brave enough to speak out about the dangers of mRNA COVID-19 injections, there are a few who refuse to be silenced. Take Andrew Bridgen, for example, a Member of Parliament from the UK who, a few days ago, stood up to give a speech in a debate on mRNA COVID-19 booster vaccinations. Speaking to an almost deserted UK House of Commons (the video shows fellow parliamentarians quickly leaving the chamber as he began to speak), Bridgen openly described the deaths and serious harms caused by the shots.
Recently suspended from the UK’s ruling Conservative Party after he had tweeted an article questioning the safety of COVID-19 vaccines and labelled them “the biggest crime against humanity since the Holocaust,” Bridgen currently sits as an independent MP in the UK parliament. Predictably, since he began speaking out about the dangers of these vaccines, there have been crude attempts to censor him. After the video of his House of Commons speech was posted on YouTube, for example, it was rapidly taken down and only reinstated by the social media platform after a public outcry. Meantime, the speech has essentially been ignored in the mainstream media.
Video
The risk of serious adverse events
One of the most powerful aspects of this speech is that, far from resorting to conjecture or hearsay, Bridgen specifically refers to the UK government’s own data. Citing the Yellow Card scheme, for example, the system for reporting and monitoring adverse reactions to drugs and vaccines in the UK, he describes how the reported number of adverse events for COVID-19 vaccines is now far higher than those for all conventional vaccines administered over the past 50 years.
Bridgen also outlines how, in order to examine the frequency of serious adverse events following vaccination with the Pfizer and Moderna mRNA COVID-19 vaccines, data held by the US Government’s National Library of Medicine was used for a research study led by Dr. Joseph Fraiman. This revealed that there are 10.1 serious adverse events for every 10,000 Pfizer vaccinations administered, meaning that one in every 990 people vaccinated with the Pfizer booster will suffer a serious adverse event.
Dr. Fraiman further discovered that the risk from the Moderna mRNA vaccine was even greater than that of the Pfizer one, with an average of 15.1 serious adverse events for every 10,000 shots given. This means that one in 662 people vaccinated with the Moderna booster will suffer a serious adverse event. Combining the data for the Pfizer and Moderna mRNA vaccines or boosters gives an average of 1,250 serious adverse events for every 1 million vaccine boosters administered – in other words, a one in 800 chance of a serious adverse event occurring.
The true cost of using mRNA vaccines to prevent hospitalization
Bridgen describes how the UK government’s own data shows that, in order to prevent just one healthy adult aged between 50 and 59 from being hospitalized due to COVID-19, 43,600 people have to be given a booster shot. Based on a serious adverse event rate of one in 800, this means that in the healthy 50 to 59-year-old group, as a result of being given mRNA boosters, 55 people would die or be hospitalized simply to prevent one COVID-19 patient being hospitalized.
The same data also shows that in the healthy 40 to 49 age group, 92,500 booster jabs were required just to prevent one person from being hospitalized due to COVID-19. This would have put 116 people at risk of death or having a serious adverse reaction. In the healthy 30 to 39 age group, a total of 210,400 booster jabs would be required to prevent one person being hospitalized. This suggests that 263 UK citizens in this age group will have been hospitalized or even died just to keep one single COVID-19 case out of the hospital.
As Bridgen points out, however, hospitalization does not necessarily mean a serious medical intervention such as intubation or oxygen. To prevent severe hospitalization from COVID-19, the numbers needed to be boosted with the vaccines become astronomical. Here, the UK government’s own data shows that, in healthy adults aged 50 to 59, it was necessary to give 256,400 booster jabs to prevent just one severe hospitalization. This would put 321 people into hospital with a serious side-effect, including risk of death.
For healthy 40 to 49-year-olds, the number needing to be boosted to keep just one COVID-19 patient out of an intensive care unit increases to 932,500. This potentially puts 1,165 people in hospital with serious harm, disability, or death.
For the most vulnerable group – the over-70s with comorbidities – UK government data suggest it would be necessary to administer 800 vaccine boosters to prevent one hospitalization. This means that, by being boosted, all this group is essentially doing is swapping the risk of being hospitalized with COVID-19 for the risk of being hospitalized from the vaccine.
Examining the financial cost of the COVID-19 vaccination program in the UK, Bridgen says the government’s own data suggest that it cost over £1.9 million ($2.34 million) to prevent a single hospitalization among healthy 50 to 59-year-olds, and over £11 million ($13.54 million) to prevent one serious hospitalization in this group. The cost of preventing the hospitalization of one healthy 40 to 49-year-old was over £4 million ($4.93 million). For healthy 30 to 39-year-olds, preventing one hospitalization costs over £9 million ($11.08 million).
State-sponsored self-harm
Summing up, Bridgen says that the data are clear: for all healthy people and all those considered at risk under 70, the probability of being seriously harmed by COVID-19 is seriously outweighed by the risks associated with the experimental mRNA vaccines and boosters. Even for the most vulnerable group – the over-70s with health problems – he says the two risks are essentially identical. Describing the use of mRNA vaccines as “absolute madness,” he argues that if the UK were to continue employing them it would be engaging in “expensive state-sponsored self-harm on a national level.”
Nor does Bridgen shy away from identifying the biggest beneficiaries from the UK’s COVID-19 vaccine program. Pointing out that mRNA vaccines have made the pharma industry billions, he describes how the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is 86 percent funded by drug companies. He additionally alleges that members of the UK’s Joint Committee on Vaccination and Immunization (JCVI), the body that advises UK health departments on immunization, have between them declared interests of more than £1 billion ($1.23 billion) in the pharma industry. Clearly, this hardly qualifies their advice as independent.
Accusing pharma companies of putting profits before people, Bridgen says governments across the globe have been their willing marketing agents in all this. He concludes by calling on the UK government to immediately stop the mRNA vaccine booster program and initiate a full public inquiry into not only the vaccine harms, but also how every UK agency and institution set up to protect the public interest has failed so abysmally in its duties.
Bridgen’s speech should be required viewing for politicians across the globe.
*
This article was originally published by Dr. Rath Health Foundation.
Executive Director of the Dr. Rath Health Foundation and one of the coauthors of our explosive book, “The Nazi Roots of the ‘Brussels EU’”, Paul is also our expert on the Codex Alimentarius Commission and has had eye-witness experience, as an official observer delegate, at its meetings. You can find Paul on Twitter at @paulanthtaylor
He is a regular contributor to Global Research.
Featured image is from DRHF
“You maybe heard about Brooke Jackson’s case in the US. She’s suing Pfizer under False Claims Act that they defrauded the government. Well, Pfizer already filed a motion to dismiss – the case hasn’t been dismissed yet – but Pfizer already in court stated that: ‘Please dismiss this case, Judge. We did not defraud the government. We delivered the fraud that the government ordered.”
BY RHODA WILSON
Feb 6, 2022
Listen to the article:
“[Pfizer] did not defraud the government. We delivered the fraud that the government ordered.” Sasha Latypova used these words to describe the basis on which Pfizer has requested the dismissal of a False Claims Act case brought against them for their covid “vaccines.”
The US Department of Defence ordered “demonstrations” from pharmaceutical companies using the same secretive framework they use to order weapons. While telling us they were pharmaceutical products, for legal reasons they described them as emergency use authorised “countermeasures.” No pharmaceutical regulation applies to countermeasures.
“They were claiming that they’re producing pharmaceutical products to the good manufacturing standards when they perfectly well knew, I assure you, they were all aware of this. They perfectly well knew that no pharmaceutical regulations apply to these things, countermeasures … They’re just lying to you that these are pharmaceuticals. They’re actually not,” Latypova explained.
The international conference ‘Pandemic Strategies: Lessons and Consequences’ held at the Stockholm Waterfront on 21-22 January 2023 gathered 15 leading doctors, researchers and lawyers from the US, Canada, UK, Germany, France, Belgium, Switzerland, Israel, Ukraine and Norway, along with 7 Swedes.
Presentations and panel discussions are being released in the order that they appeared on the program at a rate of 3 per day.
Alexandra “Sasha” Latypova was one of those who gave a presentation. She holds an MBA degree and is a former Pharmaceutical R&D Executive. Latypova has spent approximately 25 years in the pharmaceutical industry and has owned and managed several contract research organisations – conducting clinical trials for over 60 pharmaceutical clients worldwide. She became concerned about the irregularities, cover-up and apparent fraud relating to the extremely high number of deaths and injuries associated with the covid injection rollout.
In her presentation, she explained that her initial investigation was to look into the so-called covid vaccines’ compliance with good manufacturing practices. It is the practice required to conform to quality guidelines recommended by regulatory agencies and applies to drugs, food and other mass-produced products that are consumed. It is to ensure, for example, that if you buy your favourite beer today and then you go to the to buy it again a week from now or a month from now, your experience is the same. The same goes for medicines like Aspirin that you buy in a pharmacy. You don’t expect a product to be a thousand times different a week from now versus today.
“As a highly regulated industry, pharmaceutical manufacturers are supposed to comply with [good manufacturing practice]. And this means that the product that they claim that they make, with the ingredients that they claim that they make, is supposed to be in every vial, every shot, every pill, over and over and over again, and they should be almost identical to each other,” Latypova said.
In the first few months of her investigation, Latypova found evidence of “very bad manufacturing practices” in relation to the mRNA injections. “When I looked at the [ ] graph [of serious adverse events and deaths recorded in VAERS] for mRNA injections for the US, I found [the below]”
“[I’m] only looking at serious adverse events and deaths. There were almost no adverse events reported in some lots, and some lots had thousands and they had hundreds of deaths. And so, this is not a good manufacturing practice-compliant product at all,” said Latypova. “I’m not endorsing flu vaccines or any vaccines anymore, because until this is investigated fully, nobody should be taking anything. That’s my professional opinion.”
The above graph shows Johnson & Johnson (Janssen), Moderna and Pfizer. Below is a graph for Moderna. The blue colour represents serious adverse events and the orange represents death post-vaccination. “A well-manufactured product should not look like this at all,” Latypova explained.
Explaining the significance of the lot labelled in the graph above, Latypova said:
“On January 18, Orange County, California Health Department flagged this particular lot of Moderna for what they called ‘excessive number of allergic reactions’. Nothing was done about it. The injections were not stopped. In fact, this lot was being sold all over the United States until it ran out in late March.
“And as you know, if there is salmonella in a salad, they will recall the entire product from all the shelves in the country. Right? That’s what you should do as a manufacturer. All manufacturers have systems to detect this. And the majority of recalls of products are voluntary because they don’t want this to happen.
“Yet [with this lot from Moderna], nobody stopped. Not the manufacturer, not the health authorities of Orange County, not the CDC, FDA, or whoever was supposed to monitor this, they continued selling this lot. It’s now associated with over 65 deaths in the US and over 3000 serious adverse events. So, after something like this happens, everything that follows is intentional.”
Every researcher that has questioned or challenged regulatory authorities has been told: “We looked at it. It’s safe and effective. Go get vaccinated.” Why were they all behaving this way? Why are they all following the same script the world over?
Latypova has been collaborating with legal researcher Katherine Watt, who publishes articles on a Substack page titled ‘Bailiwick News’, to reveal the legal structure – or rather the pseudo-legal structure as it’s not lawful – of this government, pharma, military criminal cartel. “It actually is operating all over the world,” Latypova said.
In the 1960s a contracting framework was put into place for NASA called ‘Other Transaction Authority’. “Now eleven federal agencies use it. [The] Department of Defence is a particularly huge user of this contracting method because it allows them to contract without following any federal procurement rules and regulations with a lot of secrecy,” Latypova said. “They typically use this framework to order weapons from defence contractors, but now they’re using the same framework to order what they tell us is a pharmaceutical product.”
In addition to this, there is a US code, which Latypova highlights in her presentation, which says that the use of emergency use authorised “countermeasures” is not a clinical investigation under a public health emergency. The significance of this, Latypova explained, is that if a countermeasure cannot be a clinical investigational product, then no pharmaceutical regulation applies to these products.
“So, here’s the lie that our government told to us and told to the world and the governments all over the world repeated to their citizens:
“They were claiming that it’s a health event. They were claiming that they’re producing pharmaceutical products to the good manufacturing standards when they perfectly well knew, I assure you, they were all aware of this. They perfectly well knew that no pharmaceutical regulations apply to these things, countermeasures.
“They’re just lying to you that these are pharmaceuticals. They’re actually not … The government lied to us about this being a health event … [but] in reality, what they did, they organised the response to it as if it was war.”
Below is a slide from the presentation where the organisational structure of Operation Warp Speed was discussed. “The chief operating officer is the Department of Defence. We were told, ‘oh, they’re just doing logistics’. No, they’re not just doing logistics. They’re running the whole thing,” Latypova said.
As proof of this, Latypova cited the case where Pfizer or the FDA was refusing to release clinical trial data in less than 75 years.
“Who was arguing in court on behalf of Pfizer? Pfizer lawyers were not even in the room. It was the Department of Justice. So why is the US government defending presumably a private commercial interest of a pharmaceutical company?
“[In the slide above] you can see that the pharmaceutical companies are a third level down. They are not in charge, but they’re getting tremendous amounts of money to shut up and follow the orders and do as they’re told. [ ] The whole operation is run by the Department of Defence and the US government. I’m not absolving Pharma … of any responsibility. They are criminals in this cartel, and they’re collaborating, and they’re co-conspirators, and should be prosecuted together.”
In the same Operation Warp Speed presentation, Operation Warp Speed and BARDA were bragging about their vaccine manufacturing portfolio. On the right-hand side, they call it vaccine-supporting efforts. “These are all established defence contractors … who already had an established vaccine manufacturing base. At that time, it was called pan influenza. In early 2020, they simply switched to covid,” Latypova said. “These are the companies who are really making these products.”
“On [the left-hand] side, it’s called ‘Demo’. That’s what the government ordered, a demonstration, which is fake by definition … These words are very carefully designed. They have legal meaning, and that’s exactly what they bought. They bought demonstrations.”
They spent $47 billion on research and development contracts – $33 billion was spent on “vaccines.” All the contracts are publicly available HERE. All of them say the Department of Defence contracted these companies. And they’re managed through Advanced Technologies International, a long-standing contracts manager for the Department of Defence.
They exempt everyone who participates in this, regardless of where they’re working, as long as they’re following the orders, they’re exempt from liability under the Prep Act clause. That same Prep Act clause states that this is a dual-use civil and military application product. How they exempted themselves internationally is by Pfizer forcing countries to sign predatory contract clauses where the national governments had to lift good manufacturing practice requirements or any drug importation requirements and look the other way. Clauses that if, for example, Swedish citizens get injured and sue Pfizer, then the Swedish government has to indemnify Pfizer and put state assets such as military bases, embassies, and other state assets as collateral. “That’s because it’s the US government who wants that base, not the private commercial manufacturer,” Latypova explained.
“You maybe heard about Brooke Jackson’s case in the US. She’s suing Pfizer under False Claims Act that they defrauded the government. Well, Pfizer already filed a motion to dismiss – the case hasn’t been dismissed yet – but Pfizer already in court stated that: ‘Please dismiss this case, Judge. We did not defraud the government. We delivered the fraud that the government ordered.”
You can watch Latypova’s full presentation below.
https://rumble.com/embed/v25mv4v/?pub=4#?secret=LPY11zYJDCLakaruppropet: Covid-19 countermeasures: Evidence for an intent to harm, Alexandra Latypova (25 mins)
Do you want some studies proving that the experimental vax is lethal? Say no more!
https://www.globalresearch.ca/covid-19-vaccines-scientific-proof-lethality/5767711
By SUN
Global Research, February 03, 2023
SUN 5 January 2022
Region: Europe
Theme: Media Disinformation, Science and Medicine
***
Over One Thousand Scientific Studies Prove That the COVID-19 Vaccines Are Dangerous, and All Those Pushing This Agenda Are Committing the Indictable Crime of Gross Misconduct in Public Office
Just over 12 months from deployment of the COVID 19 emergency use experimental vaccines, scientific studies in the thousands, and reports of criminal complaints of assault and murder from the illegal, unlawful use of biochemical poisons made to police forces around the country, verify an assault on an unsuspecting UK population. Irrefutable science shows that the COVID 19 vaccine is not safe and not effective in limiting transmission or infection from the SARS-CoV-2, coronavirus pathogens.
The “safe and effective” false propaganda, put out by public officials who now are continuing to push this vaccine, is a clear breach of duty. A public office holder is subject to, and aware of, a duty to prevent death or serious injury that arises only by virtue of the functions of the public office.
Many have breached that duty and, in doing so, are recklessly causing a risk of death or serious injury, by carrying on regardless of the now-confirmed dangers associated with COVID 19 injections. Some of these risks are blood clotting, myocarditis, pericarditis, thrombosis, thrombocytopenia, anaphylaxis, Bell’s palsy, Guillain-Barre, cancer including deaths, etc.
All of these are confirmed in the following science-and-government-gathered data from the UK Health and Security agency on COVID 19 regarding vaccine damage.
The term “vaccine” was changed recently to incorporate this illegal, unlawful medical experiment to facilitate usage of mRNA technology that is demonstrably not a vaccine, and which contains biologically toxic nano-metamaterials associated with 5G urban data gathering capability.
Metal nanoparticulates are known in science to be genotoxic—a poison that can also cause sterilization. The dangers posed to the victims in the near term from this medical battery are now known. However, the long term lethality of this weapon is not as yet realized due to the debilitating effects it has on the immune system, causing Acquired Immunodeficiency Syndrome(AIDS).
The Medicines and Healthcare (products) Regulatory Agency (MHRA) had prior warning of the expected large numbers of adverse reactions before the deployment—confirming the premeditated nature of the crime and public conduct offences then and now.
- Cerebral venous thrombosis after COVID-19 vaccination in the UK: a multicentre cohort study: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01608-1/
- Vaccine-induced immune thrombotic thrombocytopenia with disseminated intravascular coagulation and death after ChAdOx1 nCoV-19 vaccination: https://www.sciencedirect.com/science/article/pii/S1052305721003414
- Fatal cerebral hemorrhage after COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33928772/
- Myocarditis after mRNA vaccination against SARS-CoV-2, a case series: https://www.sciencedirect.com/science/article/pii/S2666602221000409
- Three cases of acute venous thromboembolism in women after vaccination against COVID-19: https://www.sciencedirect.com/science/article/pii/S2213333X21003929
- Acute thrombosis of the coronary tree after vaccination against COVID-19: https://www.sciencedirect.com/science/article/abs/pii/S1936879821003988
- US case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with Ad26.COV2.S (against covid-19), March 2 to April 21, 2020: https://pubmed.ncbi.nlm.nih.gov/33929487/
- Portal vein thrombosis associated with ChAdOx1 nCov-19 vaccine: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00197-7/
- Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): position statement of the Italian Society for the Study of Hemostasis and Thrombosis (SISET): https://pubmed.ncbi.nlm.nih.gov/33871350/
- Vaccine-induced immune immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with COVID-19; a systematic review: https://www.sciencedirect.com/science/article/pii/S0022510X21003014
- Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines: https://www.sciencedirect.com/science/article/abs/pii/S0735675721004381
- Covid-19 vaccine-induced thrombosis and thrombocytopenia: a commentary on an important and practical clinical dilemma: https://www.sciencedirect.com/science/article/abs/pii/S0033062021000505
- Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector vaccines: https://www.sciencedirect.com/science/article/abs/pii/S0953620521001904
- COVID-19 vaccine-induced immune-immune thrombotic thrombocytopenia: an emerging cause of splanchnic vein thrombosis: https://www.sciencedirect.com/science/article/pii/S1665268121000557
- The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic immune thrombocytopenia (covid): https://www.sciencedirect.com/science/article/pii/S1050173821000967
- Roots of autoimmunity of thrombotic events after COVID-19 vaccination: https://www.sciencedirect.com/science/article/abs/pii/S1568997221002160
- Cerebral venous sinus thrombosis after vaccination: the United Kingdom experience: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01788-8/fulltext
- Thrombotic immune thrombocytopenia induced by SARS-CoV-2 vaccine: https://www.nejm.org/doi/full/10.1056/nejme2106315
- Myocarditis after immunization with COVID-19 mRNA vaccines in members of the US military. This article reports that in “23 male patients, including 22 previously healthy military members, myocarditis was identified within 4 days after receipt of the vaccine”: https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601
- Thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19: https://www.nejm.org/doi/full/10.1056/NEJMoa2104882?query=recirc_curatedRelated_article
- Association of myocarditis with the BNT162b2 messenger RNA COVID-19 vaccine in a case series of children: https://pubmed.ncbi.nlm.nih.gov/34374740/
- Thrombotic thrombocytopenia after vaccination with ChAdOx1 nCov-19: https://www.nejm.org/doi/full/10.1056/NEJMoa2104840?query=recirc_curatedRelated_article
- Post-mortem findings in vaccine-induced thrombotic thrombocytopenia (covid-19): https://haematologica.org/article/view/haematol.2021.279075
- Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19 mRNA vaccines reported to the Vaccine Adverse Event Reporting System (VAERS): https://www.sciencedirect.com/science/article/pii/S0264410X21005247
- Acute symptomatic myocarditis in seven adolescents after Pfizer-BioNTech COVID-19 vaccination: https://pediatrics.aappublications.org/content/early/2021/06/04/peds.2021-052478
- Aphasia seven days after the second dose of an mRNA-based SARS-CoV-2 vaccine. Brain MRI revealed an intracerebral hemorrhage (ICBH) in the left temporal lobe in a 52-year-old man. https://www.sciencedirect.com/science/article/pii/S2589238X21000292#f0005
- Comparison of vaccine-induced thrombotic episodes between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines: https://www.sciencedirect.com/science/article/abs/pii/S0896841121000895
- Hypothesis behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination: https://www.sciencedirect.com/science/article/abs/pii/S0049384821003315
- Blood clots and bleeding episodes after BNT162b2 and ChAdOx1 nCoV-19 vaccination: analysis of European data: https://www.sciencedirect.com/science/article/pii/S0896841121000937
- Cerebral venous thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine: https://www.sciencedirect.com/science/article/abs/pii/S1052305721003098
- Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia induced by the Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine (VITT): https://www.sciencedirect.com/science/article/pii/S0953620521002363
- Myocarditis and pericarditis after vaccination with COVID-19 mRNA: practical considerations for care providers: https://www.sciencedirect.com/science/article/pii/S0828282X21006243
- “Portal vein thrombosis occurring after the first dose of SARS-CoV-2 mRNA vaccine in a patient with antiphospholipid syndrome”: https://www.sciencedirect.com/science/article/pii/S2666572721000389
- Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with Ad26.COV2.S: https://www.sciencedirect.com/science/article/pii/S0196064421003425
- Myocarditis, pericarditis and cardiomyopathy after COVID-19 vaccination: https://www.sciencedirect.com/science/article/pii/S1443950621011562
- Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection: https://www.sciencedirect.com/science/article/abs/pii/S0896841121000706
- Prothrombotic immune thrombocytopenia after COVID-19 vaccination: https://www.sciencedirect.com/science/article/pii/S0006497121009411
- Vaccine-induced thrombotic thrombocytopenia: the dark chapter of a success story: https://www.sciencedirect.com/science/article/pii/S2589936821000256
- Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin based anticoagulation: https://www.sciencedirect.com/science/article/pii/S1871402121002046
- Thrombosis after COVID-19 vaccination: possible link to ACE pathways: https://www.sciencedirect.com/science/article/pii/S0049384821004369
- Cerebral venous sinus thrombosis in the U.S. population after SARS-CoV-2 vaccination with adenovirus and after COVID-19: https://www.sciencedirect.com/science/article/pii/S0735109721051949
- A rare case of a middle-aged Asian male with cerebral venous thrombosis after AstraZeneca COVID-19 vaccination: https://www.sciencedirect.com/science/article/pii/S0735675721005714
- Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom: https://www.sciencedirect.com/science/article/abs/pii/S088915912100163X
- Immune thrombocytopenic purpura after vaccination with COVID-19 vaccine (ChAdOx1 nCov-19): https://www.sciencedirect.com/science/article/abs/pii/S0006497121013963.
- Antiphospholipid antibodies and risk of thrombophilia after COVID-19 vaccination: the straw that breaks the camel’s back?: https://docs.google.com/document/d/1XzajasO8VMMnC3CdxSBKks1o7kiOLXFQ
- Vaccine-induced thrombotic thrombocytopenia, a rare but severe case of friendly fire in the battle against the COVID-19 pandemic: What pathogenesis?: https://www.sciencedirect.com/science/article/pii/S0953620521002314
- Diagnostic-therapeutic recommendations of the ad-hoc FACME expert working group on the management of cerebral venous thrombosis related to COVID-19 vaccination: https://www.sciencedirect.com/science/article/pii/S0213485321000839
- Thrombocytopenia and intracranial venous sinus thrombosis after exposure to the “AstraZeneca COVID-19 vaccine”: https://pubmed.ncbi.nlm.nih.gov/33918932/
- Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/33606296/
- Severe and refractory immune thrombocytopenia occurring after SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/33854395/
- Purpuric rash and thrombocytopenia after mRNA-1273 (Modern) COVID-19 vaccine: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996471/
- COVID-19 vaccination: information on the occurrence of arterial and venous thrombosis using data from VigiBase: https://pubmed.ncbi.nlm.nih.gov/33863748/
- Cerebral venous thrombosis associated with the covid-19 vaccine in Germany: https://onlinelibrary.wiley.com/doi/10.1002/ana.26172
- Cerebral venous thrombosis following BNT162b2 mRNA vaccination of BNT162b2 against SARS-CoV-2: a black swan event: https://pubmed.ncbi.nlm.nih.gov/34133027/
- The importance of recognizing cerebral venous thrombosis following anti-COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34001390/
- Thrombosis with thrombocytopenia after messenger RNA vaccine -1273: https://pubmed.ncbi.nlm.nih.gov/34181446/
- Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an analysis of European data: https://pubmed.ncbi.nlm.nih.gov/34174723/
- First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic, and hemorrhagic events in Scotland: https://www.nature.com/articles/s41591-021-01408-4
- Exacerbation of immune thrombocytopenia after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34075578/
- First report of a de novo iTTP episode associated with a COVID-19 mRNA-based anti-COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34105244/
- PF4 immunoassays in vaccine-induced thrombotic thrombocytopenia: https://www.nejm.org/doi/full/10.1056/NEJMc2106383
- Antibody epitopes in vaccine-induced immune immune thrombotic thrombocytopenia: https://www.nature.com/articles/s41586-021-03744-4
- Myocarditis with COVID-19 mRNA vaccines: https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.056135
- Myocarditis and pericarditis after COVID-19 vaccination: https://jamanetwork.com/journals/jama/fullarticle/2782900
- Myocarditis temporally associated with COVID-19 vaccination: https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.055891.
- COVID-19 Vaccination Associated with Myocarditis in Adolescents: https://pediatrics.aappublications.org/content/pediatrics/early/2021/08/12/peds.2021-053427.full.pdf
- Acute myocarditis after administration of BNT162b2 vaccine against COVID-19: https://pubmed.ncbi.nlm.nih.gov/33994339/
- Temporal association between COVID-19 vaccine Ad26.COV2.S and acute myocarditis: case report and review of the literature: https://www.sciencedirect.com/science/article/pii/S1553838921005789
- COVID-19 vaccine-induced myocarditis: a case report with review of the literature: https://www.sciencedirect.com/science/article/pii/S1871402121002253
- Potential association between COVID-19 vaccine and myocarditis: clinical and CMR findings: https://www.sciencedirect.com/science/article/pii/S1936878X2100485X
- Recurrence of acute myocarditis temporally associated with receipt of coronavirus mRNA disease vaccine 2019 (COVID-19) in a male adolescent: https://www.sciencedirect.com/science/article/pii/S002234762100617X
- Fulminant myocarditis and systemic hyper inflammation temporally associated with BNT162b2 COVID-19 mRNA vaccination in two patients: https://www.sciencedirect.com/science/article/pii/S0167527321012286.
- Acute myocarditis after administration of BNT162b2 vaccine: https://www.sciencedirect.com/science/article/pii/S2214250921001530
- Lymphohistocytic myocarditis after vaccination with COVID-19 Ad26.COV2.S viral vector: https://www.sciencedirect.com/science/article/pii/S2352906721001573
- Myocarditis following vaccination with BNT162b2 in a healthy male: https://www.sciencedirect.com/science/article/pii/S0735675721005362
- Acute myocarditis after Comirnaty (Pfizer) vaccination in a healthy male with previous SARS-CoV-2 infection: https://www.sciencedirect.com/science/article/pii/S1930043321005549
- Myopericarditis after Pfizer mRNA COVID-19 vaccination in adolescents: https://www.sciencedirect.com/science/article/pii/S002234762100665X
- Pericarditis after administration of BNT162b2 mRNA COVID-19 mRNA vaccine: https://www.sciencedirect.com/science/article/pii/S1885585721002218
- Acute myocarditis after vaccination with SARS-CoV-2 mRNA-1273 mRNA: https://www.sciencedirect.com/science/article/pii/S2589790X21001931
- Temporal relationship between the second dose of BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection: https://www.sciencedirect.com/science/article/pii/S2352906721000622
- Myopericarditis after vaccination with COVID-19 mRNA in adolescents 12 to 18 years of age: https://www.sciencedirect.com/science/article/pii/S0022347621007368
- Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old man: https://www.sciencedirect.com/science/article/pii/S0870255121003243
- Important information on myopericarditis after vaccination with Pfizer COVID-19 mRNA in adolescents: https://www.sciencedirect.com/science/article/pii/S0022347621007496
- A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-1279 and BNT162b2: https://www.sciencedirect.com/science/article/pii/S1936878X21004861
- Takotsubo cardiomyopathy after vaccination with mRNA COVID-19: https://www.sciencedirect.com/science/article/pii/S1443950621011331
- COVID-19 mRNA vaccination and myocarditis: https://pubmed.ncbi.nlm.nih.gov/34268277/
- COVID-19 vaccine and myocarditis: https://pubmed.ncbi.nlm.nih.gov/34399967/
- Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resourc e/en/covidwho-1360706.
- COVID-19 vaccines and myocarditis: https://pubmed.ncbi.nlm.nih.gov/34246566/
- Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccines https://www.cureus.com/articles/61030-myocarditis-and-other-cardiovascular-comp lications-of-the-mrna-based-covid-19-vaccines https://www.cureus.com/articles/61030-myocarditis-and-other-cardiovascular-complications-of-the-mrna-based-covid-19-vaccines
- Myocarditis, pericarditis, and cardiomyopathy after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34340927/
- Myocarditis with covid-19 mRNA vaccines: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056135
- Association of myocarditis with COVID-19 mRNA vaccine in children: https://media.jamanetwork.com/news-item/association-of-myocarditis-with-mrna-co vid-19-vaccine-in-children/
- Association of myocarditis with COVID-19 messenger RNA vaccine BNT162b2 in a case series of children: https://jamanetwork.com/journals/jamacardiology/fullarticle/2783052
- Myocarditis after immunization with COVID-19 mRNA vaccines in members of the U.S. military: https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601%5C
- Myocarditis occurring after immunization with COVID-19 mRNA-based COVID-19 vaccines: https://jamanetwork.com/journals/jamacardiology/fullarticle/2781600
- Myocarditis following immunization with Covid-19 mRNA: https://www.nejm.org/doi/full/10.1056/NEJMc2109975
- Patients with acute myocarditis after vaccination withCOVID-19 mRNA: https://jamanetwork.com/journals/jamacardiology/fullarticle/2781602
- Myocarditis associated with vaccination with COVID-19 mRNA: https://pubs.rsna.org/doi/10.1148/radiol.2021211430
- Symptomatic Acute Myocarditis in 7 Adolescents after Pfizer-BioNTech COVID-19 Vaccination: https://pediatrics.aappublications.org/content/148/3/e2021052478
- Cardiovascular magnetic resonance imaging findings in young adult patients with acute myocarditis after COVID-19 mRNA vaccination: a case series: https://jcmr-online.biomedcentral.com/articles/10.1186/s12968-021-00795-4
- Clinical Guidance for Young People with Myocarditis and Pericarditis after Vaccination with COVID-19 mRNA: https://www.cps.ca/en/documents/position/clinical-guidance-for-youth-with-myocarditis-and-pericarditis
- Cardiac imaging of acute myocarditis after vaccination with COVID-19 mRNA: https://pubmed.ncbi.nlm.nih.gov/34402228/
- Case report: acute myocarditis after second dose of mRNA-1273 SARS-CoV-2 mRNA vaccine: https://academic.oup.com/ehjcr/article/5/8/ytab319/6339567
- Myocarditis / pericarditis associated with COVID-19 vaccine: https://science.gc.ca/eic/site/063.nsf/eng/h_98291.html
- Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine: https://journals.lww.com/pidj/Abstract/9000/Transient_Cardiac_Injury_in_Adolesce nts_Receiving.95800.aspx
- Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine: https://academic.oup.com/jpids/advance-article/doi/10.1093/jpids/piab060/6329543
- The new COVID-19 mRNA vaccine platform and myocarditis: clues to the possible underlying mechanism: https://pubmed.ncbi.nlm.nih.gov/34312010/
- Acute myocardial injury after COVID-19 vaccination: a case report and review of current evidence from the Vaccine Adverse Event Reporting System database: https://pubmed.ncbi.nlm.nih.gov/34219532/
- Be alert to the risk of adverse cardiovascular events after COVID-19 vaccination: https://www.xiahepublishing.com/m/2472-0712/ERHM-2021-00033
- Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac tomography, and magnetic resonance imaging findings: https://www.ahajournals.org/doi/10.1161/CIRCIMAGING.121.013236
- In-depth evaluation of a case of presumed myocarditis after the second dose of COVID-19 mRNA vaccine: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056038
- Occurrence of acute infarct-like myocarditis after COVID-19 vaccination: just an accidental coincidence or rather a vaccination-associated autoimmune myocarditis?: https://pubmed.ncbi.nlm.nih.gov/34333695/
- Recurrence of acute myocarditis temporally associated with receipt of coronavirus mRNA disease vaccine 2019 (COVID-19) in a male adolescent: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216855/
- Myocarditis after SARS-CoV-2 vaccination: a vaccine-induced reaction?: https://pubmed.ncbi.nlm.nih.gov/34118375/
- Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34180390/
- Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report: https://pubmed.ncbi.nlm.nih.gov/34133825/
- Biopsy-proven lymphocytic myocarditis after first COVID-19 mRNA vaccination in a 40-year-old man: case report: https://pubmed.ncbi.nlm.nih.gov/34487236/
- Insights from a murine model of COVID-19 mRNA vaccine-induced myopericarditis: could accidental intravenous injection of a vaccine induce myopericarditis https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab741/6359059
- Unusual presentation of acute perimyocarditis after modern SARS-COV-2 mRNA-1237 vaccination: https://pubmed.ncbi.nlm.nih.gov/34447639/
- Perimyocarditis after the first dose of mRNA-1273 SARS-CoV-2 (Modern) mRNA-1273 vaccine in a young healthy male: case report: https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-021-02183
- Acute myocarditis after the second dose of SARS-CoV-2 vaccine: serendipity or causal relationship: https://pubmed.ncbi.nlm.nih.gov/34236331/
- Rhabdomyolysis and fasciitis induced by the COVID-19 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34435250/
- COVID-19 vaccine-induced rhabdomyolysis: case report with literature review: https://pubmed.ncbi.nlm.nih.gov/34186348/.
- GM1 ganglioside antibody and COVID-19-related Guillain Barre syndrome: case report, systemic review, and implications for vaccine development: https://www.sciencedirect.com/science/article/pii/S2666354621000065
- Guillain-Barré syndrome after AstraZeneca COVID-19 vaccination: causal or casual association: https://www.sciencedirect.com/science/article/pii/S0303846721004169
- Sensory Guillain-Barré syndrome after ChAdOx1 nCov-19 vaccine: report of two cases and review of the literature: https://www.sciencedirect.com/science/article/pii/S0165572821002186
- Guillain-Barré syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association: https://www.sciencedirect.com/science/article/pii/S2214250921000998.
- Guillain-Barré syndrome presenting as facial diplegia after vaccination with COVID-19: a case report: https://www.sciencedirect.com/science/article/pii/S0736467921006442
- Guillain-Barré syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first report: https://www.sciencedirect.com/science/article/pii/S0035378721005853.
- SARS-CoV-2 vaccines are not safe for those with Guillain-Barre syndrome following vaccination: https://www.sciencedirect.com/science/article/pii/S2049080121005343
- Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: a case report: https://www.sciencedirect.com/science/article/pii/S2049080121007536
- Facial nerve palsy following administration of COVID-19 mRNA vaccines: analysis of self-report database: https://www.sciencedirect.com/science/article/pii/S1201971221007049
- Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence: https://www.sciencedirect.com/science/article/pii/S0899707121003557.
- New-onset refractory status epilepticus after ChAdOx1 nCoV-19 vaccination: https://www.sciencedirect.com/science/article/pii/S0165572821001569
- Acute myelitis and ChAdOx1 nCoV-19 vaccine: coincidental or causal association: https://www.sciencedirect.com/science/article/pii/S0165572821002137
- Bell’s palsy and SARS-CoV-2 vaccines: an unfolding story: https://www.sciencedirect.com/science/article/pii/S1473309921002735
- Bell’s palsy after the second dose of the Pfizer COVID-19 vaccine in a patient with a history of recurrent Bell’s palsy: https://www.sciencedirect.com/science/article/pii/S266635462100020X
- Acute-onset central serous retinopathy after immunization with COVID-19 mRNA vaccine:. https://www.sciencedirect.com/science/article/pii/S2451993621001456.
- Bell’s palsy after COVID-19 vaccination: case report: https://www.sciencedirect.com/science/article/pii/S217358082100122X.
- An academic hospital experience assessing the risk of COVID-19 mRNA vaccine using patient’s allergy history: https://www.sciencedirect.com/science/article/pii/S2213219821007972
- COVID-19 vaccine-induced axillary and pectoral lymphadenopathy in PET: https://www.sciencedirect.com/science/article/pii/S1930043321002612
- ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine: https://www.sciencedirect.com/science/article/pii/S0272638621007423
- Late cutaneous reactions after administration of COVID-19 mRNA vaccines: https://www.sciencedirect.com/science/article/pii/S2213219821007996
- COVID-19 vaccine-induced rhabdomyolysis: case report with review of the literature: https://www.sciencedirect.com/science/article/pii/S1871402121001880
- Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-REPP: a registry-based study: https://www.sciencedirect.com/science/article/pii/S0190962221024427
- Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines:. https://www.sciencedirect.com/science/article/abs/pii/S0735675721004381.
- COVID-19 vaccine-associated anaphylaxis: a statement from the Anaphylaxis Committee of the World Allergy Organization:. https://www.sciencedirect.com/science/article/pii/S1939455121000119.
- Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in an elderly, non-comorbid Indian male treated with conventional heparin-warfarin-based anticoagulation:. https://www.sciencedirect.com/science/article/pii/S1871402121002046.
- Acute myocarditis after administration of BNT162b2 vaccine against COVID-19:. https://www.sciencedirect.com/science/article/abs/pii/S188558572100133X
- Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccine: an analysis of European data:. https://www.sciencedirect.com/science/article/pii/S0896841121000937.
- immune thrombocytopenia associated with Pfizer-BioNTech’s COVID-19 BNT162b2 mRNA vaccine:. https://www.sciencedirect.com/science/article/pii/S2214250921002018.
- Bullous drug eruption after the second dose of COVID-19 mRNA-1273 (Moderna) vaccine: Case report: https://www.sciencedirect.com/science/article/pii/S1876034121001878.
- COVID-19 RNA-based vaccines and the risk of prion disease: https://scivisionpub.com/pdfs/covid19rna-based-vaccines-and-the-risk-of-prion-dis ease-1503.pdf
- This study notes that 115 pregnant women lost their babies, out of 827 who participated in a study on the safety of covid-19 vaccines: https://www.nejm.org/doi/full/10.1056/NEJMoa2104983.
- Process-related impurities in the ChAdOx1 nCov-19 vaccine: https://www.researchsquare.com/article/rs-477964/v1
- COVID-19 mRNA vaccine causing CNS inflammation: a case series: https://link.springer.com/article/10.1007/s00415-021-10780-7
- Allergic reactions, including anaphylaxis, after receiving the first dose of the Pfizer-BioNTech COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33475702/
- Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol: https://pubmed.ncbi.nlm.nih.gov/33320974/
- Pfizer Vaccine Raises Allergy Concerns: https://pubmed.ncbi.nlm.nih.gov/33384356/
- Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14-23, 2020: https://pubmed.ncbi.nlm.nih.gov/33444297/
- Allergic reactions, including anaphylaxis, after receiving first dose of Modern COVID-19 vaccine – United States, December 21, 2020-January 10, 2021: https://pubmed.ncbi.nlm.nih.gov/33507892/
- Reports of anaphylaxis after coronavirus disease vaccination 2019, South Korea, February 26-April 30, 2021: https://pubmed.ncbi.nlm.nih.gov/34414880/
- Reports of anaphylaxis after receiving COVID-19 mRNA vaccines in the U.S.-Dec 14, 2020-Jan 18, 2021: https://pubmed.ncbi.nlm.nih.gov/33576785/
- Immunization practices and risk of anaphylaxis: a current, comprehensive update of COVID-19 vaccination data: https://pubmed.ncbi.nlm.nih.gov/34269740/
- Relationship between pre-existing allergies and anaphylactic reactions following administration of COVID-19 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34215453/
- Anaphylaxis Associated with COVID-19 mRNA Vaccines: Approach to Allergy Research: https://pubmed.ncbi.nlm.nih.gov/33932618/
- Severe Allergic Reactions after COVID-19 Vaccination with the Pfizer / BioNTech Vaccine in Great Britain and the USA: Position Statement of the German Allergy Societies: German Medical Association of Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA): https://pubmed.ncbi.nlm.nih.gov/33643776/
- Allergic reactions and anaphylaxis to LNP-based COVID-19 vaccines: https://pubmed.ncbi.nlm.nih.gov/33571463/
- Reported orofacial adverse effects from COVID-19 vaccines: the known and the unknown: https://pubmed.ncbi.nlm.nih.gov/33527524/
- Cutaneous adverse effects of available COVID-19 vaccines: https://pubmed.ncbi.nlm.nih.gov/34518015/
- Cumulative adverse event report of anaphylaxis following injections of COVID-19 mRNA vaccine (Pfizer-BioNTech) in Japan: the first month report: https://pubmed.ncbi.nlm.nih.gov/34347278/
- COVID-19 vaccines increase the risk of anaphylaxis: https://pubmed.ncbi.nlm.nih.gov/33685103/
- Biphasic anaphylaxis after exposure to the first dose of the Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34050949/
- Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation: https://pubmed.ncbi.nlm.nih.gov/33657648/
- Polyethylene glycol (PEG) is a cause of anaphylaxis to Pfizer / BioNTech mRNA COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33825239/
- Acute allergic reactions to COVID-19 mRNA vaccines: https://pubmed.ncbi.nlm.nih.gov/33683290/
- Polyethylene glycole allergy of the SARS CoV2 vaccine recipient: case report of a young adult recipient and management of future exposure to SARS-CoV2: https://pubmed.ncbi.nlm.nih.gov/33919151/
- Elevated rates of anaphylaxis after vaccination with Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers; a secondary analysis of initial post-approval safety data: https://pubmed.ncbi.nlm.nih.gov/34128049/
- Allergic reactions and adverse events associated with administration of mRNA-based vaccines. A health system experience: https://pubmed.ncbi.nlm.nih.gov/34474708/
- Allergic reactions to COVID-19 vaccines: statement of the Belgian Society of Allergy and Clinical Immunology (BelSACI): https://www.tandfonline.com/doi/abs/10.1080/17843286.2021.1909447
- .IgE-mediated allergy to polyethylene glycol (PEG) as a cause of anaphylaxis to COVID-19 mRNA vaccines: https://pubmed.ncbi.nlm.nih.gov/34318537/
- Allergic reactions after COVID-19 vaccination: putting the risk in perspective: https://pubmed.ncbi.nlm.nih.gov/34463751/
- Anaphylactic reactions to COVID-19 mRNA vaccines: a call for further studies: https://pubmed.ncbi.nlm.nih.gov/33846043/ 188.
- Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin disease: practical recommendations. An ETFAD position statement with external experts: https://pubmed.ncbi.nlm.nih.gov/33752263/
- COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis: https://pubmed.ncbi.nlm.nih.gov/34073536/
- Fatal brain hemorrhage after COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33928772/
- A case series of skin reactions to COVID-19 vaccine in the Department of Dermatology at Loma Linda University: https://pubmed.ncbi.nlm.nih.gov/34423106/
- Skin reactions reported after Moderna and Pfizer’s COVID-19 vaccination: a study based on a registry of 414 cases: https://pubmed.ncbi.nlm.nih.gov/33838206/
- Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-REPP: a registry-based study: https://pubmed.ncbi.nlm.nih.gov/34517079/
- Skin reactions after vaccination against SARS-COV-2: a nationwide Spanish cross-sectional study of 405 cases: https://pubmed.ncbi.nlm.nih.gov/34254291/
- Varicella zoster virus and herpes simplex virus reactivation after vaccination with COVID-19: review of 40 cases in an international dermatologic registry: https://pubmed.ncbi.nlm.nih.gov/34487581/
- Immune thrombosis and thrombocytopenia (VITT) associated with the COVID-19 vaccine: diagnostic and therapeutic recommendations for a new syndrome: https://pubmed.ncbi.nlm.nih.gov/33987882/
- Laboratory testing for suspicion of COVID-19 vaccine-induced thrombotic (immune) thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34138513/
- Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: the first fatal case in Korea: https://pubmed.ncbi.nlm.nih.gov/34402235/
- Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study: https://pubmed.ncbi.nlm.nih.gov/34446426/
- Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after covid-19 vaccination; a systematic review: https://pubmed.ncbi.nlm.nih.gov/34365148/.
- Nerve and muscle adverse events after vaccination with COVID-19: a systematic review and meta-analysis of clinical trials: https://pubmed.ncbi.nlm.nih.gov/34452064/.
- A rare case of cerebral venous thrombosis and disseminated intravascular coagulation temporally associated with administration of COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33917902/
- Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia induced by Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine (VITT): https://pubmed.ncbi.nlm.nih.gov/34256983/
- Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34247246/.
- Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after administration of AstraZeneca COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34132839/
- 59-year-old woman with extensive deep venous thrombosis and pulmonary thromboembolism 7 days after a first dose of Pfizer-BioNTech BNT162b2 mRNA vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34117206/
- Cerebral venous thrombosis and vaccine-induced thrombocytopenia.a. Oxford-AstraZeneca COVID-19: a missed opportunity for a rapid return on experience: https://pubmed.ncbi.nlm.nih.gov/34033927/
- Myocarditis and other cardiovascular complications of mRNA-based COVID-19 vaccines: https://pubmed.ncbi.nlm.nih.gov/34277198/
- Pericarditis after administration of COVID-19 mRNA BNT162b2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34364831/
- Unusual presentation of acute pericarditis after vaccination against SARS-COV-2 mRNA-1237 Modern: https://pubmed.ncbi.nlm.nih.gov/34447639/
- Case report: acute myocarditis after second dose of SARS-CoV-2 mRNA-1273 vaccine mRNA-1273: https://pubmed.ncbi.nlm.nih.gov/34514306/
- Immune-mediated disease outbreaks or recent-onset disease in 27 subjects after mRNA/DNA vaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/33946748/
- Insights from a murine model of myopericarditis induced by COVID-19 mRNA vaccine: could accidental intravenous injection of a vaccine induce myopericarditis: https://pubmed.ncbi.nlm.nih.gov/34453510/
- Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33476455/
- propylthiouracil-induced neutrophil anti-cytoplasmic antibody-associated vasculitis after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34451967/
- Secondary immune thrombocytopenia (ITP) associated with ChAdOx1 Covid-19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34377889/
- Thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination: risk-benefit analysis for persons <60 years in Australia: https://pubmed.ncbi.nlm.nih.gov/34272095/
- COVID-19 vaccination association and facial nerve palsy: A case-control study: https://pubmed.ncbi.nlm.nih.gov/34165512/
- The association between COVID-19 vaccination and Bell’s palsy: https://pubmed.ncbi.nlm.nih.gov/34411533/
- Bell’s palsy after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33611630/
- Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 vaccine (AZD1222): https://pubmed.ncbi.nlm.nih.gov/33981305/
- Bell’s palsy after 24 hours of mRNA-1273 SARS-CoV-2 mRNA-1273 vaccine: https://pubmed.ncbi.nlm.nih.gov/34336436/
- Sequential contralateral facial nerve palsy after first and second doses of COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34281950/.
- Transverse myelitis induced by SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34458035/
- Peripheral facial nerve palsy after vaccination with BNT162b2 (COVID-19): https://pubmed.ncbi.nlm.nih.gov/33734623/
- Acute abducens nerve palsy after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34044114/.
- Facial nerve palsy after administration of COVID-19 mRNA vaccines: analysis of self-report database: https://pubmed.ncbi.nlm.nih.gov/34492394/
- Transient oculomotor paralysis after administration of RNA-1273 messenger vaccine for SARS-CoV-2 diplopia after COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34369471/
- Bell’s palsy after Ad26.COV2.S COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34014316/
- Bell’s palsy after COVID-19 vaccination: case report: https://pubmed.ncbi.nlm.nih.gov/34330676/
- A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy following ChAdOx1 nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34272622/
- Guillian Barré syndrome after vaccination with mRNA-1273 against COVID-19: https://pubmed.ncbi.nlm.nih.gov/34477091/
- Acute facial paralysis as a possible complication of SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/33975372/.
- Bell’s palsy after COVID-19 vaccination with high antibody response in CSF: https://pubmed.ncbi.nlm.nih.gov/34322761/.
- Parsonage-Turner syndrome associated with SARS-CoV-2 or SARS-CoV-2 vaccination. Comment on: “Neuralgic amyotrophy and COVID-19 infection: 2 cases of accessory spinal nerve palsy” by Coll et al. Articular Spine 2021; 88: 10519: https://pubmed.ncbi.nlm.nih.gov/34139321/.
- Bell’s palsy after a single dose of vaccine mRNA. SARS-CoV-2: case report: https://pubmed.ncbi.nlm.nih.gov/34032902/.
- Autoimmune hepatitis developing after coronavirus disease vaccine 2019 (COVID-19): causality or victim?: https://pubmed.ncbi.nlm.nih.gov/33862041/
- Autoimmune hepatitis triggered by vaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/34332438/
- Acute autoimmune-like hepatitis with atypical antimitochondrial antibody after vaccination with COVID-19 mRNA: a new clinical entity: https://pubmed.ncbi.nlm.nih.gov/34293683/.
- Autoimmune hepatitis after COVID vaccine: https://pubmed.ncbi.nlm.nih.gov/34225251/
- A novel case of bifacial diplegia variant of Guillain-Barré syndrome after vaccination with Janssen COVID-19: https://pubmed.ncbi.nlm.nih.gov/34449715/
- Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines: https://pubmed.ncbi.nlm.nih.gov/34139631/.
- Bilateral superior ophthalmic vein thrombosis, ischemic stroke and immune thrombocytopenia after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/33864750/
- Diagnosis and treatment of cerebral venous sinus thrombosis with vaccine-induced immune-immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/33914590/
- Venous sinus thrombosis after vaccination with ChAdOx1 nCov-19: https://pubmed.ncbi.nlm.nih.gov/34420802/
- Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency: https://pubmed.ncbi.nlm.nih.gov/34293217/
- Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study: https://pubmed.ncbi.nlm.nih.gov/34446426/
- Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an analysis of European data: https://pubmed.ncbi.nlm.nih.gov/34174723/
- Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study: https://pubmed.ncbi.nlm.nih.gov/33952445/
- First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland: https://pubmed.ncbi.nlm.nih.gov/34108714/
- Cerebral venous thrombosis associated with COVID-19 vaccine in Germany: https://pubmed.ncbi.nlm.nih.gov/34288044/
- Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34341358/
- celiac artery and splenic artery thrombosis complicated by splenic infarction 7 days after the first dose of Oxford vaccine, causal relationship or coincidence: https://pubmed.ncbi.nlm.nih.gov/34261633/.
- Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 (VITT) vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34256983/
- Thrombocytopenia after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34332437/.
- Cerebral venous sinus thrombosis associated with thrombocytopenia after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33845870/.
- Thrombosis with thrombocytopenia syndrome after COVID-19 immunization: https://pubmed.ncbi.nlm.nih.gov/34236343/
- Acute myocardial infarction within 24 hours after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34364657/.
- Bilateral acute macular neuroretinopathy after SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34287612/
- central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental: https://pubmed.ncbi.nlm.nih.gov/34478433/
- Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: the first fatal case in Korea: https://pubmed.ncbi.nlm.nih.gov/34402235/
- Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin-based anticoagulation: https://pubmed.ncbi.nlm.nih.gov/34186376/
- Cerebral venous sinus thrombosis 2 weeks after first dose of SARS-CoV-2 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34101024/
- A case of multiple thrombocytopenia and thrombosis following vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/34137813/
- Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines: https://pubmed.ncbi.nlm.nih.gov/34191218/
- Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy: https://pubmed.ncbi.nlm.nih.gov/34175640/
- New-onset refractory status epilepticus after ChAdOx1 nCoV-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34153802/
- Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector vaccines: https://pubmed.ncbi.nlm.nih.gov/34092488/
- Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34261635/
- Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after administration of the AstraZeneca COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34132839/.
- Spontaneous HIT syndrome: knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34144250/
- Deep venous thrombosis (DVT) occurring shortly after second dose of SARS-CoV-2 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/33687691/
- Procoagulant antibody-mediated procoagulant platelets in immune thrombotic thrombocytopenia associated with SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34011137/.
- Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with high mortality rate: a case series: https://pubmed.ncbi.nlm.nih.gov/34393988/.
- Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis: https://pubmed.ncbi.nlm.nih.gov/34129181/.
- Atypical thrombosis associated with the vaccine VaxZevria® (AstraZeneca): data from the French network of regional pharmacovigilance centers: https://pubmed.ncbi.nlm.nih.gov/34083026/.
- Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34247246/.
- Vaccine-induced thrombosis and thrombocytopenia with bilateral adrenal haemorrhage: https://pubmed.ncbi.nlm.nih.gov/34235757/.
- Palmar digital vein thrombosis after Oxford-AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34473841/.
- Cutaneous thrombosis associated with cutaneous necrosis following Oxford-AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34189756/
- Cerebral venous thrombosis following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34045111/.
- Lipschütz ulcers after AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34366434/.
- Amyotrophic Neuralgia secondary to Vaxzevri vaccine (AstraZeneca) COVID-19: https://pubmed.ncbi.nlm.nih.gov/34330677/
- Thrombosis with thrombocytopenia after Messenger vaccine RNA-1273: https://pubmed.ncbi.nlm.nih.gov/34181446/
- Intracerebral hemorrhage twelve days after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34477089/
- Thrombotic thrombocytopenia after vaccination with COVID-19: in search of the underlying mechanism: https://pubmed.ncbi.nlm.nih.gov/34071883/
- Coronavirus (COVID-19) Vaccine-induced immune thrombotic thrombocytopenia (VITT): https://pubmed.ncbi.nlm.nih.gov/34033367/
- Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis in unusual sites: https://pubmed.ncbi.nlm.nih.gov/34375510/
- Immunoglobulin adjuvant for vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34107198/
- Severe vaccine-induced thrombotic thrombocytopenia following vaccination with COVID-19: an autopsy case report and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34355379/.
- A case of acute pulmonary embolism after immunization with SARS-CoV-2 mRNA: https://pubmed.ncbi.nlm.nih.gov/34452028/
- Neurosurgical considerations regarding decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic thrombocytopenia-VITT: https://pubmed.ncbi.nlm.nih.gov/34202817/
- Thrombosis and SARS-CoV-2 vaccines: vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34237213/.
- Acquired thrombotic thrombocytopenic thrombocytopenic purpura: a rare disease associated with the BNT162b2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34105247/.
- Immune complexes, innate immunity and NETosis in ChAdOx1 vaccine-induced thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34405870/.
- Sensory Guillain-Barré syndrome following ChAdOx1 nCov-19 vaccine: report of two cases and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34416410/.
- Vogt-Koyanagi-Harada syndrome after COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccination: https://pubmed.ncbi.nlm.nih.gov/34462013/.
- Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, after anti-SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34224024/.
- Post-vaccinal encephalitis after ChAdOx1 nCov-19: https://pubmed.ncbi.nlm.nih.gov/34324214/
- Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence?: https://pubmed.ncbi.nlm.nih.gov/34507266/
- Fatal systemic capillary leak syndrome after SARS-COV-2 vaccination in a patient with multiple myeloma: https://pubmed.ncbi.nlm.nih.gov/34459725/
- Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-19: https://pubmed.ncbi.nlm.nih.gov/34463066/
- Three cases of subacute thyroiditis after SARS-CoV-2 vaccination: post-vaccination ASIA syndrome: https://pubmed.ncbi.nlm.nih.gov/34043800/.
- Facial diplegia: a rare and atypical variant of Guillain-Barré syndrome and the Ad26.COV2.S vaccine: https://pubmed.ncbi.nlm.nih.gov/34447646/
- Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study: https://pubmed.ncbi.nlm.nih.gov/34479760/.
- fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 COVID-19 mRNA vaccination in two patients: https://pubmed.ncbi.nlm.nih.gov/34416319/.
- Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, centered on cerebral venous sinus thrombosis (CVST): https://pubmed.ncbi.nlm.nih.gov/34092166/
- Induction and exacerbation of subacute cutaneous lupus erythematosus erythematosus after mRNA- or adenoviral vector-based SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34291477/
- Petechiae and peeling of fingers after immunization with BTN162b2 messenger RNA (mRNA)-based COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34513435/
- Hepatitis C virus reactivation after COVID-19 vaccination: a case report: https://pubmed.ncbi.nlm.nih.gov/34512037/
- Bilateral immune-mediated keratolysis after immunization with SARS-CoV-2 recombinant viral vector vaccine: https://pubmed.ncbi.nlm.nih.gov/34483273/.
- Immune-mediated thrombocytopenic purpura after Pfizer-BioNTech COVID-19 vaccine in an elderly woman: https://pubmed.ncbi.nlm.nih.gov/34513446/
- Platelet activation and modulation in thrombosis with thrombocytopenia syndrome associated with the ChAdO × 1 nCov-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34474550/
- Reactive arthritis after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34033732/.
- Two cases of Graves’ disease after SARS-CoV-2 vaccination: an autoimmune / inflammatory syndrome induced by adjuvants: https://pubmed.ncbi.nlm.nih.gov/33858208/
- Acute relapse and impaired immunization after COVID-19 vaccination in a patient with multiple sclerosis treated with rituximab: https://pubmed.ncbi.nlm.nih.gov/34015240/
- Widespread fixed bullous drug eruption after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34482558/
- COVID-19 mRNA vaccine causing CNS inflammation: a case series: https://pubmed.ncbi.nlm.nih.gov/34480607/
- Thymic hyperplasia after Covid-19 mRNA-based vaccination with Covid-19: https://pubmed.ncbi.nlm.nih.gov/34462647/
- Acute disseminated encephalomyelitis following vaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/34325334/
- Tolosa-Hunt syndrome occurring after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34513398/
- Systemic capillary extravasation syndrome following vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34362727/
- Immune-mediated thrombocytopenia associated with Ad26.COV2.S vaccine (Janssen; Johnson & Johnson): https://pubmed.ncbi.nlm.nih.gov/34469919/.
- Transient thrombocytopenia with glycoprotein-specific platelet autoantibodies after vaccination with Ad26.COV2.S: case report: https://pubmed.ncbi.nlm.nih.gov/34516272/.
- Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: case report: https://pubmed.ncbi.nlm.nih.gov/34512961/
- Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34077949/
- Autoimmune hepatitis developing after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34171435/
- Severe relapse of multiple sclerosis after COVID-19 vaccination: a case report: https://pubmed.ncbi.nlm.nih.gov/34447349/
- Lymphohistocytic myocarditis after vaccination with the COVID-19 viral vector Ad26.COV2.S: https://pubmed.ncbi.nlm.nih.gov/34514078/
- Hemophagocytic lymphohistiocytosis after vaccination with ChAdOx1 nCov-19: https://pubmed.ncbi.nlm.nih.gov/34406660/.
- IgA vasculitis in adult patient after vaccination with ChadOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34509658/
- A case of leukocytoclastic vasculitis after vaccination with a SARS-CoV2 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34196469/.
- Onset / outbreak of psoriasis after Corona virus ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca / Covishield): report of two cases: https://pubmed.ncbi.nlm.nih.gov/34350668/
- Hailey-Hailey disease exacerbation after SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34436620/
- Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: https://pubmed.ncbi.nlm.nih.gov/34116295/.
- COVID-19 vaccine, immune thrombotic thrombocytopenia, jaundice, hyperviscosity: concern in cases with underlying hepatic problems: https://pubmed.ncbi.nlm.nih.gov/34509271/.
- Report of the International Cerebral Venous Thrombosis Consortium on cerebral venous thrombosis after SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34462996/
- Immune thrombocytopenia after vaccination during the COVID-19 pandemic: https://pubmed.ncbi.nlm.nih.gov/34435486/
- COVID-19: lessons from the Norwegian tragedy should be taken into account in planning for vaccine launch in less developed/developing countries: https://pubmed.ncbi.nlm.nih.gov/34435142/
- Rituximab-induced acute lympholysis and pancytopenia following vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34429981/
- Exacerbation of plaque psoriasis after COVID-19 inactivated mRNA and BNT162b2 vaccines: report of two cases: https://pubmed.ncbi.nlm.nih.gov/34427024/
- Vaccine-induced interstitial lung disease: a rare reaction to COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34510014/.
- Vesiculobullous cutaneous reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34236711/
- Vaccine-induced thrombocytopenia with severe headache: https://pubmed.ncbi.nlm.nih.gov/34525282/
- Acute perimyocarditis after the first dose of COVID-19 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34515024/
- Rhabdomyolysis and fasciitis induced by COVID-19 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34435250/.
- Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34363637/
- Immune thrombocytopenia associated with the Pfizer-BioNTech COVID-19 mRNA vaccine BNT162b2: https://www.sciencedirect.com/science/article/pii/S2214250921002018
- Secondary immune thrombocytopenia putatively attributable to COVID-19 vaccination: https://casereports.bmj.com/content/14/5/e242220.abstract.
- Immune thrombocytopenia following Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34155844/
- Newly diagnosed idiopathic thrombocytopenia after COVID-19 vaccine administration: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176657/.
- Idiopathic thrombocytopenic purpura and the Modern Covid-19 vaccine: https://www.annemergmed.com/article/S0196-0644(21)00122-0/fulltext.
- Thrombocytopenia after Pfizer and Moderna SARS vaccination – CoV -2: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014568/.
- Immune thrombocytopenic purpura and acute liver injury after COVID-19 vaccination: https://casereports.bmj.com/content/14/7/e242678.
- Collection of complement-mediated and autoimmune-mediated hematologic conditions after SARS-CoV-2 vaccination: https://ashpublications.org/bloodadvances/article/5/13/2794/476324/Autoimmune-and-complement-mediated-hematologic
- Petechial rash associated with CoronaVac vaccination: first report of cutaneous side effects before phase 3 results: https://ejhp.bmj.com/content/early/2021/05/23/ejhpharm-2021-002794
- COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria: https://ashpublications.org/blood/article/137/26/3670/475905/COVID-19-vaccines-induce-severe-hemolysis-in
- Cerebral venous thrombosis associated with COVID-19 vaccine in Germany: https://pubmed.ncbi.nlm.nih.gov/34288044/.
- Cerebral venous sinus thrombosis after COVID-19 vaccination : Neurological and radiological management: https://pubmed.ncbi.nlm.nih.gov/34327553/.
- Cerebral venous thrombosis and thrombocytopenia after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33878469/.
- Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom: https://pubmed.ncbi.nlm.nih.gov/33857630/.
- Cerebral venous thrombosis induced by SARS-CoV-2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34090750/.
- Carotid artery immune thrombosis induced by adenovirus-vectored COVID-19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34312301/.
- Cerebral venous sinus thrombosis associated with vaccine-induced thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34333995/
- The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune-immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34455073/
- Cerebral venous thrombosis after the BNT162b2 mRNA SARS-CoV-2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34111775/.
- Cerebral venous thrombosis after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34045111/
- Lethal cerebral venous sinus thrombosis after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33983464/
- Cerebral venous sinus thrombosis in the U.S. population, After SARS-CoV-2 vaccination with adenovirus and after COVID-19: https://pubmed.ncbi.nlm.nih.gov/34116145/
- Cerebral venous thrombosis after COVID-19 vaccination: is the risk of thrombosis increased by intravascular administration of the vaccine: https://pubmed.ncbi.nlm.nih.gov/34286453/.
- Central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental: https://pubmed.ncbi.nlm.nih.gov/34478433/
- Cerebral venous sinus thrombosis after ChAdOx1 nCov-19 vaccination with a misleading first brain MRI: https://pubmed.ncbi.nlm.nih.gov/34244448/
- Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with Ad26.COV2.S: https://pubmed.ncbi.nlm.nih.gov/34226070/
- Cerebral venous sinus thrombosis associated with post-vaccination thrombocytopenia by COVID-19: https://pubmed.ncbi.nlm.nih.gov/33845870/.
- Cerebral venous sinus thrombosis 2 weeks after the first dose of SARS-CoV-2 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34101024/.
- Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with a high mortality rate: a case series: https://pubmed.ncbi.nlm.nih.gov/34393988/.
- Adenovirus interactions with platelets and coagulation and vaccine-associated autoimmune thrombocytopenia thrombosis syndrome: https://pubmed.ncbi.nlm.nih.gov/34407607/.
- Headache attributed to COVID-19 (SARS-CoV-2 coronavirus) vaccination with the ChAdOx1 nCoV-19 (AZD1222) vaccine: a multicenter observational cohort study: https://pubmed.ncbi.nlm.nih.gov/34313952/
- Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, focus on cerebral venous sinus thrombosis (CVST): https://pubmed.ncbi.nlm.nih.gov/34092166/
- Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency: https://pubmed.ncbi.nlm.nih.gov/34293217/
- A rare case of a middle-age Asian male with cerebral venous thrombosis after COVID-19 AstraZeneca vaccination: https://pubmed.ncbi.nlm.nih.gov/34274191/
- Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin-based anticoagulation: https://pubmed.ncbi.nlm.nih.gov/34186376/
- Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study: https://pubmed.ncbi.nlm.nih.gov/33952445/
- Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis: https://pubmed.ncbi.nlm.nih.gov/34129181/
- S. case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with Ad26.COV2.S, March 2-April 21, 2021: https://pubmed.ncbi.nlm.nih.gov/33929487/.
- Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34341358/
- Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy: https://pubmed.ncbi.nlm.nih.gov/34175640/
- Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations: https://pubmed.ncbi.nlm.nih.gov/34159588/.
- Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34402666/
- Autoimmunity roots of thrombotic events after vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34508917/
- Cerebral venous sinus thrombosis after vaccination: the UK experience: https://pubmed.ncbi.nlm.nih.gov/34370974/
- Massive cerebral venous thrombosis and venous basin infarction as late complications of COVID-19: a case report: https://pubmed.ncbi.nlm.nih.gov/34373991/
- Australian and New Zealand approach to the diagnosis and treatment of vaccine-induced immune thrombosis and immune thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34490632/
- An observational study to identify the prevalence of thrombocytopenia and anti-PF4 / polyanion antibodies in Norwegian health care workers after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33909350/
- Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 (AZD1222) vaccine: https://pubmed.ncbi.nlm.nih.gov/33981305/.
- A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine:. https://pubmed.ncbi.nlm.nih.gov/34272622/
- Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine:. https://pubmed.ncbi.nlm.nih.gov/33877737/
- Predicted and observed incidence of thromboembolic events among Koreans vaccinated with the ChAdOx1 nCoV-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34254476/
- First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic, and hemorrhagic events in Scotland: https://pubmed.ncbi.nlm.nih.gov/34108714/
- ChAdOx1 nCoV-19 vaccine-associated thrombocytopenia: three cases of immune thrombocytopenia after 107,720 doses of ChAdOx1 vaccination in Thailand: https://pubmed.ncbi.nlm.nih.gov/34483267/.
- Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34261635/
- Neurosurgical considerations with respect to decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic thrombocytopenia-VITT: https://pubmed.ncbi.nlm.nih.gov/34202817/
- Large hemorrhagic stroke after vaccination against ChAdOx1 nCoV-19: a case report: https://pubmed.ncbi.nlm.nih.gov/34273119/
- Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-19: https://pubmed.ncbi.nlm.nih.gov/34463066/
- A rare case of thrombosis and thrombocytopenia of the superior ophthalmic vein after ChAdOx1 nCoV-19 vaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/34276917/
- Thrombosis and severe acute respiratory syndrome Coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34237213/.
- Renal vein thrombosis and pulmonary embolism secondary to vaccine-induced thrombotic immune thrombocytopenia (VITT): https://pubmed.ncbi.nlm.nih.gov/34268278/.
- Limb ischemia and pulmonary artery thrombosis after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): a case of vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/33990339/.
- Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study: https://pubmed.ncbi.nlm.nih.gov/34479760/.
- Secondary thrombocytopenia after SARS-CoV-2 vaccination: case report of haemorrhage and hematoma after minor oral surgery: https://pubmed.ncbi.nlm.nih.gov/34314875/.
- Venous thromboembolism and mild thrombocytopenia after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34384129/
- Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after successful initial therapy with intravenous immunoglobulins: a rationale for monitoring immunoglobulin G levels: https://pubmed.ncbi.nlm.nih.gov/34382387/
- A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?: https://pubmed.ncbi.nlm.nih.gov/34416184/.
- Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman: https://pubmed.ncbi.nlm.nih.gov/34261297/
- Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34261296/
- Nephrotic syndrome after ChAdOx1 nCoV-19 vaccine against SARScoV-2: https://pubmed.ncbi.nlm.nih.gov/34250318/.
- A case of vaccine-induced immune-immune thrombotic thrombocytopenia with massive arteriovenous thrombosis: https://pubmed.ncbi.nlm.nih.gov/34059191/
- Cutaneous thrombosis associated with cutaneous necrosis following Oxford-AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34189756/
- Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34331506/
- Vaccine-induced thrombocytopenia with severe headache: https://pubmed.ncbi.nlm.nih.gov/34525282/
- Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17 years: stratified analysis of a national database: https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1
- COVID-19 mRNA vaccination and development of CMR-confirmed myopericarditis: https://www.medrxiv.org/content/10.1101/2021.09.13.21262182v1.full?s=09.
- Severe autoimmune hemolytic anemia after receipt of SARS-CoV-2 mRNA vaccine: https://onlinelibrary.wiley.com/doi/10.1111/trf.16672
- Intravenous injection of coronavirus disease 2019 (COVID-19) mRNA vaccine can induce acute myopericarditis in a mouse model: https://t.co/j0IEM8cMXI
- A report of myocarditis adverse events in the U.S. Vaccine Adverse Event Reporting System. (VAERS) in association with COVID-19 injectable biologics: https://pubmed.ncbi.nlm.nih.gov/34601006/
- This study concludes that: “The vaccine was associated with an excess risk of myocarditis (1 to 5 events per 100,000 persons). The risk of this potentially serious adverse event and of many other serious adverse events increased substantially after SARS-CoV-2 infection”: https://www.nejm.org/doi/full/10.1056/NEJMoa2110475
- Bilateral uveitis after inoculation with COVID-19 vaccine: a case report: https://www.sciencedirect.com/science/article/pii/S1201971221007797
- Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17 years: stratified analysis of a national database: https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1.
- Immune-mediated hepatitis with the Moderna vaccine is no longer a coincidence but confirmed: https://www.sciencedirect.com/science/article/pii/S0168827821020936
- Extensive investigations revealed consistent pathophysiologic alterations after vaccination with COVID-19 vaccines: https://www.nature.com/articles/s41421-021-00329-3
- Lobar hemorrhage with ventricular rupture shortly after the first dose of an mRNA-based SARS-CoV-2 vaccine: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8553377/
- Mrna COVID vaccines dramatically increase endothelial inflammatory markers and risk of Acute Coronary Syndrome as measured by PULS cardiac testing: a caution: https://www.ahajournals.org/doi/10.1161/circ.144.suppl_1.10712
- ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome:https://www.science.org/doi/10.1126/sciadv.abl8213
- Lethal vaccine-induced immune thrombotic immune thrombocytopenia (VITT) following announcement 26.COV2.S: first documented case outside the U.S.: https://pubmed.ncbi.nlm.nih.gov/34626338/
- A prothrombotic thrombocytopenic disorder resembling heparin-induced thrombocytopenia after coronavirus-19 vaccination: https://europepmc.org/article/PPR/PPR304469 435.
- VITT (vaccine-induced immune thrombotic thrombocytopenia) after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34731555/
- Vaccine-induced immune thrombotic thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations: https://pubmed.ncbi.nlm.nih.gov/34159588/
- Treatment of acute ischemic stroke associated with ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34461442/
- Spectrum of neurological complications after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34719776/.
- Cerebral venous sinus thrombosis after vaccination: the UK experience: https://pubmed.ncbi.nlm.nih.gov/34370974/
- Cerebral venous vein/venous sinus thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34373413/
- Portal vein thrombosis due to vaccine-induced immune thrombotic immune thrombocytopenia (VITT) after Covid vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34598301/
- Hematuria, a generalized petechial rash and headaches after Oxford AstraZeneca ChAdOx1 nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34620638/
- Myocardial infarction and azygos vein thrombosis after vaccination with ChAdOx1 nCoV-19 in a hemodialysis patient: https://pubmed.ncbi.nlm.nih.gov/34650896/
- Takotsubo (stress) cardiomyopathy after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34625447/
- Humoral response induced by Prime-Boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines in a patient with multiple sclerosis treated with teriflunomide: https://pubmed.ncbi.nlm.nih.gov/34696248/
- Guillain-Barré syndrome after ChAdOx1 nCoV-19 COVID-19 vaccination: a case series: https://pubmed.ncbi.nlm.nih.gov/34548920/
- Refractory vaccine-induced immune thrombotic thrombocytopenia (VITT) treated with delayed therapeutic plasma exchange (TPE): https://pubmed.ncbi.nlm.nih.gov/34672380/.
- Rare case of COVID-19 vaccine-associated intracranial hemorrhage with venous sinus thrombosis: https://pubmed.ncbi.nlm.nih.gov/34556531/.
- Delayed headache after COVID-19 vaccination: a warning sign for vaccine-induced cerebral venous thrombosis: https://pubmed.ncbi.nlm.nih.gov/34535076/.
- Clinical features of vaccine-induced thrombocytopenia and immune thrombosis: https://pubmed.ncbi.nlm.nih.gov/34379914/.
- Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score: https://pubmed.ncbi.nlm.nih.gov/34545400/
- Ischemic stroke as a presenting feature of immune thrombotic thrombocytopenia induced by ChAdOx1-nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34035134/
- In-hospital observational study of neurological disorders in patients recently vaccinated with COVID-19 mRNA vaccines: https://pubmed.ncbi.nlm.nih.gov/34688190/
- Endovascular treatment for vaccine-induced cerebral venous sinus thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19: report of three cases: https://pubmed.ncbi.nlm.nih.gov/34782400/
- Cardiovascular, neurological, and pulmonary events after vaccination with BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: an analysis of European data: https://pubmed.ncbi.nlm.nih.gov/34710832/
- Cerebral venous thrombosis developing after vaccination. COVID-19: VITT, VATT, TTS and more: https://pubmed.ncbi.nlm.nih.gov/34695859/
- Cerebral venous thrombosis and myeloproliferative neoplasms: a three-center study of 74 consecutive cases: https://pubmed.ncbi.nlm.nih.gov/34453762/.
- Possible triggers of thrombocytopenia and/or hemorrhage by BNT162b2 vaccine, Pfizer-BioNTech: https://pubmed.ncbi.nlm.nih.gov/34660652/.
- Multiple sites of arterial thrombosis in a 35-year-old patient after vaccination with ChAdOx1 (AstraZeneca), which required emergency femoral and carotid surgical thrombectomy: https://pubmed.ncbi.nlm.nih.gov/34644642/
- Case series of vaccine-induced thrombotic thrombocytopenia in a London teaching hospital: https://pubmed.ncbi.nlm.nih.gov/34694650/
- Neuro-ophthalmic complications with thrombocytopenia and thrombosis induced by ChAdOx1 nCoV-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34726934/
- Thrombotic events after COVID-19 vaccination in over 50 years of age: results of a population-based study in Italy: https://pubmed.ncbi.nlm.nih.gov/34835237/
- Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman: https://pubmed.ncbi.nlm.nih.gov/34261297/
- Age- and sex-specific incidence of cerebral venous sinus thrombosis associated with Ad26.COV2.S COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34724036/.
- Genital necrosis with cutaneous thrombosis following vaccination with COVID-19 mRNA: https://pubmed.ncbi.nlm.nih.gov/34839563/
- Cerebral venous sinus thrombosis after mRNA-based COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34783932/.
- COVID-19 vaccine-induced immune thrombosis with thrombocytopenia thrombosis (VITT) and shades of gray in thrombus formation: https://pubmed.ncbi.nlm.nih.gov/34624910/
- Inflammatory myositis after vaccination with ChAdOx1: https://pubmed.ncbi.nlm.nih.gov/34585145/
- Acute ST-segment elevation myocardial infarction secondary to vaccine-induced immune thrombosis with thrombocytopenia (VITT): https://pubmed.ncbi.nlm.nih.gov/34580132/.
- A rare case of COVID-19 vaccine-induced thrombotic thrombocytopenia (VITT) affecting the venosplanchnic and pulmonary arterial circulation from a UK district general hospital: https://pubmed.ncbi.nlm.nih.gov/34535492/
- COVID-19 vaccine-induced thrombotic thrombocytopenia: a case series: https://pubmed.ncbi.nlm.nih.gov/34527501/
- Thrombosis with thrombocytopenia syndrome (TTS) after vaccination with AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19: a risk-benefit analysis for persons <60% risk-benefit analysis for people <60 years in Australia: https://pubmed.ncbi.nlm.nih.gov/34272095/
- Immune thrombocytopenia after immunization with Vaxzevria ChadOx1-S vaccine (AstraZeneca), Victoria, Australia: https://pubmed.ncbi.nlm.nih.gov/34756770/
- Characteristics and outcomes of patients with cerebral venous sinus thrombosis in thrombotic immune thrombocytopenia induced by SARS-CoV-2 vaccine: https://jamanetwork.com/journals/jamaneurology/fullarticle/2784622
- Case study of thrombosis and thrombocytopenia syndrome after administration of the AstraZeneca COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34781321/
- Thrombosis with Thrombocytopenia Syndrome Associated with COVID-19 Vaccines: https://pubmed.ncbi.nlm.nih.gov/34062319/
- Cerebral venous sinus thrombosis following vaccination with ChAdOx1: the first case of definite thrombosis with thrombocytopenia syndrome in India: https://pubmed.ncbi.nlm.nih.gov/34706921/
- COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome (TTS): systematic review and post hoc analysis: https://pubmed.ncbi.nlm.nih.gov/34698582/.
- Case report of immune thrombocytopenia after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34751013/.
- Acute transverse myelitis after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34684047/.
- Concerns for adverse effects of thrombocytopenia and thrombosis after adenovirus-vectored COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34541935/
- Major hemorrhagic stroke after ChAdOx1 nCoV-19 vaccination: a case report: https://pubmed.ncbi.nlm.nih.gov/34273119/
- Cerebral venous sinus thrombosis after COVID-19 vaccination: neurologic and radiologic management: https://pubmed.ncbi.nlm.nih.gov/34327553/.
- Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33877737/
- Intracerebral hemorrhage and thrombocytopenia after AstraZeneca COVID-19 vaccine: clinical and diagnostic challenges of vaccine-induced thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34646685/
- Minimal change disease with severe acute kidney injury after Oxford-AstraZeneca COVID-19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34242687/.
- Case report: cerebral sinus vein thrombosis in two patients with AstraZeneca SARS-CoV-2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34609603/
- Case report: Pityriasis rosea-like rash after vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34557507/
- Extensive longitudinal transverse myelitis after ChAdOx1 nCOV-19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34641797/.
- Acute eosinophilic pneumonia associated with anti-COVID-19 vaccine AZD1222: https://pubmed.ncbi.nlm.nih.gov/34812326/.
- Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19 mRNA vaccines reported to the Vaccine Adverse Event Reporting System (VAERS): https://pubmed.ncbi.nlm.nih.gov/34006408/
- A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?: https://pubmed.ncbi.nlm.nih.gov/34416184/
- Vaccine-induced immune thrombosis and thrombocytopenia syndrome after adenovirus-vectored severe acute respiratory syndrome coronavirus 2 vaccination: a new hypothesis on mechanisms and implications for future vaccine development: https://pubmed.ncbi.nlm.nih.gov/34664303/.
- Thrombosis in peripheral artery disease and thrombotic thrombocytopenia following adenoviral COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34649281/.
- Newly diagnosed immune thrombocytopenia in a pregnant patient after coronavirus disease 2019 vaccination: https://pubmed.ncbi.nlm.nih.gov/34420249/
- Cerebral venous sinus thrombosis and thrombotic events after vector-based COVID-19 vaccines: systematic review and meta-analysis: https://pubmed.ncbi.nlm.nih.gov/34610990/.
- Sweet’s syndrome after Oxford-AstraZeneca COVID-19 vaccine (AZD1222) in an elderly woman: https://pubmed.ncbi.nlm.nih.gov/34590397/
- Sudden sensorineural hearing loss after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34670143/.
- Prevalence of serious adverse events among health care professionals after receiving the first dose of ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021: https://pubmed.ncbi.nlm.nih.gov/34819146/.
- Acute hemichorea-hemibalismus after COVID-19 (AZD1222) vaccination: https://pubmed.ncbi.nlm.nih.gov/34581453/
- Recurrence of alopecia areata after covid-19 vaccination: a report of three cases in Italy: https://pubmed.ncbi.nlm.nih.gov/34741583/
- Shingles-like skin lesion after vaccination with AstraZeneca for COVID-19: a case report: https://pubmed.ncbi.nlm.nih.gov/34631069/
- Thrombosis after COVID-19 vaccination: possible link to ACE pathways: https://pubmed.ncbi.nlm.nih.gov/34479129/
- Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34331506/
- Leukocytoclastic vasculitis as a cutaneous manifestation of ChAdOx1 corona virus vaccine nCoV-19 (recombinant): https://pubmed.ncbi.nlm.nih.gov/34546608/
- Abdominal pain and bilateral adrenal hemorrhage from immune thrombotic thrombocytopenia induced by COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34546343/
- Longitudinally extensive cervical myelitis after vaccination with inactivated virus based COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34849183/
- Induction of cutaneous leukocytoclastic vasculitis after ChAdOx1 nCoV-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34853744/.
- A case of toxic epidermal necrolysis after vaccination with ChAdOx1 nCoV-19 (AZD1222): https://pubmed.ncbi.nlm.nih.gov/34751429/.
- Ocular adverse events following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34559576/
- Depression after ChAdOx1-S / nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34608345/.
- Venous thromboembolism and mild thrombocytopenia after ChAdOx1 nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34384129/.
- Recurrent ANCA-associated vasculitis after Oxford AstraZeneca ChAdOx1-S COVID-19 vaccination: a case series of two patients: https://pubmed.ncbi.nlm.nih.gov/34755433/
- Major artery thrombosis and vaccination against ChAdOx1 nCov-19: https://pubmed.ncbi.nlm.nih.gov/34839830/
- Rare case of contralateral supraclavicular lymphadenopathy after vaccination with COVID-19: computed tomography and ultrasound findings: https://pubmed.ncbi.nlm.nih.gov/34667486/
- Cutaneous lymphocytic vasculitis after administration of the second dose of AZD1222 (Oxford-AstraZeneca) Severe acute respiratory syndrome Coronavirus 2 vaccine: chance or causality: https://pubmed.ncbi.nlm.nih.gov/34726187/.
- Pancreas allograft rejection after ChAdOx1 nCoV-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34781027/
- Understanding the risk of thrombosis with thrombocytopenia syndrome following Ad26.COV2.S vaccination: https://pubmed.ncbi.nlm.nih.gov/34595694/
- Cutaneous adverse reactions of 35,229 doses of COVID-19 Sinovac and AstraZeneca vaccine COVID-19: a prospective cohort study in health care workers: https://pubmed.ncbi.nlm.nih.gov/34661934/
- Comments on thrombosis after vaccination: spike protein leader sequence could be responsible for thrombosis and antibody-mediated thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34788138
- Eosinophilic dermatosis after AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34753210/.
- Severe immune thrombocytopenia following COVID-19 vaccination: report of four cases and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34653943/.
- Relapse of immune thrombocytopenia after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34591991/
- Thrombosis in pre- and post-vaccination phase of COVID-19; https://pubmed.ncbi.nlm.nih.gov/34650382/
- A look at the role of postmortem immunohistochemistry in understanding the inflammatory pathophysiology of COVID-19 disease and vaccine-related thrombotic adverse events: a narrative review: https://pubmed.ncbi.nlm.nih.gov/34769454/
- COVID-19 vaccine in patients with hypercoagulability disorders: a clinical perspective: https://pubmed.ncbi.nlm.nih.gov/34786893/
- Vaccine-associated thrombocytopenia and thrombosis: venous endotheliopathy leading to combined venous micro-macrothrombosis: https://pubmed.ncbi.nlm.nih.gov/34833382/
- Thrombosis and thrombocytopenia syndrome causing isolated symptomatic carotid occlusion after COVID-19 Ad26.COV2.S vaccine (Janssen): https://pubmed.ncbi.nlm.nih.gov/34670287/
- An unusual presentation of acute deep vein thrombosis after Modern COVID-19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34790811/
- Immediate high-dose intravenous immunoglobulins followed by direct treatment with thrombin inhibitors is crucial for survival in vaccine-induced immune thrombotic thrombocytopenia Sars-Covid-19-vector adenoviral VITT with venous thrombosis of the cerebral sinus and portal vein: https://pubmed.ncbi.nlm.nih.gov/34023956/.
- Thrombosis formation after COVID-19 vaccination immunologic aspects: review article: https://pubmed.ncbi.nlm.nih.gov/34629931/
- Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34402666/
- Spectrum of neuroimaging findings in post-CoVID-19 vaccination: a case series and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34842783/
- Cerebral venous sinus thrombosis, pulmonary embolism, and thrombocytopenia after COVID-19 vaccination in a Taiwanese man: a case report and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34630307/
- Fatal cerebral venous sinus thrombosis after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33983464/
- Autoimmune roots of thrombotic events after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34508917/.
- New portal vein thrombosis in cirrhosis: is thrombophilia exacerbated by vaccine or COVID-19: https://www.jcehepatology.com/article/S0973-6883(21)00545-4/fulltext.
- Images of immune thrombotic thrombocytopenia induced by Oxford / AstraZeneca® COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33962903/.
- Cerebral venous sinus thrombosis after vaccination with COVID-19 mRNA of BNT162b2: https://pubmed.ncbi.nlm.nih.gov/34796065/.
- Increased risk of urticaria/angioedema after BNT162b2 mRNA COVID-19 vaccination in health care workers taking ACE inhibitors: https://pubmed.ncbi.nlm.nih.gov/34579248/
- A case of unusual mild clinical presentation of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with splanchnic vein thrombosis: https://pubmed.ncbi.nlm.nih.gov/34843991/
- Cerebral venous sinus thrombosis following vaccination with Pfizer-BioNTech COVID-19 (BNT162b2): https://pubmed.ncbi.nlm.nih.gov/34595867/
- A case of idiopathic thrombocytopenic purpura after a booster dose of COVID-19 BNT162b2 vaccine (Pfizer-Biontech): https://pubmed.ncbi.nlm.nih.gov/34820240/
- Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): targeting pathologic mechanisms with Bruton’s tyrosine kinase inhibitors: https://pubmed.ncbi.nlm.nih.gov/33851389/
- Thrombotic thrombocytopenic purpura after vaccination with Ad26.COV2-S: https://pubmed.ncbi.nlm.nih.gov/33980419/
- Thromboembolic events in younger females exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines: https://pubmed.ncbi.nlm.nih.gov/34264151/
- Potential risk of thrombotic events after COVID-19 vaccination with Oxford-AstraZeneca in women receiving estrogen: https://pubmed.ncbi.nlm.nih.gov/34734086/
- Thrombosis after adenovirus-vectored COVID-19 vaccination: a concern for underlying disease: https://pubmed.ncbi.nlm.nih.gov/34755555/
- Adenovirus interactions with platelets and coagulation and vaccine-induced immune thrombotic thrombocytopenia syndrome: https://pubmed.ncbi.nlm.nih.gov/34407607/
- Thrombotic thrombocytopenic purpura: a new threat after COVID bnt162b2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34264514/.
- Unusual site of deep vein thrombosis after vaccination against coronavirus mRNA-2019 coronavirus disease (COVID-19): https://pubmed.ncbi.nlm.nih.gov/34840204/
- Neurological side effects of SARS-CoV-2 vaccines: https://pubmed.ncbi.nlm.nih.gov/34750810/
- Coagulopathies after SARS-CoV-2 vaccination may derive from a combined effect of SARS-CoV-2 spike protein and adenovirus vector-activated signaling pathways: https://pubmed.ncbi.nlm.nih.gov/34639132/
- Isolated pulmonary embolism after COVID vaccination: 2 case reports and a review of acute pulmonary embolism complications and follow-up: https://pubmed.ncbi.nlm.nih.gov/34804412/
- Central retinal vein occlusion after vaccination with SARS-CoV-2 mRNA: case report: https://pubmed.ncbi.nlm.nih.gov/34571653/.
- Complicated case report of long-term vaccine-induced thrombotic immune thrombocytopenia A: https://pubmed.ncbi.nlm.nih.gov/34835275/.
- Deep venous thrombosis after vaccination with Ad26.COV2.S in adult males: https://pubmed.ncbi.nlm.nih.gov/34659839/.
- Neurological autoimmune diseases after SARS-CoV-2 vaccination: a case series: https://pubmed.ncbi.nlm.nih.gov/34668274/.
- Severe autoimmune hemolytic autoimmune anemia after receiving SARS-CoV-2 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34549821/
- Occurrence of COVID-19 variants among recipients of ChAdOx1 nCoV-19 vaccine (recombinant): https://pubmed.ncbi.nlm.nih.gov/34528522/
- Prevalence of thrombocytopenia, anti-platelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34568726/
- Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab989/644 5179.
- Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and determination of incidence rate: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab926/6420408
- Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine types: https://www.mdpi.com/2075-4426/11/11/1106
- Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study: https://pubmed.ncbi.nlm.nih.gov/34402230/
- Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients: https://pubmed.ncbi.nlm.nih.gov/34696294/
- Myocarditis Following mRNA COVID-19 Vaccine: https://journals.lww.com/pec-online/Abstract/2021/11000/Myocarditis_Following_ mRNA_COVID_19_Vaccine.9.aspx.
- Myocarditis following BNT162b2 mRNA Covid-19 mRNA vaccine in Israel: https://pubmed.ncbi.nlm.nih.gov/34614328/.
- Myocarditis, pericarditis, and cardiomyopathy following COVID-19 vaccination: https://www.heartlungcirc.org/article/S1443-9506(21)01156-2/fulltext
- Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccines: https://pubmed.ncbi.nlm.nih.gov/34277198/
- Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings: https://pubmed.ncbi.nlm.nih.gov/34246586/
- Hypersensitivity Myocarditis and COVID-19 Vaccines: https://pubmed.ncbi.nlm.nih.gov/34856634/.
- Severe myocarditis associated with COVID-19 vaccine: zebra or unicorn?: https://www.internationaljournalofcardiology.com/article/S0167-5273(21)01477-7/fulltext.
- Acute myocardial infarction and myocarditis after COVID-19 vaccination: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8522388/
- Myocarditis after Covid-19 vaccination in a large healthcare organization: https://www.nejm.org/doi/10.1056/NEJMoa2110737
- Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine in a case series of children: https://jamanetwork.com/journals/jamacardiology/fullarticle/2783052
- Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.121.056583?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
- STEMI mimicry: focal myocarditis in an adolescent patient after COVID-19 mRNA vaccination:. https://pubmed.ncbi.nlm.nih.gov/34756746/
- Myocarditis and pericarditis in association with COVID-19 mRNA vaccination: cases from a regional pharmacovigilance center: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8587334/
- Myocarditis after COVID-19 mRNA vaccines: https://pubmed.ncbi.nlm.nih.gov/34546329/.
- Patients with acute myocarditis after COVID-19 mRNA vaccination:. https://jamanetwork.com/journals/jamacardiology/fullarticle/2781602.
- Myocarditis after COVID-19 vaccination: a case series: https://www.sciencedirect.com/science/article/pii/S0264410X21011725?via%3Dihub.
- Myocarditis associated with COVID-19 vaccination in adolescents: https://publications.aap.org/pediatrics/article/148/5/e2021053427/181357
- Myocarditis findings on cardiac magnetic resonance imaging after vaccination with COVID-19 mRNA in adolescents:. https://pubmed.ncbi.nlm.nih.gov/34704459/
- Myocarditis after COVID-19 vaccination: magnetic resonance imaging study: https://academic.oup.com/ehjcimaging/advance-article/doi/10.1093/ehjci/jeab230/6 421640.
- Acute myocarditis after administration of the second dose of BNT162b2 COVID-19 vaccine: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8599115/
- Myocarditis after COVID-19 vaccination: https://www.sciencedirect.com/science/article/pii/S2352906721001603
- Case report: probable myocarditis after Covid-19 mRNA vaccine in a patient with arrhythmogenic left ventricular cardiomyopathy: https://pubmed.ncbi.nlm.nih.gov/34712717/.
- Acute myocarditis after administration of BNT162b2 vaccine against COVID-19: https://www.revespcardiol.org/en-linkresolver-acute-myocarditis-after-administration-bnt162b2-S188558572100133X.
- Myocarditis associated with COVID-19 mRNA vaccination: https://pubs.rsna.org/doi/10.1148/radiol.2021211430
- Acute myocarditis after COVID-19 vaccination: a case report: https://www.sciencedirect.com/science/article/pii/S0248866321007098
- Acute myopericarditis after COVID-19 vaccination in adolescents:. https://pubmed.ncbi.nlm.nih.gov/34589238/.
- Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccination: https://academic.oup.com/jpids/article/10/10/962/6329543.
- Acute myocarditis associated with anti-COVID-19 vaccination: https://ecevr.org/DOIx.php?id=10.7774/cevr.2021.10.2.196.
- Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac CT, and MRI findings:. https://pubmed.ncbi.nlm.nih.gov/34428917/.
- Acute symptomatic myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination:. https://pubmed.ncbi.nlm.nih.gov/34088762/.
- Myocarditis and pericarditis in adolescents after first and second doses of COVID-19 mRNA vaccines:. https://academic.oup.com/ehjqcco/advance-article/doi/10.1093/ehjqcco/qcab090/64 42104.
- COVID 19 vaccine for adolescents. Concern for myocarditis and pericarditis: https://www.mdpi.com/2036-7503/13/3/61.
- Cardiac imaging of acute myocarditis after vaccination with COVID-19 mRNA: https://pubmed.ncbi.nlm.nih.gov/34402228/
- Myocarditis temporally associated with COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34133885/
- Acute myocardial injury after COVID-19 vaccination: a case report and review of current evidence from the vaccine adverse event reporting system database: https://pubmed.ncbi.nlm.nih.gov/34219532/
- Acute myocarditis associated with COVID-19 vaccination: report of a case: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8639400/
- Myocarditis following vaccination with COVID-19 messenger RNA: a Japanese case series: https://pubmed.ncbi.nlm.nih.gov/34840235/.
- Myocarditis in the setting of a recent COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34712497/.
- Acute myocarditis after a second dose of COVID-19 mRNA vaccine: report of two cases: https://www.clinicalimaging.org/article/S0899-7071(21)00265-5/fulltext.
- Prevalence of thrombocytopenia, antiplatelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34568726/
- Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab989/6445179
- Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and incidence rate determination: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab926/6420408.
- Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine types: https://www.mdpi.com/2075-4426/11/11/1106
- Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study: https://pubmed.ncbi.nlm.nih.gov/34402230/
- Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients: https://pubmed.ncbi.nlm.nih.gov/34696294/
- Diffuse prothrombotic syndrome after administration of ChAdOx1 nCoV-19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34615534/
- Three cases of acute venous thromboembolism in women after coronavirus 2019 vaccination: https://pubmed.ncbi.nlm.nih.gov/34352418/
- Clinical and biological features of cerebral venous sinus thrombosis after vaccination with ChAdOx1 nCov-19; https://jnnp.bmj.com/content/early/2021/09/29/jnnp-2021-327340.
- COV2-S vaccination may reveal hereditary thrombophilia: massive cerebral venous sinus thrombosis in a young man with normal platelet count: https://pubmed.ncbi.nlm.nih.gov/34632750/
- Post-mortem findings in vaccine-induced thrombotic thrombocytopenia: https://haematologica.org/article/view/haematol.2021.279075
- COVID-19 vaccine-induced thrombosis: https://pubmed.ncbi.nlm.nih.gov/34802488/.
- Inflammation and platelet activation after COVID-19 vaccines: possible mechanisms behind vaccine-induced immune thrombocytopenia and thrombosis: https://pubmed.ncbi.nlm.nih.gov/34887867/.
- Anaphylactoid reaction and coronary thrombosis related to COVID-19 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34863404/.
- Vaccine-induced cerebral venous thrombosis and thrombocytopenia. Oxford-AstraZeneca COVID-19: a missed opportunity for rapid return on experience: https://www.sciencedirect.com/science/article/pii/S235255682100093X
- Occurrence of splenic infarction due to arterial thrombosis after vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34876440/
- Deep venous thrombosis more than two weeks after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33928773/
- Case report: Take a second look: Cerebral venous thrombosis related to Covid-19 vaccination and thrombotic thrombocytopenia syndrome: https://pubmed.ncbi.nlm.nih.gov/34880826/
- Information on ChAdOx1 nCoV-19 vaccine-induced immune-mediated thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34587242/
- Change in blood viscosity after COVID-19 vaccination: estimation for persons with underlying metabolic syndrome: https://pubmed.ncbi.nlm.nih.gov/34868465/
- Management of a patient with a rare congenital limb malformation syndrome after SARS-CoV-2 vaccine-induced thrombosis and thrombocytopenia (VITT): https://pubmed.ncbi.nlm.nih.gov/34097311/
- Bilateral thalamic stroke: a case of COVID-19 (VITT) vaccine-induced immune thrombotic thrombocytopenia or a coincidence due to underlying risk factors: https://pubmed.ncbi.nlm.nih.gov/34820232/.
- Thrombocytopenia and splanchnic thrombosis after vaccination with Ad26.COV2.S successfully treated with transjugular intrahepatic intrahepatic portosystemic shunt and thrombectomy: https://onlinelibrary.wiley.com/doi/10.1002/ajh.26258
- Incidence of acute ischemic stroke after coronavirus vaccination in Indonesia: case series: https://pubmed.ncbi.nlm.nih.gov/34579636/
- Successful treatment of vaccine-induced immune immune thrombotic thrombocytopenia in a 26-year-old female patient: https://pubmed.ncbi.nlm.nih.gov/34614491/
- Case report: vaccine-induced immune immune thrombotic thrombocytopenia in a patient with pancreatic cancer after vaccination with messenger RNA-1273: https://pubmed.ncbi.nlm.nih.gov/34790684/
- Idiopathic idiopathic external jugular vein thrombophlebitis after coronavirus disease vaccination (COVID-19): https://pubmed.ncbi.nlm.nih.gov/33624509/.
- Squamous cell carcinoma of the lung with hemoptysis following vaccination with tozinameran (BNT162b2, Pfizer-BioNTech): https://pubmed.ncbi.nlm.nih.gov/34612003/
- Vaccine-induced thrombotic thrombocytopenia after Ad26.COV2.S vaccination in a man presenting as acute venous thromboembolism: https://pubmed.ncbi.nlm.nih.gov/34096082/
- Myocarditis associated with COVID-19 vaccination in three adolescent boys: https://pubmed.ncbi.nlm.nih.gov/34851078/.
- Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis after COVID-19 mRNA vaccination: a case series: https://pubmed.ncbi.nlm.nih.gov/34496880/
- Perimyocarditis after vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34866957/
- Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: https://pubmed.ncbi.nlm.nih.gov/34849657/.
- Myocarditis-induced sudden death after BNT162b2 COVID-19 mRNA vaccination in Korea: case report focusing on histopathological findings: https://pubmed.ncbi.nlm.nih.gov/34664804/
- Acute myocarditis after vaccination with COVID-19 mRNA in adults aged 18 years or older: https://pubmed.ncbi.nlm.nih.gov/34605853/
- Recurrence of acute myocarditis temporally associated with receipt of the 2019 coronavirus mRNA disease vaccine (COVID-19) in an adolescent male: https://pubmed.ncbi.nlm.nih.gov/34166671/
- Young male with myocarditis after mRNA-1273 coronavirus disease-2019 (COVID-19) mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34744118/
- Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old male: https://pubmed.ncbi.nlm.nih.gov/34334935/.
- Ga-DOTATOC digital PET images of inflammatory cell infiltrates in myocarditis after vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34746968/
- Occurrence of acute infarct-like myocarditis after vaccination with COVID-19: just an accidental coincidence or rather a vaccination-associated autoimmune myocarditis?”: https://pubmed.ncbi.nlm.nih.gov/34333695/.
- Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with BNT162b2 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34180390/
- Myocarditis Following Immunization with COVID-19 mRNA Vaccines in Members of the U.S. Military: https://pubmed.ncbi.nlm.nih.gov/34185045/
- Myocarditis after BNT162b2 vaccination in a healthy male: https://pubmed.ncbi.nlm.nih.gov/34229940/
- Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report: https://pubmed.ncbi.nlm.nih.gov/34133825/
- Acute myocarditis after SARS-CoV-2 mRNA-1273 mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34308326/.
- Chest pain with abnormal electrocardiogram redevelopment after injection of COVID-19 vaccine manufactured by Moderna: https://pubmed.ncbi.nlm.nih.gov/34866106/
- Biopsy-proven lymphocytic myocarditis after first vaccination with COVID-19 mRNA in a 40-year-old man: case report: https://pubmed.ncbi.nlm.nih.gov/34487236/
- Multimodality imaging and histopathology in a young man presenting with fulminant lymphocytic myocarditis and cardiogenic shock after vaccination with mRNA-1273: https://pubmed.ncbi.nlm.nih.gov/34848416/
- Report of a case of myopericarditis after vaccination with BNT162b2 COVID-19 mRNA in a young Korean male: https://pubmed.ncbi.nlm.nih.gov/34636504/
- Acute myocarditis after Comirnaty vaccination in a healthy male with previous SARS-CoV-2 infection: https://pubmed.ncbi.nlm.nih.gov/34367386/
- Acute myocarditis in a young adult two days after vaccination with Pfizer: https://pubmed.ncbi.nlm.nih.gov/34709227/
- Case report: acute fulminant myocarditis and cardiogenic shock after messenger RNA coronavirus vaccination in 2019 requiring extracorporeal cardiopulmonary resuscitation: https://pubmed.ncbi.nlm.nih.gov/34778411/
- Acute myocarditis after 2019 coronavirus disease vaccination: https://pubmed.ncbi.nlm.nih.gov/34734821/
- A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-1279 and BNT162b2: https://pubmed.ncbi.nlm.nih.gov/34246585/
- Myopericarditis after Pfizer messenger ribonucleic acid coronavirus coronavirus disease vaccine in adolescents: https://pubmed.ncbi.nlm.nih.gov/34228985/
- Post-vaccination multisystem inflammatory syndrome in adults without evidence of prior SARS-CoV-2 infection: https://pubmed.ncbi.nlm.nih.gov/34852213/
- Acute myocarditis defined after vaccination with 2019 mRNA of coronavirus disease: https://pubmed.ncbi.nlm.nih.gov/34866122/
- Biventricular systolic dysfunction in acute myocarditis after SARS-CoV-2 mRNA-1273 vaccination: https://pubmed.ncbi.nlm.nih.gov/34601566/
- Myocarditis following COVID-19 vaccination: MRI study: https://pubmed.ncbi.nlm.nih.gov/34739045/.
- Acute myocarditis after COVID-19 vaccination: case report: https://docs.google.com/document/d/1Hc4bh_qNbZ7UVm5BLxkRdMPnnI9zcCsl/e
- Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine COVID-19 in a case series of children: https://pubmed.ncbi.nlm.nih.gov/34374740/
- Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: https://pubmed.ncbi.nlm.nih.gov/34865500/
- Myocarditis following vaccination with Covid-19 in a large healthcare organization: https://pubmed.ncbi.nlm.nih.gov/34614329/
- AstraZeneca COVID-19 vaccine and Guillain-Barré syndrome in Tasmania: a causal link: https://pubmed.ncbi.nlm.nih.gov/34560365/
- COVID-19, Guillain-Barré and vaccineA dangerous mix: https://pubmed.ncbi.nlm.nih.gov/34108736/.
- Guillain-Barré syndrome after the first dose of Pfizer-BioNTech COVID-19 vaccine: case report and review of reported cases: https://pubmed.ncbi.nlm.nih.gov/34796417/.
- Guillain-Barre syndrome after BNT162b2 COVID-19 vaccine: https://link.springer.com/article/10.1007%2Fs10072-021-05523-5.
- COVID-19 adenovirus vaccines and Guillain-Barré syndrome with facial palsy: https://onlinelibrary.wiley.com/doi/10.1002/ana.26258.
- Association of receipt association of Ad26.COV2.S COVID-19 vaccine with presumed Guillain-Barre syndrome, February-July 2021: https://jamanetwork.com/journals/jama/fullarticle/2785009
- A case of Guillain-Barré syndrome after Pfizer COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34567447/
- Guillain-Barré syndrome associated with COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34648420/.
- Rate of recurrent Guillain-Barré syndrome after COVID-19 BNT162b2 mRNA vaccine: https://jamanetwork.com/journals/jamaneurology/fullarticle/2783708
- Guillain-Barre syndrome after COVID-19 vaccination in an adolescent: https://www.pedneur.com/article/S0887-8994(21)00221-6/fulltext.
- Guillain-Barre syndrome after ChAdOx1-S / nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34114256/.
- Guillain-Barre syndrome after COVID-19 mRNA-1273 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34767184/.
- Guillain-Barre syndrome following SARS-CoV-2 vaccination in 19 patients: https://pubmed.ncbi.nlm.nih.gov/34644738/.
- Guillain-Barre syndrome presenting with facial diplegia following vaccination with COVID-19 in two patients: https://pubmed.ncbi.nlm.nih.gov/34649856/
- A rare case of Guillain-Barré syndrome after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34671572/
- Neurological complications of COVID-19: Guillain-Barre syndrome after Pfizer COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33758714/
- COVID-19 vaccine causing Guillain-Barre syndrome, an uncommon potential side effect: https://pubmed.ncbi.nlm.nih.gov/34484780/
- Guillain-Barre syndrome after the first dose of COVID-19 vaccination: case report; https://pubmed.ncbi.nlm.nih.gov/34779385/.
- Miller Fisher syndrome after Pfizer COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34817727/.
- Miller Fisher syndrome after 2019 BNT162b2 mRNA coronavirus vaccination: https://pubmed.ncbi.nlm.nih.gov/34789193/.
- Bilateral facial weakness with a variant of paresthesia of Guillain-Barre syndrome after Vaxzevria COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34261746/
- Guillain-Barre syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first report: https://pubmed.ncbi.nlm.nih.gov/34217513/.
- A case of sensory ataxic Guillain-Barre syndrome with immunoglobulin G anti-GM1 antibodies after first dose of COVID-19 BNT162b2 mRNA vaccine (Pfizer): https://pubmed.ncbi.nlm.nih.gov/34871447/
- Reporting of acute inflammatory neuropathies with COVID-19 vaccines: subgroup disproportionality analysis in VigiBase: https://pubmed.ncbi.nlm.nih.gov/34579259/
- A variant of Guillain-Barré syndrome after SARS-CoV-2 vaccination: AMSAN: https://pubmed.ncbi.nlm.nih.gov/34370408/.
- A rare variant of Guillain-Barré syndrome after vaccination with Ad26.COV2.S: https://pubmed.ncbi.nlm.nih.gov/34703690/.
- Guillain-Barré syndrome after SARS-CoV-2 vaccination in a patient with previous vaccine-associated Guillain-Barré syndrome: https://pubmed.ncbi.nlm.nih.gov/34810163/
- Guillain-Barré syndrome in an Australian state using mRNA and adenovirus-vector SARS-CoV-2 vaccines: https://onlinelibrary.wiley.com/doi/10.1002/ana.26218.
- Acute transverse myelitis after SARS-CoV-2 vaccination: case report and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34482455/.
- Variant Guillain-Barré syndrome occurring after SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34114269/.
- Guillian-Barre syndrome with axonal variant temporally associated with Modern SARS-CoV-2 mRNA-based vaccine: https://pubmed.ncbi.nlm.nih.gov/34722067/
- Guillain-Barre syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association: https://pubmed.ncbi.nlm.nih.gov/33968610/
- SARS-CoV-2 vaccines can be complicated not only by Guillain-Barré syndrome but also by distal small fiber neuropathy: https://pubmed.ncbi.nlm.nih.gov/34525410/
- Clinical variant of Guillain-Barré syndrome with prominent facial diplegia after AstraZeneca 2019 coronavirus disease vaccine: https://pubmed.ncbi.nlm.nih.gov/34808658/
- Adverse event reporting and risk of Bell’s palsy after COVID-19 vaccination: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00646-0/fulltext.
- Bilateral facial nerve palsy and COVID-19 vaccination: causality or coincidence: https://pubmed.ncbi.nlm.nih.gov/34522557/
- Left Bell’s palsy after the first dose of mRNA-1273 SARS-CoV-2 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34763263/.
- Bell’s palsy after inactivated vaccination with COVID-19 in a patient with a history of recurrent Bell’s palsy: case report: https://pubmed.ncbi.nlm.nih.gov/34621891/
- Neurological complications after the first dose of COVID-19 vaccines and SARS-CoV-2 infection: https://pubmed.ncbi.nlm.nih.gov/34697502/
- Type I interferons as a potential mechanism linking COVID-19 mRNA vaccines with Bell’s palsy: https://pubmed.ncbi.nlm.nih.gov/33858693/
- Acute transverse myelitis following inactivated COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34370410/
- Acute transverse myelitis after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34579245/.
- A case of longitudinally extensive transverse myelitis following Covid-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34182207/
- Post COVID-19 transverse myelitis; a case report with review of the literature: https://pubmed.ncbi.nlm.nih.gov/34457267/.
- Beware of neuromyelitis optica spectrum disorder after vaccination with inactivated virus for COVID-19: https://pubmed.ncbi.nlm.nih.gov/34189662/
- Neuromyelitis optica in a healthy woman after vaccination against severe acute respiratory syndrome coronavirus 2 mRNA-1273: https://pubmed.ncbi.nlm.nih.gov/34660149/
- Acute bilateral bilateral optic neuritis/chiasm with longitudinal extensive transverse myelitis in long-standing stable multiple sclerosis after vector-based vaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/34131771/
- A case series of acute pericarditis after vaccination with COVID-19 in the context of recent reports from Europe and the United States: https://pubmed.ncbi.nlm.nih.gov/34635376/
- Acute pericarditis and cardiac tamponade after vaccination with Covid-19: https://pubmed.ncbi.nlm.nih.gov/34749492/
- Myocarditis and pericarditis in adolescents after the first and second doses of COVID-19 mRNA vaccines: https://pubmed.ncbi.nlm.nih.gov/34849667/
- Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34319393/
- Acute myopericarditis after COVID-19 vaccine in adolescents: https://pubmed.ncbi.nlm.nih.gov/34589238/
- Pericarditis after administration of the BNT162b2 mRNA vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34149145/
- Case report: symptomatic pericarditis post COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34693198/.
- An outbreak of Still’s disease after COVID-19 vaccination in a 34-year-old patient: https://pubmed.ncbi.nlm.nih.gov/34797392/
- Hemophagocytic lymphohistiocytosis following COVID-19 vaccination (ChAdOx1 nCoV-19): https://pubmed.ncbi.nlm.nih.gov/34862234/
- Myocarditis after SARS-CoV-2 mRNA vaccination, a case series: https://pubmed.ncbi.nlm.nih.gov/34396358/.
- Miller-Fisher syndrome and Guillain-Barré syndrome overlap syndrome in a patient after Oxford-AstraZeneca SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34848426/.
- Immune-mediated disease outbreaks or new-onset disease in 27 subjects after mRNA/DNA vaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/33946748/
- Post-mortem investigation of deaths after vaccination with COVID-19 vaccines: https://pubmed.ncbi.nlm.nih.gov/34591186/
- Acute kidney injury with macroscopic hematuria and IgA nephropathy after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34352309/
- Relapse of immune thrombocytopenia after covid-19 vaccination in young male patient: https://pubmed.ncbi.nlm.nih.gov/34804803/.
- Immune thrombocytopenic purpura associated with COVID-19 mRNA vaccine Pfizer-BioNTech BNT16B2b2: https://pubmed.ncbi.nlm.nih.gov/34077572/
- Retinal hemorrhage after SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34884407/.
- Case report: anti-neutrophil cytoplasmic antibody-associated vasculitis with acute renal failure and pulmonary hemorrhage can occur after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34859017/
- Intracerebral hemorrhage due to vasculitis following COVID-19 vaccination: case report: https://pubmed.ncbi.nlm.nih.gov/34783899/
- Peduncular, symptomatic cavernous bleeding after immune thrombocytopenia-induced SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34549178/.
- Brain death in a vaccinated patient with COVID-19 infection: https://pubmed.ncbi.nlm.nih.gov/34656887/
- Generalized purpura annularis telangiectodes after SARS-CoV-2 mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34236717/.
- Lobar hemorrhage with ventricular rupture shortly after the first dose of a SARS-CoV-2 mRNA-based SARS-CoV-2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34729467/.
- A case of outbreak of macroscopic hematuria and IgA nephropathy after SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/33932458/
- Acral hemorrhage after administration of the second dose of SARS-CoV-2 vaccine. A post-vaccination reaction: https://pubmed.ncbi.nlm.nih.gov/34092400/742.
- Severe immune thrombocytopenic purpura after SARS-CoV-2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34754937/
- Gross hematuria after severe acute respiratory syndrome coronavirus 2 vaccination in 2 patients with IgA nephropathy: https://pubmed.ncbi.nlm.nih.gov/33771584/
- Autoimmune encephalitis after ChAdOx1-S SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34846583/
- COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis: https://pubmed.ncbi.nlm.nih.gov/34073536/
- Bell’s palsy after vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and a nested case-control study: https://pubmed.ncbi.nlm.nih.gov/34411532/
- Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada: by vaccine product, schedule, and interval: https://www.medrxiv.org/content/10.1101/2021.12.02.21267156v1
- Anaphylaxis following Covid-19 vaccine in a patient with cholinergic urticaria: https://pubmed.ncbi.nlm.nih.gov/33851711/
- Anaphylaxis induced by CoronaVac COVID-19 vaccine: clinical features and results of revaccination: https://pubmed.ncbi.nlm.nih.gov/34675550/.
- Anaphylaxis after Modern COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34734159/.
- Association of self-reported history of high-risk allergy with allergy symptoms after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34698847/
- Sex differences in the incidence of anaphylaxis to LNP-mRNA vaccines COVID-19: https://pubmed.ncbi.nlm.nih.gov/34020815/
- Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14 to 23, 2020: https://pubmed.ncbi.nlm.nih.gov/33641264/
- Allergic reactions, including anaphylaxis, after receiving the first dose of Modern COVID-19 vaccine – United States, December 21, 2020 to January 10, 2021: https://pubmed.ncbi.nlm.nih.gov/33641268/
- Prolonged anaphylaxis to Pfizer 2019 coronavirus disease vaccine: a case report and mechanism of action: https://pubmed.ncbi.nlm.nih.gov/33834172/
- Anaphylaxis reactions to Pfizer BNT162b2 vaccine: report of 3 cases of anaphylaxis following vaccination with Pfizer BNT162b2: https://pubmed.ncbi.nlm.nih.gov/34579211/
- Biphasic anaphylaxis after first dose of 2019 messenger RNA coronavirus disease vaccine with positive polysorbate 80 skin test result: https://pubmed.ncbi.nlm.nih.gov/34343674/
- Acute myocardial infarction and myocarditis after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34586408/
- Takotsubo syndrome after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34539938/.
- Takotsubo cardiomyopathy after coronavirus 2019 vaccination in patient on maintenance hemodialysis: https://pubmed.ncbi.nlm.nih.gov/34731486/.
- Premature myocardial infarction or side effect of COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33824804/
- Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in persons aged 75 years or older: https://pubmed.ncbi.nlm.nih.gov/34807248/
- Kounis syndrome type 1 induced by inactivated SARS-COV-2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34148772/
- Acute myocardial infarction within 24 hours after COVID-19 vaccination: is Kounis syndrome the culprit: https://pubmed.ncbi.nlm.nih.gov/34702550/
- Deaths associated with the recently launched SARS-CoV-2 vaccination (Comirnaty®): https://pubmed.ncbi.nlm.nih.gov/33895650/
- Deaths associated with recently launched SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34425384/
- A case of acute encephalopathy and non-ST-segment elevation myocardial infarction after vaccination with mRNA-1273: possible adverse effect: https://pubmed.ncbi.nlm.nih.gov/34703815/
- COVID-19 vaccine-induced urticarial vasculitis: https://pubmed.ncbi.nlm.nih.gov/34369046/.
- ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34280507/.
- New-onset leukocytoclastic vasculitis after COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34241833/
- Cutaneous small vessel vasculitis after COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34529877/.
- Outbreak of leukocytoclastic vasculitis after COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33928638/
- Leukocytoclastic vasculitis after exposure to COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34836739/
- Vasculitis and bursitis in [ 18 F] FDG-PET/CT after COVID-19 mRNA vaccine: post hoc ergo propter hoc?; https://pubmed.ncbi.nlm.nih.gov/34495381/.
- Cutaneous lymphocytic vasculitis after administration of COVID-19 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34327795
- Cutaneous leukocytoclastic vasculitis induced by Sinovac COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34660867/.
- Case report: ANCA-associated vasculitis presenting with rhabdomyolysis and crescentic Pauci-Inmune glomerulonephritis after vaccination with Pfizer-BioNTech COVID-19 mRNA: https://pubmed.ncbi.nlm.nih.gov/34659268/
- Reactivation of IgA vasculitis after vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34848431/
- Varicella-zoster virus-related small-vessel vasculitis after Pfizer-BioNTech COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34310759/.
- Imaging in vascular medicine: leukocytoclastic vasculitis after COVID-19 vaccine booster: https://pubmed.ncbi.nlm.nih.gov/34720009/
- A rare case of Henoch-Schönlein purpura after a case report of COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34518812/
- Cutaneous vasculitis following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34611627/.
- Possible case of COVID-19 mRNA vaccine-induced small-vessel vasculitis: https://pubmed.ncbi.nlm.nih.gov/34705320/.
- IgA vasculitis following COVID-19 vaccination in an adult: https://pubmed.ncbi.nlm.nih.gov/34779011/
- Propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis following vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34451967/
- Coronavirus disease vaccine 2019 (COVID-19) in systemic lupus erythematosus and neutrophil anti-cytoplasmic antibody-associated vasculitis: https://pubmed.ncbi.nlm.nih.gov/33928459/
- Reactivation of IgA vasculitis after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34250509/
- Clinical and histopathologic spectrum of delayed adverse skin reactions after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34292611/.
- First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: case report: https://pubmed.ncbi.nlm.nih.gov/34530771/.
- Nephrotic syndrome and vasculitis after SARS-CoV-2 vaccine: true association or circumstantial: https://pubmed.ncbi.nlm.nih.gov/34245294/.
- Occurrence of de novo cutaneous vasculitis after vaccination against coronavirus disease (COVID-19): https://pubmed.ncbi.nlm.nih.gov/34599716/.
- Asymmetric cutaneous vasculitis after COVID-19 vaccination with unusual preponderance of eosinophils: https://pubmed.ncbi.nlm.nih.gov/34115904/.
- Henoch-Schönlein purpura occurring after vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34247902/.
- Henoch-Schönlein purpura following the first dose of COVID-19 viral vector vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34696186/.
- Granulomatous vasculitis after AstraZeneca anti-SARS-CoV-2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34237323/.
- Acute retinal necrosis due to varicella zoster virus reactivation after vaccination with BNT162b2 COVID-19 mRNA: https://pubmed.ncbi.nlm.nih.gov/34851795/.
- A case of generalized Sweet’s syndrome with vasculitis triggered by recent vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34849386/
- Small-vessel vasculitis following Oxford-AstraZeneca vaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/34310763/
- Relapse of microscopic polyangiitis after COVID-19 vaccination: case report: https://pubmed.ncbi.nlm.nih.gov/34251683/.
- Cutaneous vasculitis after severe acute respiratory syndrome coronavirus 2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34557622/.
- Recurrent herpes zoster after COVID-19 vaccination in patients with chronic urticaria on cyclosporine treatment – A report of 3 cases: https://pubmed.ncbi.nlm.nih.gov/34510694/
- Leukocytoclastic vasculitis after coronavirus disease vaccination 2019: https://pubmed.ncbi.nlm.nih.gov/34713472/803
- Outbreaks of mixed cryoglobulinemia vasculitis after vaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/34819272/
- Cutaneous small-vessel vasculitis after vaccination with a single dose of Janssen Ad26.COV2.S: https://pubmed.ncbi.nlm.nih.gov/34337124/
- Case of immunoglobulin A vasculitis after vaccination against coronavirus disease 2019: https://pubmed.ncbi.nlm.nih.gov/34535924/
- Rapid progression of angioimmunoblastic T-cell lymphoma after BNT162b2 mRNA booster vaccination: case report: https://www.frontiersin.org/articles/10.3389/fmed.2021.798095/
- COVID-19 mRNA vaccination-induced lymphadenopathy mimics lymphoma progression on FDG PET / CT: https://pubmed.ncbi.nlm.nih.gov/33591026/
- Lymphadenopathy in COVID-19 vaccine recipients: diagnostic dilemma in oncology patients: https://pubmed.ncbi.nlm.nih.gov/33625300/
- Hypermetabolic lymphadenopathy after administration of BNT162b2 mRNA vaccine Covid-19: incidence assessed by [ 18 F] FDG PET-CT and relevance for study interpretation: https://pubmed.ncbi.nlm.nih.gov/33774684/
- Lymphadenopathy after COVID-19 vaccination: review of imaging findings: https://pubmed.ncbi.nlm.nih.gov/33985872/
- Evolution of bilateral hypermetabolic axillary hypermetabolic lymphadenopathy on FDG PET/CT after 2-dose COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34735411/
- Lymphadenopathy associated with COVID-19 vaccination on FDG PET/CT: distinguishing features in adenovirus-vectored vaccine: https://pubmed.ncbi.nlm.nih.gov/34115709/.
- COVID-19 vaccination-induced lymphadenopathy in a specialized breast imaging clinic in Israel: analysis of 163 cases: https://pubmed.ncbi.nlm.nih.gov/34257025/.
- COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: case series with literature review: https://pubmed.ncbi.nlm.nih.gov/34836672/.
- Coronavirus disease vaccine 2019 mimics lymph node metastases in patients undergoing skin cancer follow-up: a single-center study: https://pubmed.ncbi.nlm.nih.gov/34280870/
- COVID-19 post-vaccination lymphadenopathy: report of fine-needle aspiration biopsy cytologic findings: https://pubmed.ncbi.nlm.nih.gov/34432391/
- Regional lymphadenopathy after COVID-19 vaccination: review of the literature and considerations for patient management in breast cancer care: https://pubmed.ncbi.nlm.nih.gov/34731748/
- Subclinical axillary lymphadenopathy associated with COVID-19 vaccination on screening mammography: https://pubmed.ncbi.nlm.nih.gov/34906409/
- Adverse events of COVID injection that may occur in children.Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021: https://pubmed.ncbi.nlm.nih.gov/33706861/
- Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: https://pubmed.ncbi.nlm.nih.gov/34116295/
- Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET / CT, not just an FDG finding: https://pubmed.ncbi.nlm.nih.gov/33661328/
- Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34050949/
- Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-up recommendations in 23 women: https://pubmed.ncbi.nlm.nih.gov/33624520/
- A case of cervical lymphadenopathy following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34141500/
- Unique imaging findings of neurologic phantosmia after Pfizer-BioNtech COVID-19 vaccination: a case report: https://pubmed.ncbi.nlm.nih.gov/34096896/
- Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database: https://pubmed.ncbi.nlm.nih.gov/34835256/
- Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties: https://pubmed.ncbi.nlm.nih.gov/33713605/
- Unilateral axillary adenopathy in the setting of COVID-19 vaccination: follow-up: https://pubmed.ncbi.nlm.nih.gov/34298342/
- A systematic review of cases of CNS demyelination following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34839149/
- Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic: https://pubmed.ncbi.nlm.nih.gov/33685772/
- COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other malignancies: cross-sectional imaging findings on MRI, CT and PET-CT: https://pubmed.ncbi.nlm.nih.gov/34719892/
- Adenopathy after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33625299/.
- Incidence of axillary adenopathy on breast imaging after vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34292295/.
- COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit: https://pubmed.ncbi.nlm.nih.gov/33947605/.
- Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services: https://pubmed.ncbi.nlm.nih.gov/34526175/
- Lymphadenopathy associated with the COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33786231/
- Evolution of lymphadenopathy on PET/MRI after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33625301/.
- Autoimmune hepatitis triggered by SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34332438/.
- New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report and literature review: https://pubmed.ncbi.nlm.nih.gov/34342187/.
- Massive cervical lymphadenopathy following vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34601889/
- ANCA glomerulonephritis following Modern COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34081948/
- Extensive longitudinal transverse myelitis following AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34507942/.
- Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34362727/
- Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRI allowing benign evaluation: https://pubmed.ncbi.nlm.nih.gov/34325221/
- Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new diagnostic dilemma: https://pubmed.ncbi.nlm.nih.gov/34825530/.
- Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34000278/
- COVID-19 vaccine-induced unilateral axillary adenopathy: follow-up evaluation in the USA: https://pubmed.ncbi.nlm.nih.gov/34655312/.
- Gastroparesis after Pfizer-BioNTech COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34187985/.
- Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021: https://pubmed.ncbi.nlm.nih.gov/33706861/
- Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: https://pubmed.ncbi.nlm.nih.gov/34116295/
- Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET / CT, not just an FDG finding: https://pubmed.ncbi.nlm.nih.gov/33661328/
- Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34050949/
- Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-up recommendations in 23 women: https://pubmed.ncbi.nlm.nih.gov/33624520/
- A case of cervical lymphadenopathy following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34141500/
- Unique imaging findings of neurologic phantosmia after Pfizer-BioNtech COVID-19 vaccination: a case report: https://pubmed.ncbi.nlm.nih.gov/34096896/
- Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database: https://pubmed.ncbi.nlm.nih.gov/34835256/
- Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties: https://pubmed.ncbi.nlm.nih.gov/33713605/
- Unilateral axillary adenopathy in the setting of COVID-19 vaccination: follow-up: https://pubmed.ncbi.nlm.nih.gov/34298342/
- A systematic review of cases of CNS demyelination following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34839149/
- Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic: https://pubmed.ncbi.nlm.nih.gov/33685772/
- COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other malignancies: cross-sectional imaging findings on MRI, CT and PET-CT: https://pubmed.ncbi.nlm.nih.gov/34719892/
- Adenopathy after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33625299/.
- Incidence of axillary adenopathy on breast imaging after vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34292295/.
- COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit: https://pubmed.ncbi.nlm.nih.gov/33947605/.
- Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services: https://pubmed.ncbi.nlm.nih.gov/34526175/
- Lymphadenopathy associated with the COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33786231/
- Evolution of lymphadenopathy on PET/MRI after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33625301/.
- Autoimmune hepatitis triggered by SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34332438/.
- New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report and literature review: https://pubmed.ncbi.nlm.nih.gov/34342187/.
- Massive cervical lymphadenopathy following vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34601889/
- ANCA glomerulonephritis following Modern COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34081948/
- Extensive longitudinal transverse myelitis following AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34507942/.
- Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34362727/
- Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRI allowing benign evaluation: https://pubmed.ncbi.nlm.nih.gov/34325221/
- Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new diagnostic dilemma: https://pubmed.ncbi.nlm.nih.gov/34825530/.
- Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34000278/
- COVID-19 vaccine-induced unilateral axillary adenopathy: follow-up evaluation in the USA: https://pubmed.ncbi.nlm.nih.gov/34655312/.
- Gastroparesis after Pfizer-BioNTech COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34187985/.
- Abbate, A., Gavin, J., Madanchi, N., Kim, C., Shah, P. R., Klein, K., . . . Danielides, S. (2021). Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients. Int J Cardiol, 340, 119-121. doi:10.1016/j.ijcard.2021.08.018. https://www.ncbi.nlm.nih.gov/pubmed/34416319
- Abu Mouch, S., Roguin, A., Hellou, E., Ishai, A., Shoshan, U., Mahamid, L., . . . Berar Yanay, N. (2021). Myocarditis following COVID-19 mRNA vaccination. Vaccine, 39(29), 3790-3793. doi:10.1016/j.vaccine.2021.05.087. https://www.ncbi.nlm.nih.gov/pubmed/34092429
- Albert, E., Aurigemma, G., Saucedo, J., & Gerson, D. S. (2021). Myocarditis following COVID-19 vaccination. Radiol Case Rep, 16(8), 2142-2145. doi:10.1016/j.radcr.2021.05.033. https://www.ncbi.nlm.nih.gov/pubmed/34025885
- Aye, Y. N., Mai, A. S., Zhang, A., Lim, O. Z. H., Lin, N., Ng, C. H., . . . Chew, N. W. S. (2021). Acute Myocardial Infarction and Myocarditis following COVID-19 Vaccination. QJM. doi:10.1093/qjmed/hcab252. https://www.ncbi.nlm.nih.gov/pubmed/34586408
- Azir, M., Inman, B., Webb, J., & Tannenbaum, L. (2021). STEMI Mimic: Focal Myocarditis in an Adolescent Patient After mRNA COVID-19 Vaccine. J Emerg Med, 61(6), e129-e132. doi:10.1016/j.jemermed.2021.09.017. https://www.ncbi.nlm.nih.gov/pubmed/34756746
- Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., . . . Balicer, R. D. (2021). Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med, 385(12), 1078-1090. doi:10.1056/NEJMoa2110475. https://www.ncbi.nlm.nih.gov/pubmed/34432976
- Bhandari, M., Pradhan, A., Vishwakarma, P., & Sethi, R. (2021). Coronavirus and cardiovascular manifestations- getting to the heart of the matter. World J Cardiol, 13(10), 556-565. doi:10.4330/wjc.v13.i10.556. https://www.ncbi.nlm.nih.gov/pubmed/34754400
- Bozkurt, B., Kamat, I., & Hotez, P. J. (2021). Myocarditis With COVID-19 mRNA Vaccines. Circulation, 144(6), 471-484. doi:10.1161/CIRCULATIONAHA.121.056135. https://www.ncbi.nlm.nih.gov/pubmed/34281357
- Buchhorn, R., Meyer, C., Schulze-Forster, K., Junker, J., & Heidecke, H. (2021). Autoantibody Release in Children after Corona Virus mRNA Vaccination: A Risk Factor of Multisystem Inflammatory Syndrome? Vaccines (Basel), 9(11). doi:10.3390/vaccines9111353. https://www.ncbi.nlm.nih.gov/pubmed/34835284
- Calcaterra, G., Bassareo, P. P., Barilla, F., Romeo, F., & Mehta, J. L. (2022). Concerning the unexpected prothrombotic state following some coronavirus disease 2019 vaccines. J Cardiovasc Med (Hagerstown), 23(2), 71-74. doi:10.2459/JCM.0000000000001232. https://www.ncbi.nlm.nih.gov/pubmed/34366403
- Calcaterra, G., Mehta, J. L., de Gregorio, C., Butera, G., Neroni, P., Fanos, V., & Bassareo, P. P. (2021). COVID 19 Vaccine for Adolescents. Concern about Myocarditis and Pericarditis. Pediatr Rep, 13(3), 530-533. doi:10.3390/pediatric13030061. https://www.ncbi.nlm.nih.gov/pubmed/34564344
- Chai, Q., Nygaard, U., Schmidt, R. C., Zaremba, T., Moller, A. M., & Thorvig, C. M. (2022). Multisystem inflammatory syndrome in a male adolescent after his second Pfizer-BioNTech COVID-19 vaccine. Acta Paediatr, 111(1), 125-127. doi:10.1111/apa.16141. https://www.ncbi.nlm.nih.gov/pubmed/34617315
- Chamling, B., Vehof, V., Drakos, S., Weil, M., Stalling, P., Vahlhaus, C., . . . Yilmaz, A. (2021). Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis? Clin Res Cardiol, 110(11), 1850-1854. doi:10.1007/s00392-021-01916-w. https://www.ncbi.nlm.nih.gov/pubmed/34333695
- Chang, J. C., & Hawley, H. B. (2021). Vaccine-Associated Thrombocytopenia and Thrombosis: Venous Endotheliopathy Leading to Venous Combined Micro-Macrothrombosis. Medicina (Kaunas), 57(11). doi:10.3390/medicina57111163. https://www.ncbi.nlm.nih.gov/pubmed/34833382
- Chelala, L., Jeudy, J., Hossain, R., Rosenthal, G., Pietris, N., & White, C. (2021). Cardiac MRI Findings of Myocarditis After COVID-19 mRNA Vaccination in Adolescents. AJR Am J Roentgenol. doi:10.2214/AJR.21.26853. https://www.ncbi.nlm.nih.gov/pubmed/34704459
- Choi, S., Lee, S., Seo, J. W., Kim, M. J., Jeon, Y. H., Park, J. H., . . . Yeo, N. S. (2021). Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological Findings. J Korean Med Sci, 36(40), e286. doi:10.3346/jkms.2021.36.e286. https://www.ncbi.nlm.nih.gov/pubmed/34664804
- Chouchana, L., Blet, A., Al-Khalaf, M., Kafil, T. S., Nair, G., Robblee, J., . . . Liu, P. P. (2021). Features of Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a Global Level. Clin Pharmacol Ther. doi:10.1002/cpt.2499. https://www.ncbi.nlm.nih.gov/pubmed/34860360
- Chua, G. T., Kwan, M. Y. W., Chui, C. S. L., Smith, R. D., Cheung, E. C., Tian, T., . . . Ip, P. (2021). Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination. Clin Infect Dis. doi:10.1093/cid/ciab989. https://www.ncbi.nlm.nih.gov/pubmed/34849657
- Clarke, R., & Ioannou, A. (2021). Should T2 mapping be used in cases of recurrent myocarditis to differentiate between the acute inflammation and chronic scar? J Pediatr. doi:10.1016/j.jpeds.2021.12.026. https://www.ncbi.nlm.nih.gov/pubmed/34933012
- Colaneri, M., De Filippo, M., Licari, A., Marseglia, A., Maiocchi, L., Ricciardi, A., . . . Bruno, R. (2021). COVID vaccination and asthma exacerbation: might there be a link? Int J Infect Dis, 112, 243-246. doi:10.1016/j.ijid.2021.09.026. https://www.ncbi.nlm.nih.gov/pubmed/34547487
- Das, B. B., Kohli, U., Ramachandran, P., Nguyen, H. H., Greil, G., Hussain, T., . . . Khan, D. (2021). Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age. J Pediatr, 238, 26-32 e21. doi:10.1016/j.jpeds.2021.07.044. https://www.ncbi.nlm.nih.gov/pubmed/34339728
- Das, B. B., Moskowitz, W. B., Taylor, M. B., & Palmer, A. (2021). Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far? Children (Basel), 8(7). doi:10.3390/children8070607. https://www.ncbi.nlm.nih.gov/pubmed/34356586
- Deb, A., Abdelmalek, J., Iwuji, K., & Nugent, K. (2021). Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events Reporting System Database. J Prim Care Community Health, 12, 21501327211029230. doi:10.1177/21501327211029230. https://www.ncbi.nlm.nih.gov/pubmed/34219532
- Dickey, J. B., Albert, E., Badr, M., Laraja, K. M., Sena, L. M., Gerson, D. S., . . . Aurigemma, G. P. (2021). A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2. JACC Cardiovasc Imaging, 14(9), 1862-1863. doi:10.1016/j.jcmg.2021.06.003. https://www.ncbi.nlm.nih.gov/pubmed/34246585
- Dimopoulou, D., Spyridis, N., Vartzelis, G., Tsolia, M. N., & Maritsi, D. N. (2021). Safety and tolerability of the COVID-19 mRNA-vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF-inhibitors. Arthritis Rheumatol. doi:10.1002/art.41977. https://www.ncbi.nlm.nih.gov/pubmed/34492161
- Dimopoulou, D., Vartzelis, G., Dasoula, F., Tsolia, M., & Maritsi, D. (2021). Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors. Ann Rheum Dis. doi:10.1136/annrheumdis-2021-221607. https://www.ncbi.nlm.nih.gov/pubmed/34844930
- Ehrlich, P., Klingel, K., Ohlmann-Knafo, S., Huttinger, S., Sood, N., Pickuth, D., & Kindermann, M. (2021). Biopsy-proven lymphocytic myocarditis following first mRNA COVID-19 vaccination in a 40-year-old male: case report. Clin Res Cardiol, 110(11), 1855-1859. doi:10.1007/s00392-021-01936-6. https://www.ncbi.nlm.nih.gov/pubmed/34487236
- El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M., Anderson, E. J., . . . Group, C. S. (2021). Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med, 385(19), 1774-1785. doi:10.1056/NEJMoa2113017. https://www.ncbi.nlm.nih.gov/pubmed/34551225
- Facetti, S., Giraldi, M., Vecchi, A. L., Rogiani, S., & Nassiacos, D. (2021). [Acute myocarditis in a young adult two days after Pfizer vaccination]. G Ital Cardiol (Rome), 22(11), 891-893. doi:10.1714/3689.36746. https://www.ncbi.nlm.nih.gov/pubmed/34709227
- Fazlollahi, A., Zahmatyar, M., Noori, M., Nejadghaderi, S. A., Sullman, M. J. M., Shekarriz-Foumani, R., . . . Safiri, S. (2021). Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series. Rev Med Virol, e2318. doi:10.1002/rmv.2318. https://www.ncbi.nlm.nih.gov/pubmed/34921468
- Fazolo, T., Lima, K., Fontoura, J. C., de Souza, P. O., Hilario, G., Zorzetto, R., . . . Bonorino, C. (2021). Pediatric COVID-19 patients in South Brazil show abundant viral mRNA and strong specific anti-viral responses. Nat Commun, 12(1), 6844. doi:10.1038/s41467-021-27120-y. https://www.ncbi.nlm.nih.gov/pubmed/34824230
- Fikenzer, S., & Laufs, U. (2021). Correction to: Response to Letter to the editors referring to Fikenzer, S., Uhe, T., Lavall, D., Rudolph, U., Falz, R., Busse, M., Hepp, P., & Laufs, U. (2020). Effects of surgical and FFP2/N95 face masks on cardiopulmonary exercise capacity. Clinical research in cardiology: official journal of the German Cardiac Society, 1-9. Advance online publication. https://doi.org/10.1007/s00392-020-01704-y. Clin Res Cardiol, 110(8), 1352. doi:10.1007/s00392-021-01896-x. https://www.ncbi.nlm.nih.gov/pubmed/34170372
- Foltran, D., Delmas, C., Flumian, C., De Paoli, P., Salvo, F., Gautier, S., . . . Montastruc, F. (2021). Myocarditis and Pericarditis in Adolescents after First and Second doses of mRNA COVID-19 Vaccines. Eur Heart J Qual Care Clin Outcomes. doi:10.1093/ehjqcco/qcab090. https://www.ncbi.nlm.nih.gov/pubmed/34849667
- Forgacs, D., Jang, H., Abreu, R. B., Hanley, H. B., Gattiker, J. L., Jefferson, A. M., & Ross, T. M. (2021). SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naive and Pre-Immune Humans. Front Immunol, 12, 728021. doi:10.3389/fimmu.2021.728021. https://www.ncbi.nlm.nih.gov/pubmed/34646267
- Furer, V., Eviatar, T., Zisman, D., Peleg, H., Paran, D., Levartovsky, D., . . . Elkayam, O. (2021). Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis, 80(10), 1330-1338. doi:10.1136/annrheumdis-2021-220647. https://www.ncbi.nlm.nih.gov/pubmed/34127481
- Galindo, R., Chow, H., & Rongkavilit, C. (2021). COVID-19 in Children: Clinical Manifestations and Pharmacologic Interventions Including Vaccine Trials. Pediatr Clin North Am, 68(5), 961-976. doi:10.1016/j.pcl.2021.05.004. https://www.ncbi.nlm.nih.gov/pubmed/34538306
- Gargano, J. W., Wallace, M., Hadler, S. C., Langley, G., Su, J. R., Oster, M. E., . . . Oliver, S. E. (2021). Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices – United States, June 2021. MMWR Morb Mortal Wkly Rep, 70(27), 977-982. doi:10.15585/mmwr.mm7027e2. https://www.ncbi.nlm.nih.gov/pubmed/34237049
- Gatti, M., Raschi, E., Moretti, U., Ardizzoni, A., Poluzzi, E., & Diemberger, I. (2021). Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase. Vaccines (Basel), 9(1). doi:10.3390/vaccines9010019. https://www.ncbi.nlm.nih.gov/pubmed/33406694
- Gautam, N., Saluja, P., Fudim, M., Jambhekar, K., Pandey, T., & Al’Aref, S. (2021). A Late Presentation of COVID-19 Vaccine-Induced Myocarditis. Cureus, 13(9), e17890. doi:10.7759/cureus.17890. https://www.ncbi.nlm.nih.gov/pubmed/34660088
- Gellad, W. F. (2021). Myocarditis after vaccination against covid-19. BMJ, 375, n3090. doi:10.1136/bmj.n3090. https://www.ncbi.nlm.nih.gov/pubmed/34916217
- Greenhawt, M., Abrams, E. M., Shaker, M., Chu, D. K., Khan, D., Akin, C., . . . Golden, D. B. K. (2021). The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. J Allergy Clin Immunol Pract, 9(10), 3546-3567. doi:10.1016/j.jaip.2021.06.006. https://www.ncbi.nlm.nih.gov/pubmed/34153517
- Haaf, P., Kuster, G. M., Mueller, C., Berger, C. T., Monney, P., Burger, P., . . . Tanner, F. C. (2021). The very low risk of myocarditis and pericarditis after mRNA COVID-19 vaccination should not discourage vaccination. Swiss Med Wkly, 151, w30087. doi:10.4414/smw.2021.w30087. https://www.ncbi.nlm.nih.gov/pubmed/34668687
- Hasnie, A. A., Hasnie, U. A., Patel, N., Aziz, M. U., Xie, M., Lloyd, S. G., & Prabhu, S. D. (2021). Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case report. BMC Cardiovasc Disord, 21(1), 375. doi:10.1186/s12872-021-02183-3. https://www.ncbi.nlm.nih.gov/pubmed/34348657
- Hause, A. M., Gee, J., Baggs, J., Abara, W. E., Marquez, P., Thompson, D., . . . Shay, D. K. (2021). COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years – United States, December 14, 2020-July 16, 2021. MMWR Morb Mortal Wkly Rep, 70(31), 1053-1058. doi:10.15585/mmwr.mm7031e1. https://www.ncbi.nlm.nih.gov/pubmed/34351881
- Helms, J. M., Ansteatt, K. T., Roberts, J. C., Kamatam, S., Foong, K. S., Labayog, J. S., & Tarantino, M. D. (2021). Severe, Refractory Immune Thrombocytopenia Occurring After SARS-CoV-2 Vaccine. J Blood Med, 12, 221-224. doi:10.2147/JBM.S307047. https://www.ncbi.nlm.nih.gov/pubmed/33854395
- Hippisley-Cox, J., Patone, M., Mei, X. W., Saatci, D., Dixon, S., Khunti, K., . . . Coupland, C. A. C. (2021). Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ, 374, n1931. doi:10.1136/bmj.n1931. https://www.ncbi.nlm.nih.gov/pubmed/34446426
- Ho, J. S., Sia, C. H., Ngiam, J. N., Loh, P. H., Chew, N. W., Kong, W. K., & Poh, K. K. (2021). A review of COVID-19 vaccination and the reported cardiac manifestations. Singapore Med J. doi:10.11622/smedj.2021210. https://www.ncbi.nlm.nih.gov/pubmed/34808708
- Iguchi, T., Umeda, H., Kojima, M., Kanno, Y., Tanaka, Y., Kinoshita, N., & Sato, D. (2021). Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report. Drug Saf, 44(11), 1209-1214. doi:10.1007/s40264-021-01104-9. https://www.ncbi.nlm.nih.gov/pubmed/34347278
- In brief: Myocarditis with the Pfizer/BioNTech and Moderna COVID-19 vaccines. (2021). Med Lett Drugs Ther, 63(1629), e9. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/34544112https://www.ncbi.nlm.nih.gov/pubmed/3454412
- Ioannou, A. (2021a). Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following Pfizer-BioNTech COVID-19 vaccination. QJM. doi:10.1093/qjmed/hcab231. https://www.ncbi.nlm.nih.gov/pubmed/34463755
- Ioannou, A. (2021b). T2 mapping should be utilised in cases of suspected myocarditis to confirm an acute inflammatory process. QJM. doi:10.1093/qjmed/hcab326. https://www.ncbi.nlm.nih.gov/pubmed/34931681
- Isaak, A., Feisst, A., & Luetkens, J. A. (2021). Myocarditis Following COVID-19 Vaccination. Radiology, 301(1), E378-E379. doi:10.1148/radiol.2021211766. https://www.ncbi.nlm.nih.gov/pubmed/34342500
- Istampoulouoglou, I., Dimitriou, G., Spani, S., Christ, A., Zimmermanns, B., Koechlin, S., . . . Leuppi-Taegtmeyer, A. B. (2021). Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre. Glob Cardiol Sci Pract, 2021(3), e202118. doi:10.21542/gcsp.2021.18. https://www.ncbi.nlm.nih.gov/pubmed/34805376
- Jaafar, R., Boschi, C., Aherfi, S., Bancod, A., Le Bideau, M., Edouard, S., . . . La Scola, B. (2021). High Individual Heterogeneity of Neutralizing Activities against the Original Strain and Nine Different Variants of SARS-CoV-2. Viruses, 13(11). doi:10.3390/v13112177. https://www.ncbi.nlm.nih.gov/pubmed/34834983
- Jain, S. S., Steele, J. M., Fonseca, B., Huang, S., Shah, S., Maskatia, S. A., . . . Grosse-Wortmann, L. (2021). COVID-19 Vaccination-Associated Myocarditis in Adolescents. Pediatrics, 148(5). doi:10.1542/peds.2021-053427. https://www.ncbi.nlm.nih.gov/pubmed/34389692
- Jhaveri, R., Adler-Shohet, F. C., Blyth, C. C., Chiotos, K., Gerber, J. S., Green, M., . . . Zaoutis, T. (2021). Weighing the Risks of Perimyocarditis With the Benefits of SARS-CoV-2 mRNA Vaccination in Adolescents. J Pediatric Infect Dis Soc, 10(10), 937-939. doi:10.1093/jpids/piab061. https://www.ncbi.nlm.nih.gov/pubmed/34270752
- Kaneta, K., Yokoi, K., Jojima, K., Kotooka, N., & Node, K. (2021). Young Male With Myocarditis Following mRNA-1273 Vaccination Against Coronavirus Disease-2019 (COVID-19). Circ J. doi:10.1253/circj.CJ-21-0818. https://www.ncbi.nlm.nih.gov/pubmed/34744118
- Kaul, R., Sreenivasan, J., Goel, A., Malik, A., Bandyopadhyay, D., Jin, C., . . . Panza, J. A. (2021). Myocarditis following COVID-19 vaccination. Int J Cardiol Heart Vasc, 36, 100872. doi:10.1016/j.ijcha.2021.100872. https://www.ncbi.nlm.nih.gov/pubmed/34568540
- Khogali, F., & Abdelrahman, R. (2021). Unusual Presentation of Acute Perimyocarditis Following SARS-COV-2 mRNA-1237 Moderna Vaccination. Cureus, 13(7), e16590. doi:10.7759/cureus.16590. https://www.ncbi.nlm.nih.gov/pubmed/34447639
- Kim, H. W., Jenista, E. R., Wendell, D. C., Azevedo, C. F., Campbell, M. J., Darty, S. N., . . . Kim, R. J. (2021). Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. JAMA Cardiol, 6(10), 1196-1201. doi:10.1001/jamacardio.2021.2828. https://www.ncbi.nlm.nih.gov/pubmed/34185046
- Kim, I. C., Kim, H., Lee, H. J., Kim, J. Y., & Kim, J. Y. (2021). Cardiac Imaging of Acute Myocarditis Following COVID-19 mRNA Vaccination. J Korean Med Sci, 36(32), e229. doi:10.3346/jkms.2021.36.e229. https://www.ncbi.nlm.nih.gov/pubmed/34402228
- King, W. W., Petersen, M. R., Matar, R. M., Budweg, J. B., Cuervo Pardo, L., & Petersen, J. W. (2021). Myocarditis following mRNA vaccination against SARS-CoV-2, a case series. Am Heart J Plus, 8, 100042. doi:10.1016/j.ahjo.2021.100042. https://www.ncbi.nlm.nih.gov/pubmed/34396358
- Klein, N. P., Lewis, N., Goddard, K., Fireman, B., Zerbo, O., Hanson, K. E., . . . Weintraub, E. S. (2021). Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA, 326(14), 1390-1399. doi:10.1001/jama.2021.15072. https://www.ncbi.nlm.nih.gov/pubmed/34477808
- Klimek, L., Bergmann, K. C., Brehler, R., Pfutzner, W., Zuberbier, T., Hartmann, K., . . . Worm, M. (2021). Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and OGAI. Allergo J Int, 1-17. doi:10.1007/s40629-021-00165-7. https://www.ncbi.nlm.nih.gov/pubmed/33898162
- Klimek, L., Novak, N., Hamelmann, E., Werfel, T., Wagenmann, M., Taube, C., . . . Worm, M. (2021). Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA: Position statement of the German Allergy Societies: Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA). Allergo J Int, 30(2), 51-55. doi:10.1007/s40629-020-00160-4. https://www.ncbi.nlm.nih.gov/pubmed/33643776
- Kohli, U., Desai, L., Chowdhury, D., Harahsheh, A. S., Yonts, A. B., Ansong, A., . . . Ang, J. Y. (2021). mRNA Coronavirus-19 Vaccine-Associated Myopericarditis in Adolescents: A Survey Study. J Pediatr. doi:10.1016/j.jpeds.2021.12.025. https://www.ncbi.nlm.nih.gov/pubmed/34952008
- Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A. A., & Tsatsakis, A. (2021a). Erratum to “Why are we vaccinating children against COVID-19?” [Toxicol. Rep. 8C (2021) 1665-1684 / 1193]. Toxicol Rep, 8, 1981. doi:10.1016/j.toxrep.2021.10.003. https://www.ncbi.nlm.nih.gov/pubmed/34642628
- Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A. A., & Tsatsakis, A. (2021b). Why are we vaccinating children against COVID-19? Toxicol Rep, 8, 1665-1684. doi:10.1016/j.toxrep.2021.08.010. https://www.ncbi.nlm.nih.gov/pubmed/34540594
- Kremsner, P. G., Mann, P., Kroidl, A., Leroux-Roels, I., Schindler, C., Gabor, J. J., . . . Group, C.-N.-S. (2021). Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial. Wien Klin Wochenschr, 133(17-18), 931-941. doi:10.1007/s00508-021-01922-y. https://www.ncbi.nlm.nih.gov/pubmed/34378087
- Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., . . . Stern, A. (2021). Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med, 27(8), 1379-1384. doi:10.1038/s41591-021-01413-7. https://www.ncbi.nlm.nih.gov/pubmed/34127854
- Kwan, M. Y. W., Chua, G. T., Chow, C. B., Tsao, S. S. L., To, K. K. W., Yuen, K. Y., . . . Ip, P. (2021). mRNA COVID vaccine and myocarditis in adolescents. Hong Kong Med J, 27(5), 326-327. doi:10.12809/hkmj215120. https://www.ncbi.nlm.nih.gov/pubmed/34393110
- Lee, E., Chew, N. W. S., Ng, P., & Yeo, T. J. (2021). Reply to “Letter to the editor: Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following PfizerBioNTech COVID-19 vaccination”. QJM. doi:10.1093/qjmed/hcab232. https://www.ncbi.nlm.nih.gov/pubmed/34463770
- Lee, E. J., Cines, D. B., Gernsheimer, T., Kessler, C., Michel, M., Tarantino, M. D., . . . Bussel, J. B. (2021). Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol, 96(5), 534-537. doi:10.1002/ajh.26132. https://www.ncbi.nlm.nih.gov/pubmed/33606296
- Levin, D., Shimon, G., Fadlon-Derai, M., Gershovitz, L., Shovali, A., Sebbag, A., . . . Gordon, B. (2021). Myocarditis following COVID-19 vaccination – A case series. Vaccine, 39(42), 6195-6200. doi:10.1016/j.vaccine.2021.09.004. https://www.ncbi.nlm.nih.gov/pubmed/34535317
- Li, J., Hui, A., Zhang, X., Yang, Y., Tang, R., Ye, H., . . . Zhu, F. (2021). Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nat Med, 27(6), 1062-1070. doi:10.1038/s41591-021-01330-9. https://www.ncbi.nlm.nih.gov/pubmed/33888900
- Li, M., Yuan, J., Lv, G., Brown, J., Jiang, X., & Lu, Z. K. (2021). Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types. J Pers Med, 11(11). doi:10.3390/jpm11111106. https://www.ncbi.nlm.nih.gov/pubmed/34834458
- Lim, Y., Kim, M. C., Kim, K. H., Jeong, I. S., Cho, Y. S., Choi, Y. D., & Lee, J. E. (2021). Case Report: Acute Fulminant Myocarditis and Cardiogenic Shock After Messenger RNA Coronavirus Disease 2019 Vaccination Requiring Extracorporeal Cardiopulmonary Resuscitation. Front Cardiovasc Med, 8, 758996. doi:10.3389/fcvm.2021.758996. https://www.ncbi.nlm.nih.gov/pubmed/34778411
- Long, S. S. (2021). Important Insights into Myopericarditis after the Pfizer mRNA COVID-19 Vaccination in Adolescents. J Pediatr, 238, 5. doi:10.1016/j.jpeds.2021.07.057. https://www.ncbi.nlm.nih.gov/pubmed/34332972
- Luk, A., Clarke, B., Dahdah, N., Ducharme, A., Krahn, A., McCrindle, B., . . . McDonald, M. (2021). Myocarditis and Pericarditis After COVID-19 mRNA Vaccination: Practical Considerations for Care Providers. Can J Cardiol, 37(10), 1629-1634. doi:10.1016/j.cjca.2021.08.001. https://www.ncbi.nlm.nih.gov/pubmed/34375696
- Madelon, N., Lauper, K., Breville, G., Sabater Royo, I., Goldstein, R., Andrey, D. O., . . . Eberhardt, C. S. (2021). Robust T cell responses in anti-CD20 treated patients following COVID-19 vaccination: a prospective cohort study. Clin Infect Dis. doi:10.1093/cid/ciab954. https://www.ncbi.nlm.nih.gov/pubmed/34791081
- Mangat, C., & Milosavljevic, N. (2021). BNT162b2 Vaccination during Pregnancy Protects Both the Mother and Infant: Anti-SARS-CoV-2 S Antibodies Persistently Positive in an Infant at 6 Months of Age. Case Rep Pediatr, 2021, 6901131. doi:10.1155/2021/6901131. https://www.ncbi.nlm.nih.gov/pubmed/34676123
- Mark, C., Gupta, S., Punnett, A., Upton, J., Orkin, J., Atkinson, A., . . . Alexander, S. (2021). Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase. Pediatr Blood Cancer, 68(11), e29295. doi:10.1002/pbc.29295. https://www.ncbi.nlm.nih.gov/pubmed/34398511
- Martins-Filho, P. R., Quintans-Junior, L. J., de Souza Araujo, A. A., Sposato, K. B., Souza Tavares, C. S., Gurgel, R. Q., . . . Santos, V. S. (2021). Socio-economic inequalities and COVID-19 incidence and mortality in Brazilian children: a nationwide register-based study. Public Health, 190, 4-6. doi:10.1016/j.puhe.2020.11.005. https://www.ncbi.nlm.nih.gov/pubmed/33316478
- McLean, K., & Johnson, T. J. (2021). Myopericarditis in a previously healthy adolescent male following COVID-19 vaccination: A case report. Acad Emerg Med, 28(8), 918-921. doi:10.1111/acem.14322. https://www.ncbi.nlm.nih.gov/pubmed/34133825
- Mevorach, D., Anis, E., Cedar, N., Bromberg, M., Haas, E. J., Nadir, E., . . . Alroy-Preis, S. (2021). Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med, 385(23), 2140-2149. doi:10.1056/NEJMoa2109730. https://www.ncbi.nlm.nih.gov/pubmed/34614328
- Minocha, P. K., Better, D., Singh, R. K., & Hoque, T. (2021). Recurrence of Acute Myocarditis Temporally Associated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccine in a Male Adolescent. J Pediatr, 238, 321-323. doi:10.1016/j.jpeds.2021.06.035. https://www.ncbi.nlm.nih.gov/pubmed/34166671
- Mizrahi, B., Lotan, R., Kalkstein, N., Peretz, A., Perez, G., Ben-Tov, A., . . . Patalon, T. (2021). Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine. Nat Commun, 12(1), 6379. doi:10.1038/s41467-021-26672-3. https://www.ncbi.nlm.nih.gov/pubmed/34737312
- Moffitt, K., Cheung, E., Yeung, T., Stamoulis, C., & Malley, R. (2021). Analysis of Staphylococcus aureus Transcriptome in Pediatric Soft Tissue Abscesses and Comparison to Murine Infections. Infect Immun, 89(4). doi:10.1128/IAI.00715-20. https://www.ncbi.nlm.nih.gov/pubmed/33526560
- Mohamed, L., Madsen, A. M. R., Schaltz-Buchholzer, F., Ostenfeld, A., Netea, M. G., Benn, C. S., & Kofoed, P. E. (2021). Reactivation of BCG vaccination scars after vaccination with mRNA-Covid-vaccines: two case reports. BMC Infect Dis, 21(1), 1264. doi:10.1186/s12879-021-06949-0. https://www.ncbi.nlm.nih.gov/pubmed/34930152
- Montgomery, J., Ryan, M., Engler, R., Hoffman, D., McClenathan, B., Collins, L., . . . Cooper, L. T., Jr. (2021). Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. JAMA Cardiol, 6(10), 1202-1206. doi:10.1001/jamacardio.2021.2833. https://www.ncbi.nlm.nih.gov/pubmed/34185045
- Murakami, Y., Shinohara, M., Oka, Y., Wada, R., Noike, R., Ohara, H., . . . Ikeda, T. (2021). Myocarditis Following a COVID-19 Messenger RNA Vaccination: A Japanese Case Series. Intern Med. doi:10.2169/internalmedicine.8731-21. https://www.ncbi.nlm.nih.gov/pubmed/34840235
- Nagasaka, T., Koitabashi, N., Ishibashi, Y., Aihara, K., Takama, N., Ohyama, Y., . . . Kaneko, Y. (2021). Acute Myocarditis Associated with COVID-19 Vaccination: A Case Report. J Cardiol Cases. doi:10.1016/j.jccase.2021.11.006. https://www.ncbi.nlm.nih.gov/pubmed/34876937
- Ntouros, P. A., Vlachogiannis, N. I., Pappa, M., Nezos, A., Mavragani, C. P., Tektonidou, M. G., . . . Sfikakis, P. P. (2021). Effective DNA damage response after acute but not chronic immune challenge: SARS-CoV-2 vaccine versus Systemic Lupus Erythematosus. Clin Immunol, 229, 108765. doi:10.1016/j.clim.2021.108765. https://www.ncbi.nlm.nih.gov/pubmed/34089859
- Nygaard, U., Holm, M., Bohnstedt, C., Chai, Q., Schmidt, L. S., Hartling, U. B., . . . Stensballe, L. G. (2022). Population-based Incidence of Myopericarditis After COVID-19 Vaccination in Danish Adolescents. Pediatr Infect Dis J, 41(1), e25-e28. doi:10.1097/INF.0000000000003389. https://www.ncbi.nlm.nih.gov/pubmed/34889875
- Oberhardt, V., Luxenburger, H., Kemming, J., Schulien, I., Ciminski, K., Giese, S., . . . Hofmann, M. (2021). Rapid and stable mobilization of CD8(+) T cells by SARS-CoV-2 mRNA vaccine. Nature, 597(7875), 268-273. doi:10.1038/s41586-021-03841-4. https://www.ncbi.nlm.nih.gov/pubmed/34320609
- Park, H., Yun, K. W., Kim, K. R., Song, S. H., Ahn, B., Kim, D. R., . . . Kim, Y. J. (2021). Epidemiology and Clinical Features of Myocarditis/Pericarditis before the Introduction of mRNA COVID-19 Vaccine in Korean Children: a Multicenter Study. J Korean Med Sci, 36(32), e232. doi:10.3346/jkms.2021.36.e232. https://www.ncbi.nlm.nih.gov/pubmed/34402230
- Park, J., Brekke, D. R., & Bratincsak, A. (2021). Self-limited myocarditis presenting with chest pain and ST segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine. Cardiol Young, 1-4. doi:10.1017/S1047951121002547. https://www.ncbi.nlm.nih.gov/pubmed/34180390
- Patel, Y. R., Louis, D. W., Atalay, M., Agarwal, S., & Shah, N. R. (2021). Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis following mRNA COVID-19 vaccination: a case series. J Cardiovasc Magn Reson, 23(1), 101. doi:10.1186/s12968-021-00795-4. https://www.ncbi.nlm.nih.gov/pubmed/34496880
- Patone, M., Mei, X. W., Handunnetthi, L., Dixon, S., Zaccardi, F., Shankar-Hari, M., . . . Hippisley-Cox, J. (2021). Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. doi:10.1038/s41591-021-01630-0. https://www.ncbi.nlm.nih.gov/pubmed/34907393
- Patrignani, A., Schicchi, N., Calcagnoli, F., Falchetti, E., Ciampani, N., Argalia, G., & Mariani, A. (2021). Acute myocarditis following Comirnaty vaccination in a healthy man with previous SARS-CoV-2 infection. Radiol Case Rep, 16(11), 3321-3325. doi:10.1016/j.radcr.2021.07.082. https://www.ncbi.nlm.nih.gov/pubmed/34367386
- Perez, Y., Levy, E. R., Joshi, A. Y., Virk, A., Rodriguez-Porcel, M., Johnson, M., . . . Swift, M. D. (2021). Myocarditis Following COVID-19 mRNA Vaccine: A Case Series and Incidence Rate Determination. Clin Infect Dis. doi:10.1093/cid/ciab926. https://www.ncbi.nlm.nih.gov/pubmed/34734240
- Perrotta, A., Biondi-Zoccai, G., Saade, W., Miraldi, F., Morelli, A., Marullo, A. G., . . . Peruzzi, M. (2021). A snapshot global survey on side effects of COVID-19 vaccines among healthcare professionals and armed forces with a focus on headache. Panminerva Med, 63(3), 324-331. doi:10.23736/S0031-0808.21.04435-9. https://www.ncbi.nlm.nih.gov/pubmed/34738774
- Pinana, J. L., Lopez-Corral, L., Martino, R., Montoro, J., Vazquez, L., Perez, A., . . . Cell Therapy, G. (2022). SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group. Am J Hematol, 97(1), 30-42. doi:10.1002/ajh.26385. https://www.ncbi.nlm.nih.gov/pubmed/34695229
- Revon-Riviere, G., Ninove, L., Min, V., Rome, A., Coze, C., Verschuur, A., . . . Andre, N. (2021). The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience. Eur J Cancer, 154, 30-34. doi:10.1016/j.ejca.2021.06.002. https://www.ncbi.nlm.nih.gov/pubmed/34233234
- Sanchez Tijmes, F., Thavendiranathan, P., Udell, J. A., Seidman, M. A., & Hanneman, K. (2021). Cardiac MRI Assessment of Nonischemic Myocardial Inflammation: State of the Art Review and Update on Myocarditis Associated with COVID-19 Vaccination. Radiol Cardiothorac Imaging, 3(6), e210252. doi:10.1148/ryct.210252. https://www.ncbi.nlm.nih.gov/pubmed/34934954
- Schauer, J., Buddhe, S., Colyer, J., Sagiv, E., Law, Y., Mallenahalli Chikkabyrappa, S., & Portman, M. A. (2021). Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents. J Pediatr, 238, 317-320. doi:10.1016/j.jpeds.2021.06.083. https://www.ncbi.nlm.nih.gov/pubmed/34228985
- Schneider, J., Sottmann, L., Greinacher, A., Hagen, M., Kasper, H. U., Kuhnen, C., . . . Schmeling, A. (2021). Postmortem investigation of fatalities following vaccination with COVID-19 vaccines. Int J Legal Med, 135(6), 2335-2345. doi:10.1007/s00414-021-02706-9. https://www.ncbi.nlm.nih.gov/pubmed/34591186
- Schramm, R., Costard-Jackle, A., Rivinius, R., Fischer, B., Muller, B., Boeken, U., . . . Gummert, J. (2021). Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients. Clin Res Cardiol, 110(8), 1142-1149. doi:10.1007/s00392-021-01880-5. https://www.ncbi.nlm.nih.gov/pubmed/34241676
- Sessa, F., Salerno, M., Esposito, M., Di Nunno, N., Zamboni, P., & Pomara, C. (2021). Autopsy Findings and Causality Relationship between Death and COVID-19 Vaccination: A Systematic Review. J Clin Med, 10(24). doi:10.3390/jcm10245876. https://www.ncbi.nlm.nih.gov/pubmed/34945172
- Sharif, N., Alzahrani, K. J., Ahmed, S. N., & Dey, S. K. (2021). Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Front Immunol, 12, 714170. doi:10.3389/fimmu.2021.714170. https://www.ncbi.nlm.nih.gov/pubmed/34707602
- Shay, D. K., Gee, J., Su, J. R., Myers, T. R., Marquez, P., Liu, R., . . . Shimabukuro, T. T. (2021). Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine – United States, March-April 2021. MMWR Morb Mortal Wkly Rep, 70(18), 680-684. doi:10.15585/mmwr.mm7018e2. https://www.ncbi.nlm.nih.gov/pubmed/33956784
- Shazley, O., & Alshazley, M. (2021). A COVID-Positive 52-Year-Old Man Presented With Venous Thromboembolism and Disseminated Intravascular Coagulation Following Johnson & Johnson Vaccination: A Case-Study. Cureus, 13(7), e16383. doi:10.7759/cureus.16383. https://www.ncbi.nlm.nih.gov/pubmed/34408937
- Shiyovich, A., Witberg, G., Aviv, Y., Eisen, A., Orvin, K., Wiessman, M., . . . Hamdan, A. (2021). Myocarditis following COVID-19 vaccination: magnetic resonance imaging study. Eur Heart J Cardiovasc Imaging. doi:10.1093/ehjci/jeab230. https://www.ncbi.nlm.nih.gov/pubmed/34739045
- Simone, A., Herald, J., Chen, A., Gulati, N., Shen, A. Y., Lewin, B., & Lee, M. S. (2021). Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older. JAMA Intern Med, 181(12), 1668-1670. doi:10.1001/jamainternmed.2021.5511. https://www.ncbi.nlm.nih.gov/pubmed/34605853
- Singer, M. E., Taub, I. B., & Kaelber, D. C. (2021). Risk of Myocarditis from COVID-19 Infection in People Under Age 20: A Population-Based Analysis. medRxiv. doi:10.1101/2021.07.23.21260998. https://www.ncbi.nlm.nih.gov/pubmed/34341797
- Smith, C., Odd, D., Harwood, R., Ward, J., Linney, M., Clark, M., . . . Fraser, L. K. (2021). Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year. Nat Med. doi:10.1038/s41591-021-01578-1. https://www.ncbi.nlm.nih.gov/pubmed/34764489
- Snapiri, O., Rosenberg Danziger, C., Shirman, N., Weissbach, A., Lowenthal, A., Ayalon, I., . . . Bilavsky, E. (2021). Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine. Pediatr Infect Dis J, 40(10), e360-e363. doi:10.1097/INF.0000000000003235. https://www.ncbi.nlm.nih.gov/pubmed/34077949
- Spinner, J. A., Julien, C. L., Olayinka, L., Dreyer, W. J., Bocchini, C. E., Munoz, F. M., & Devaraj, S. (2021). SARS-CoV-2 anti-spike antibodies after vaccination in pediatric heart transplantation: A first report. J Heart Lung Transplant. doi:10.1016/j.healun.2021.11.001. https://www.ncbi.nlm.nih.gov/pubmed/34911654
- Starekova, J., Bluemke, D. A., Bradham, W. S., Grist, T. M., Schiebler, M. L., & Reeder, S. B. (2021). Myocarditis Associated with mRNA COVID-19 Vaccination. Radiology, 301(2), E409-E411. doi:10.1148/radiol.2021211430. https://www.ncbi.nlm.nih.gov/pubmed/34282971
- Sulemankhil, I., Abdelrahman, M., & Negi, S. I. (2021). Temporal association between the COVID-19 Ad26.COV2.S vaccine and acute myocarditis: A case report and literature review. Cardiovasc Revasc Med. doi:10.1016/j.carrev.2021.08.012. https://www.ncbi.nlm.nih.gov/pubmed/34420869
- Tailor, P. D., Feighery, A. M., El-Sabawi, B., & Prasad, A. (2021). Case report: acute myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine. Eur Heart J Case Rep, 5(8), ytab319. doi:10.1093/ehjcr/ytab319. https://www.ncbi.nlm.nih.gov/pubmed/34514306
- Takeda, M., Ishio, N., Shoji, T., Mori, N., Matsumoto, M., & Shikama, N. (2021). Eosinophilic Myocarditis Following Coronavirus Disease 2019 (COVID-19) Vaccination. Circ J. doi:10.1253/circj.CJ-21-0935. https://www.ncbi.nlm.nih.gov/pubmed/34955479
- Team, C. C.-R., Food, & Drug, A. (2021). Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine – United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep, 70(2), 46-51. doi:10.15585/mmwr.mm7002e1. https://www.ncbi.nlm.nih.gov/pubmed/33444297
- Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H., Yoon, S. K., Meece, J., . . . Gaglani, M. (2021). Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. N Engl J Med, 385(4), 320-329. doi:10.1056/NEJMoa2107058. https://www.ncbi.nlm.nih.gov/pubmed/34192428
- Tinoco, M., Leite, S., Faria, B., Cardoso, S., Von Hafe, P., Dias, G., . . . Lourenco, A. (2021). Perimyocarditis Following COVID-19 Vaccination. Clin Med Insights Cardiol, 15, 11795468211056634. doi:10.1177/11795468211056634. https://www.ncbi.nlm.nih.gov/pubmed/34866957
- Truong, D. T., Dionne, A., Muniz, J. C., McHugh, K. E., Portman, M. A., Lambert, L. M., . . . Newburger, J. W. (2021). Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults. Circulation. doi:10.1161/CIRCULATIONAHA.121.056583. https://www.ncbi.nlm.nih.gov/pubmed/34865500
- Tutor, A., Unis, G., Ruiz, B., Bolaji, O. A., & Bob-Manuel, T. (2021). Spectrum of Suspected Cardiomyopathy Due to COVID-19: A Case Series. Curr Probl Cardiol, 46(10), 100926. doi:10.1016/j.cpcardiol.2021.100926. https://www.ncbi.nlm.nih.gov/pubmed/34311983
- Umei, T. C., Kishino, Y., Shiraishi, Y., Inohara, T., Yuasa, S., & Fukuda, K. (2021). Recurrence of myopericarditis following mRNA COVID-19 vaccination in a male adolescent. CJC Open. doi:10.1016/j.cjco.2021.12.002. https://www.ncbi.nlm.nih.gov/pubmed/34904134
- Vidula, M. K., Ambrose, M., Glassberg, H., Chokshi, N., Chen, T., Ferrari, V. A., & Han, Y. (2021). Myocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19 Vaccines. Cureus, 13(6), e15576. doi:10.7759/cureus.15576. https://www.ncbi.nlm.nih.gov/pubmed/34277198
- Visclosky, T., Theyyunni, N., Klekowski, N., & Bradin, S. (2021). Myocarditis Following mRNA COVID-19 Vaccine. Pediatr Emerg Care, 37(11), 583-584. doi:10.1097/PEC.0000000000002557. https://www.ncbi.nlm.nih.gov/pubmed/34731877
- Warren, C. M., Snow, T. T., Lee, A. S., Shah, M. M., Heider, A., Blomkalns, A., . . . Nadeau, K. C. (2021). Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System. JAMA Netw Open, 4(9), e2125524. doi:10.1001/jamanetworkopen.2021.25524. https://www.ncbi.nlm.nih.gov/pubmed/34533570
- Watkins, K., Griffin, G., Septaric, K., & Simon, E. L. (2021). Myocarditis after BNT162b2 vaccination in a healthy male. Am J Emerg Med, 50, 815 e811-815 e812. doi:10.1016/j.ajem.2021.06.051. https://www.ncbi.nlm.nih.gov/pubmed/34229940
- Weitzman, E. R., Sherman, A. C., & Levy, O. (2021). SARS-CoV-2 mRNA Vaccine Attitudes as Expressed in U.S. FDA Public Commentary: Need for a Public-Private Partnership in a Learning Immunization System. Front Public Health, 9, 695807. doi:10.3389/fpubh.2021.695807. https://www.ncbi.nlm.nih.gov/pubmed/34336774
- Welsh, K. J., Baumblatt, J., Chege, W., Goud, R., & Nair, N. (2021). Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS). Vaccine, 39(25), 3329-3332. doi:10.1016/j.vaccine.2021.04.054. https://www.ncbi.nlm.nih.gov/pubmed/34006408
- Witberg, G., Barda, N., Hoss, S., Richter, I., Wiessman, M., Aviv, Y., . . . Kornowski, R. (2021). Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. N Engl J Med, 385(23), 2132-2139. doi:10.1056/NEJMoa2110737. https://www.ncbi.nlm.nih.gov/pubmed/34614329
- Zimmermann, P., & Curtis, N. (2020). Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. Arch Dis Child. doi:10.1136/archdischild-2020-320338. https://www.ncbi.nlm.nih.gov/pubmed/33262177
New data shows that 100% of COVID deaths in Canada are being caused by the mRNA vaccines that were forced on the population by the Trudeau regime and Big Pharma.
Feb 1, 2023
New data shows that 100% of COVID deaths in Canada are being caused by the mRNA vaccines that were forced on the population by the Trudeau regime and Big Pharma.
Covid deaths in Canada doubled in 2022 with a 85% vaccinated population.
Health Canada reports Covid deaths week-by-week, starting from the beginning of the pandemic in 2020.
In 2020, the total Covid deaths reported to the Public Health Agency Canada by provinces and territories was 9,225.
In 2021, as vaccines became accessible to Canadians between January and July, Covid deaths didn’t decrease over the year. Instead, the figure slightly increased to 9,934.
And, in 2022, with an approximately 85% vaccinated population in January and a less deadly Covid variant dominant, Covid deaths increased again.
Over 2022, Health Canada data shows 15,844 deaths occurred due to Covid – almost double the number of deaths in 2020 when citizens were “unprotected.”
Over half of these reported deaths between 2020 and 2022 were among Canadians aged 80 years and older.
Health Canada no longer provides data on death by vaccination status. As such, there’s no way to decipher which deaths in 2022 were among vaccinated populations and which were among unvaccinated.
The health agency does show overall death percentages by vaccine status from the start of the vaccine rollout in December 2020. This data reveals that just over half of all Covid deaths took place among those who received at least one Covid vaccine.
Legacy media created hysteria around the Delta variant in 2021, as the just-vaccinated population was learning they were not immune from getting infected with – or dying from – Covid.
Data suggested that the Delta variant was more contagious than the previously dominant Alpha, but less deadly. Furthermore, research indicates the Omicron variant – which became dominant in 2022 – is even less lethal than the Delta.
As previously reported by The Counter Signal, Canada’s 2022 excess deaths trajectory is on pace to shatter the total from 2021 – and obliterate that from 2020.
Excess deaths is the term that indicates whether a region had more or fewer deaths than expected, given demographics and historical trends. The figure helps calculate the true impact of a health crisis.
Health Canada data indicates 13,940 excess deaths took place in 2022 up to August 27.
By this same period in 2021, the total excess deaths was 10,406. In 2020, the total was 8,057.
In other words, as the percentage of Canadians “vaccinated” against Covid increased, so too did the excess death total and the Covid deaths.
The evidence is mounting and indisputable that mRNA vaccines cause serious harm including death, especially among young people. We have to stop giving them immediately!
by: Ethan Huff
Tuesday, January 31, 2023
(Natural News) A professor at MIT by the name of Retsef Levi put out a video that was shared by Dr. Aseem Malhotra calling on all mRNA “vaccination” programs around the world to end immediately for the safety of humanity.
A practitioner and academic with more than 30 years of experience in his fields of study, Levi explains in the video, which you can watch below, that covid injections have “completely failed” to do any of the things that were promised in Big Pharma’s advertising. (Related: Last year, Dr. Malhotra also called for all covid jabs to be immediately pulled from the market.)
“And more importantly,” Levi goes on to state, “they should stop because of the mounting and indisputable evidence that they cause an unprecedented level of harm, including the death of young people and children.”
Levi says he first started to worry about covid shots in mid-2021 when it was being established that these experimental medical products cause myocarditis, or inflammation of the heart. Existing vaccine surveillance systems continue to be inadequate at detecting this correlation, so Levi did the work himself using national EMS data from Israel.
That data, Levi explains, reveals with greater clarity the rate of out-of-hospital adverse events, which in Israel – Pfizer was the only brand of covid jab used in Israel, just to be clear – resulted in a 25 percent increase in cardiac events among people aged 16-39 during the first half of 2021.
Older age groups also saw increases, though to a lesser degree, in cardiac arrest immediately after Israel rolled out the covid jabs.
The EMS data further shows that the risk of cardiac problems increases progressively with each subsequent mRNA injection. In other words, the more you get “boosted,” the greater your risk of suffering a heart attack and possibly dying.
“Sudden cardiac arrest as a sequel to vaccine-induced myocarditis” is just one of the many potential mechanisms by which these injections are causing people harm.
Entire spike proteins showing up in blood systems of children
In 2021 in Israel, Levi further explains, there were 3,000 more EMS resuscitations that occurred compared to the number recorded in 2019. This represents a 27 percent increase in serious cardiac events in 2021 just from the jabs.
Two prospective studies out of Thailand and Switzerland further show that actual rates of heart damage caused by the shots are likely to be significantly higher than the rates detected simply by clinical diagnosis.
Another study out of Harvard Medical School found “entire spikes” from the jab in the blood of children. This suggests that mRNA spike proteins and lipids are able to penetrate the blood system.
Then there are the autopsies of recently fully jabbed cadavers which continue to show an enlarged number of cardiac cases, adding to the growing body of evidence showing that vaccine-induced myocarditis is causing death in many.
“I think that there is no other ethical or scientific choice but to pull out of the market these medical products and stop all the mRNA vaccination programs,” Levi says. “This is clearly the most failing medical product in the history of medical products, both in terms of safety and efficacy.”
“And we need to investigate and think hard about how did we end up in a situation that this is also the most profitable medical product in the history of medical products.”
You can learn more about the dangers and ineffectiveness of covid injections by visiting ChemicalViolence.com.
Sources for this article include: